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mAChR Muscarinic acetylcholine receptor(s)
MAO Monoamine oxidase
MBTA 4-(N-maleimido)-benzyl trimethylammonium iodide
nAChR Nicotinic acetylcholine receptor(s)
NSTX Neosurugatoxin
PBS Phosphate-buffered saline







A synaptosomal perfusion system was developed to study a pre- 
synaptic nicotinic acetylcholine receptor (nAChR) which facilitates 
dopamine (DA) release in the striatum.
2
Rat striatal synaptosomes, preloaded with [ H]DA, were layered
onto glassfibre filters in perfusion chambers, washed with Krebs-
bicarbonate medium and repeatedly stimulated. The identity of the 
3
released [ H]DA was confirmed by HPLC, furthermore both basal and 
stimulated release were Ca^+-dependent.
2
Collection of small (340 Ml) fractions, and the use of [ H ] DA 
of high specific activity conferred high sensitivity on the system. 
K+ (16 - 60 mM) , veratridine (10 - 100 yM) and (-)-nicotine
3
(0.01 yM - 1 mM) evoked [ H]DA release in a dose-dependent manner.
The EC,_,- value for (-)-nicotine was 3.8 yM and a 100 fold 60
difference in the relative potency of (-)-nicotine to (+)-nicotine 
was demonstrated. Acetylcholine and the ganglionic agonists
1,l-dimethyl-4-phenylpiperazinium and cytisine were equipotent to 
(-)-nicotine. The pharmacological specificity of the nicotinic 
response was investigated using a range of antagonists. Neosuru- 
gatoxin, mecamylamine, pempidine and dihydro-3-erythroidine blocked 
the nicotinic facilitation, although a-BGT and decamethonium were 
less effective, suggesting that the nicotinic heteroreceptor shows 
characteristics of both ganglionic and neuromuscular nAChR. The 
nicotinic ion channel blockers perhydrohistrionicotoxin and 
ketamine also blocked the action of nicotine whereas tetrodotoxin 
was ineffective.
In parallel studies, synaptosomal membranes from striata were
shown to have nicotinic binding sites measured by the specific
3 125
binding of [ Hjnicotine and [ I]a-BGT.
3
Preliminary experiments measuring the release of [ H]ACh from 
hippocampal synaptosomes confirmed the presence of a nicotinic 
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"What is clear is that there is a mixture of stimulant and 
depressant properties at a variety of levels. These involve the 
central and peripheral nervous systems, the cardiovascular and 
endocrine systems. This complex of effects is further 
intermingled with personality and other variables that result 
in the complicated behaviour ... that is the phenomenon of 
tobacco smoking"
Domino, 1979.
Nicotine is a pharmacologically active alkaloid of the tobacco 
plant Nicotiana tabacum and has been used as a stimulating agent by 
man for centuries(Ashton and Stepney, 1983). The use of tobacco and 
its associated medical problems can be attributed to the addictive 
properties of nicotine(Ashton and Stepney, 1983).
Nicotine is readily absorbed from the stomach after oral 
administration and from the lungs after inhalation. Nicotine is 
soluble in both water and lipid and therefore rapidly penetrates 
the brain and all body organs. It is metabolised (with a half-life 
of 2 h) mainly in the liver and kidney and also the lung, to form 
cotinine and nicotine-1'-N-oxide. Nicotine and its metabolites are 
rapidly removed from the body by the kidney (Taylor, 1985a). 
However, when nicotine is present in the body many behavioural and 
pharmacological actions have been recorded such as increased motor 
activity, raised blood pressure and heart rate, the release of 
adrenaline from the adrenal glands, and increased tone and activity 
of the gastrointestinal tract (Taylor, 1985b). Nicotine therefore 
acts at many central and peripheral sites. Although the sites at 
which nicotine acts in the periphery have been characterised, 
relatively little is known about its sites of action in the brain.
This introduction describes how nicotine was first used in the 
classification of acetylcholine receptors and how within the 
peripheral nervous system there are two pharmacologically distinct 
types of nicotinic receptor. This is followed by a review of the 
present knowledge of the biochemistry of the nicotinic acetyl­
choline receptor purified from peripheral sources. Finally, an 
account is given of the evidence for nicotinic receptors in the 
central nervous system.
1.1.1 The classification of cholinergic receptors
In 1905, Langley reported that low doses of nicotine 
stimulated and high doses paralysed autonomic ganglia (Langley, 
1905). At about the same time as these observations the theory of 
chemical transmission was being developed. Ramon y Cajal (1888) 
proposed that nerve cells were discrete units, each enclosing its 
own cytoplasmic content and making close contact with each other. 
The theory of chemical transmission suggested that transfer of 
information from the neurone to a neuro-effector tissue (or between 
neurones) was achieved by the release of a chemical from the nerve 
terminal. This chemical then diffused across the gap between the 
nerve terminal and the effector tissue and combined with a recog­
nition site. The gap separating the neurone and effector tissue was 
termed the synapse (Sherrington, 1925) and the recognition site, 
after Langley (1907) 'a receptive substance', known later as 'a 
receptor'.
Otto Loewi (1921) in his classical experiments on the vagal 
nerve stimulation of perfused frog hearts, provided the first 
evidence for the actual release of a chemical in response to
activation of a nerve. The chemical (or neurotransmitter) released 
upon vagal stimulation was later identified as acetylcholine (ACh).
There are two distinct responses to ACh; those which are 
mimicked by nicotine, and those which are mimicked by muscarine 
(from'the mushroom Amanita musoaria; Dale, 1914). The response to 
nicotine is excitatory and although it was originally shown by Dale 
(1914) that muscarine responses were inhibitory, excitatory 
muscarinic responses have also been shown (see Krnjevic, 1975).
Under this original classification two types of cholinergic 
receptors were defined, nicotinic acetylcholine receptors (nAChR) 
and muscarinic acetylcholine receptors (mAChR). The action of 
nicotine is characterised by a fast resj&nse (1 - 2 ms) and is 
blocked by excess nicotine or by d-tubocurar'ine. In contrast, the 
muscarinic response tends to be slow in onset and prolonged 
(~ 100 ms) and is blocked by atropine.
1.1.2 Neuromuscular transmission
An early account of the molecular events of cholinergic 
transmission at the neuromuscular junction was provided by Katz 
(1966). Described below is a more recent account based on this 
work.
An action potential initiated in the cell body of a motor 
neurone passes along the axon and invades the nerve terminal. This 
temporary depolarisation of the nerve ending opens voltage-
P I p
sensitive Ca channels and leads to an influx of Ca +. The release 
of ACh is triggered either directly by the sudden increase in 
intracellular Ca2+ (Blaustein, 1979; Silinsky, 1985) or by a
calcium/calmodulin-dependent protein kinase (DeLorenzo, 1982). The 
excess Ca^+ is taken up by intracellular Ca^+ pools such as 
mitochondria or the endoplasmic reticulum and the final steady Ca^+ 
balance is re-established by means of a transmembrane Na+/Ca^+ 
exchange (Blaustein, 1979). The ACh released into the synaptic 
cleft diffuses across to the post-synaptic membrane and binds to 
the nAChR. This results in a conformational change in the receptor 
and the opening of an associated ion-channel. Na+ and K+ ions flow 
through the channel down their respective electrochemical 
gradients, with more Na+ ions passing in that K+ moving out, 
resulting in a net influx of positive charge. This local depolar­
isation produces an 'end-plate potential' (E.P.P.). If the 
summation of E.P.P.s causes depolarisation to the threshold value 
then an action potential is generated which is propagated along the 
muscle fibre and causes contraction. The 'quantal' theory of 
chemical transmission was formulated after the discovery of 
spontaneous miniature end-plate potentials (M.E.P.P.s; Katz, 1969). 
M.E.P.P.s are the result of the random release of 'packets' of ACh 
from the motor nerve terminal which interact with the receptors at 
the end-plate. Such packets, termed quanta, were considered to 
represent a discrete, minimum amount of ACh that could be released 
from the presynaptic terminal. The isolation of synaptic vesicles 
from nerve terminals (De Robertis et at., 1962; Whittaker et at. , 
1964) was taken in support of the quantal theory in that individual 
vesicles were considered to represent quanta but such speculations 
have never been substantiated experimentally. However, the exact 
mechanism of ACh release is still controversial and release is
considered by some groups to be from cytoplasmic rather than 
vesicular pools (Dunant and Israel, 1985).
Studies have also shown that there is another type of ACh
release at the neuromuscular junction. This release is Ca^+-
/
independent, non-quantal in nature and consists of molecular 
leakage of ACh from the nerve terminal (Katz and Miledi, 1977).
This efflux is not part of normal synaptic transmission and 
although it is quantitatively large its physiological role is 
unknown.
1.1.3 The vertebrate nervous system and the distribution of
cholinergic receptors
In the vertebrate, the nervous system is divided into two 
main parts, the central nervous system (CNS) comprising the brain 
and spinal cord, and the peripheral nervous system (PNS) which is 
made up of all the nervous system that is outside the CNS. The PNS 
is further subdivided into the somatic nervous system (which is 
made up of the voluntary motor nerves to skeletal muscle, and 
sensory nerves) and the autonomic nervous system which innervates 
the muscle, glands and blood vessels of the internal body organs. A 
further functional and anatomical subdivision of the autonomic 
nervous system can be made to define the sympathetic and the 
parasympathetic nervous systems. The main neurotransmitter in the 
sympathetic nervous system is noradrenaline whereas in the 
parasympathetic nervous system ACh is the major transmitter at the 
end organ.
6.
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Adrenal medulla_ _ ^  Ad and NAo-
AChAC It  
< o- Sweat glands
N(M)
Fig. 1.1. Location of cholinergic synapses in the nervous system.
N : Postsynaptic nicotinic receptors
M : Postsynaptic muscarinic receptors
Ad: Adrenaline release from adrenal medulla
NA: Noradrenaline release from sympathetic nerve
ending.
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Fig. 1.1 shows the main sites at which ACh acts in the 
vertebrate nervous system. These can be summarised as follows:-
1 . Autonomic effector sites, innervated by postganglionic para­
sympathetic fibres.
2. Sympathetic and parasympathetic ganglion cells and the adrenal 
medulla, innervated by preganglionic autonomic fibres.
3. Motor end-plates on skeletal muscle, innervated by somatic 
motor nerves.
4. Certain synapses within the CNS including the Renshaw cells in 
the spinal cord.
nAChR and mAChR are widely distributed throughout the nervous 
system. In general, muscarinic synapses are found mainly in smooth and 
cardiac muscle and brain. Different sub-classes of mAChR r have 
been defined pharmacologically (reviewed by Birdsall and Hulme,
1985) although all mAChR are activated by ACh and the muscarinic
agonist oxotremorine and are inhibited by the muscarinic antagonist
atropine.
1.1.4 The pharmacology of peripheral nAChR
Nicotinic synapses are found mainly at the neuromuscular
junction and in autonomic ganglia. The pharmacology of the receptor
at these two locations is different. In 1951, Paton and Zaimis
reported that nAChR at the neuromuscular junction and the ganglia
can be classified on the basis of antagonist selectivity to bis-
trimethy1ammonium salts, (CH ) N+ - (CH ) - N+(CH ) . Receptors in
o vj ^ n o o
ganglia show a peak antagonist action at n = 5 or 6 , whereas
receptors in the muscle show a peak when n = 10. This led to the
classification of ganglionic receptors as "CgM (sensitive to
hexamethonium) and neuromuscular receptors as "C^q " (sensitive to
decamethonium; Paton and Zaimis, 1951). Apart from this very
general classification there are also several other differences in
the pharmacology of the two receptors (reviewed by Koelle, 1975;
Brown, 1980; and Taylor, 1985a,b). However, most nicotinic
compounds act at both C_ and C,- nAChR, making the classification
o 1U
less well defined (see below).
Compounds which act at the nAChR may be divided into two 
groups.
I t Agonists - compounds which bind at the agonist binding 
site and activate the receptor.
II,Antagonists - compounds which prevent the action of 
agonists.
I. Agonists
Nicotine, ACh and choline esters are all agonists of peripheral
C„ and C._ receptors. Both C„ and C._ receptors are stereoselective 
o ±U o 1U
with respect to nicotine, the naturally occurring isomer
(-)-nicotine being more potent than (+)-nicotine (Barlow and
Hamilton, 1965).
There are also several agonists specific for C_ nAChR, ; theseo
include, 1,l-dimethyl-4-phenylpiperazinium (DMPP), lobeline, 
cytisine and coniine. DMPP is most commonly used as it is about 
three times more potent than nicotine (Taylor, 1985a).
The classification of agonists is complicated by the fact that 
in high doses ACh and nicotine block the action of the receptor 
(Taylor, 1985b) and in this respect ACh and nicotine behave as 
nicotinic antagonists. DMPP differs from nicotine in that much 
larger doses are required before blockade occurs (Taylor, 1985a). 
The depolarising agent decamethonium (originally used to charact­
erise neuromuscular receptors) has also been shown to act as a 
nicotinic agonist (e.g. Gardner et at., 1984).
Electrophysiological studies have been carried out mainly at 
the neuromuscular junction to study the opening and closing of the 
nAChR-ionophore in response to agonists, and hence the functioning 
of the receptor. When an agonist binds, the receptor is activated 
and the channel opens (Adams, 1975). However, prolonged exposure of 
the receptor to the agonist leads to receptor desensitisation (Katz 
and Thesleff, 1957) which results in the closing of the channel and 
an increase in the receptor's affinity for agonists (Weber, 1975). 
To explain these results a three state model of the receptor was 
proposed, each state possibly representing a different conform­
ational state of the receptor (reviewed by Changeux, 1981).
Three state model:
1. R, a resting state (channel closed, affinity for agonists low).
2. A, an activated state (channel open, affinity unknown)
3. D, a desensitised state (channel closed, affinity for agonist 
high).
However, more detailed studies have shown the need for at least a 
four state model of the receptor in which resting, open, fast-onset 
desensitised and slow-onset desensitised states are defined
10.
(reviewed by Changeux, 1984; Karlin et al., 1986).
R = resting state.
A = active state.
I = rapidly desensitised 
state
D - slowly desensitised 
state
The effect of noncompetitive blockers (see below) on ion flux and 
binding kinetics has provided further support for this allosteric 
four state model (Changeux, 1984).
II. Antagonists
Nicotinic antagonists may be divided into a) those which are 
non-depolarising blockers and b) those which are depolarising 
blockers.
a) Non-depolarising blockers
This group of compounds may be further subdivided into: 
i) Competitive inhibitors: compounds which compete with 
the agonist for the binding site and hence prevent the 
opening of the ion channel, 
ii) Noncompetitive inhibitors: compounds which prevent the 
activation of the nAChR but do not bind at the agonist 
binding site. These compounds inhibit the functioning of 
the receptor by one or more of three mechanisms:
1) stabilisation of the resting state;
D
Table 1.1. Summary of the classification of some nicotinic agents.
Type of Compound





































2) blockade of the open channel;
3) promotion of desensitisation.
(Changeux et a t 1984; Boyd and Cohen, 1984).
i) Competitive inhibitors
At the neuromuscular junction there are two well character­
ised competitive inhibitors, the a-neurotoxins and d-tubocurarine.
a-Neurotoxins: These are small polypeptides first purified by Chang
and Lee (1962) from the venom of the elapid and hydrophobid snakes.
An example is o-bungarotoxin (q-BGT) from Bungarus multicinctus
which binds with high affinity to nAChR at the neuromuscular
junction and hence causes paralysis of the victim. The binding of
some a-neurotoxins (e.g. from Naja naja siamensis venom) is readily
reversible whereas the reversibility of a-BGT takes several days
(Lee, 1972, 1979). These compounds have proved to be extremely
useful in the identification and purification of nAChRs (as will be
discussed later).
The failure of a-BGT to block C_ receptors has been reported
6
several times (see Brown, 1979). Recently, attention has been 
focused on Kappa-bungarotoxin (<-BGT),a neurotoxin isolated from 
the same venom as a-BGT (Grant and Chiapinelli, 1985). Unlike 
a-BGT, k-BGT has been shown to bind with moderate affinity to both 
Cg and C^q receptors(Grant and Chiapinelli, 1985).
d-Tubocurarine: Curare is a generic name for various South American 
arrow poisons. d-Tubocurarine is one of the pharmacologically 
active alkaloids which has been purified from curare 
and is a reversible competitive inhibitor at C receptors
(see Koelle, 1975). d-Tubocurarine has also been shown to be an 
antagonist at receptors (Ascher et at., 1979).
Dihydro-g-erythroidine (DH0E): DH3E is a potent derivative of the
alkaloid 3-erythroidine. At the neuromuscular junction DH0E is a 
competitive antagonist resembling d-tubocurarine. However, although 
originally classified as a neuromuscular blocking antagonist it has 
also been shown to be an antagonist of equal potency at cat ganglia 
(Megirian et at., 1955).
At ganglia, there is only one true competitive antagonist, 
neosurugatoxin.
Neosurugatoxin (NSTX): NSTX is a toxin isolated from the Japanese
ivory shell Babytonioa japonica (Kosuge et at., 1981; 1982). A
different compound called surugatoxin has been previously described
(Kosuge et at., 1972) although the potency of surugatoxin was later
found to be a result of contamination by neosurugatoxin (Kosuge
et at., 1982). NSTX is highly specific for C„ receptors and iso
ineffective at the neuromuscular junction (Hayashi and Yamada,
1975).
ii) Noncompetitive inhibitors
Classification of most non-depolarising antagonists is 
difficult, because many show both competitive and noncompetitive 
inhibition (see Brown, 1980). More recent studies have also shown 
that some 'competitive' ganglionic antagonists (e.g. hexamethonium)
may act at the ion channel rather than the agonist binding site 
(Rang, 1982; Gurney and Rang, 1984). The ganglionic antagonists 
(hexamethonium, mecamylamine and pempidine) have therefore been 
classified as noncompetitive inhibitors in Table 1.1.
A range of compounds has been shown to act as noncompetitive 
inhibitors at receptors (see Spivak and Albuquerque, 1982).
Some of these compounds are listed in Table 1.1. In the studies 
reported in this thesis two of these noncompetitive inhibitors were 
used; perhydrohistrionicotoxin (H^HTX) ketamine. Histrio- 
nicotoxin (HTX) is a spiropiperidine alkaloid originally isolated 
from the skin of the Columbian frog Dendrobates histrionicus 
(Daly et at., 1971). It acts as a noncompetitive inhibitor by 
blocking the ion channel of the nAChR. HTX has been shown to be 
effective at nAChR at the neuromuscular junction (Albuquerque 
et at. , 1973) and at those on adrenal medullary cells 
(Kilpatrick et at., 1981). The synthetic derivative H^HTX Qf 
equal potency as HTX (Spivak et at., 1982). The anaesthetic 
ketamine has also been shown to interact with the ion channel of 
the peripheral C ^  receptor (Maleque et at., 1981).
b) Depolarising blockers; e.g. Decamethonium
Decamethonium is a depolarising agent used in the original 
classification of C ^  receptors. However, it has also been shown to 
act as an agonist (e.g. Gardner et at., 1984) and causes desensi­
tisation (see Grundy, 1985). There is also evidence that addition­
ally decamethonium acts at ganglionic receptors by blocking the 
channel opened by cholinergic agonists (Ascher et at., 1979).
The pharmacological specificity of the nAChR has therefore been 
extensively studied. Electrophysiological studies have also 
provided information about the release of ACh at the neuromuscular 
junction and the functioning of the nAChR on postsynaptic 
membrahes. In contrast, our understanding of the biochemistry of 
the nAChR has only been developed over the last 15 years. The 
biochemist has taken advantage of the cholinergic system present in 
the electric fish (Torpedo genus) and electric eel (Electrophorus 
electrtcus). Present within these organisms are electric organs 
consisting of stacks of flattened, multinucleated cells arranged in 
prisms. The cells are known as electroplaques or electroplax and 
are phylogenetically derived from muscle cells (reviewed by 
Aronstam, 1982). All synapses within electric organs respond to ACh 
and have a purely nicotinic pharmacology which means that they are 
a rich source of nAChR.
With the use of the specific probes the a-neurotoxins, purifi­
cation of the nAChR has been possible. As a result the nAChR is the 
most widely studied and best understood neurotransmitter receptor 
(recently reviewed by Changeux, 1984; Dolly and Barnard, 1984; 
McCarthy et at. s 1986; and Hucho et at., 1986).
The next section summarises the present knowledge of the nAChR 
from Torpedo.
1.2 THE nAChR
1.2.1 A pentameric transmembrane protein
The nAChR from fish electroplaques has been isolated from 
detergent extracts using affinity chromatography with purified 
snake-venom neurotoxins as affinity ligands (Olsen et at,, 1972; 
Schmidt and Raftery, 1972; Klett et at., 1973). The total molecular 
weight of the receptor isolated from Torpedo is about 250,000. It 
is composed of four different subunits with apparent molecular 
weights of 40,000, 50,000, 60,000 and 65,000, designated a, B , y, 6 
respectively. Each subunit is a glycoprotein containing 4 - 7 %  
carbohydrate (Raftery et at., 1976) and the four different 
subunits are assembled to form a pentamer, ByS (Reynolds and
Karlin, 1978; Lindstrom et at., 1979; Raftery et at., 1980). 
Associated with these five polypeptides is a peripheral protein of 
molecular weight 43,000 on the cytoplasmic surface of the membrane 
(Sobel et at., 1977). This protein has been assigned a structural 
role (Barrantes et at., 1980) and possibly acts as a link between 
the membrane containing the receptor and the cytoskeleton (Porter 
and Froehner, 1983; Burden et at., 1983; Walker et at., 1984a).
The nAChR from Torpedo has been shown by sucrose density 
centrifugation to exist in two forms, a heavy (dimer) form and a 
light (monomer) form (Chang and Bock, 1977; Reynolds and Karlin, 
1978). The dimer results from the formation of a disulphide bond 
between the 6-subunits of two single receptors (Sobel et 
at., 1977; Suarez-Isla and Hucho, 1977). The nAChR isolated from 
mammalian muscle is of similar size to the Torpedo receptor but no 




Fig. 1.2. Quaternary configuration of the nAChR, determined by
3-D electron image analysis of tubular crystals grown from 
native Torpedo marmorata membrane vesicles (from Brisson 
and Unwin, 1985).
a) Receptor viewed from the top (looking from extracellular side). 
The receptor consists of 5 subunits (regions indicated by 
the dotted lines) equally spaced around a central pore 
thought to be the ion channel.
cytoplasm
b) Side view (through the channel axis) of the receptor. 
The central plane of the bilayer is indicated by the 
broken line.
From X-ray diffraction, electron microscope staining studies 
and immunological studies (Ross et al. , 1977; Klymkowsky and 
Stroud, 1979; Tarrab-Hazdai et al. , 1978; Strader et al., 1979) 
the Torpedo nAChR has been shown to be a transmembrane protein with 
its pblypeptides arranged in a circle around a central pore. The 
work of Brisson and Unwin (1985) has provided the most recent 
picture of the quaternary structure of the receptor (Fig. 1.2).
From these studies the receptor is seen to be highly symmetrical 
around the axis of the presumed pore, the protein extending above 
and below the lipid bilayer.
1.2.2 The primary structure of the subunits
Once the subunits of the Torpedo nAChR had been isolated 
attempts were made to sequence them (Devillers-Thiery et al. > 1979; 
Raftery et al., 1980). Total (100%) homology was found between the 
first twenty amino acids at the N-terminus of the a-chain from 
Torpedo marmorata and Torpedo calif omica. Homology (35 - 50%) was 
also shown between all four subunits in this region (Raftery 
et al. y 1980). However, complete sequences of the nAChR subunits 
were not determined using this method, instead the primary 
sequences were obtained using recombinant DNA techniques. A short 
stretch of known N-terminal amino acid sequence was used to con­
struct an equivalent DNA fragment so that it could be used as a 
32P-labelled probe to screen a cDNA library prepared from Torpedo 
electroplaques. Using similar techniques the cDNA sequences coding 
for the respective precursors of the a, 3, Y and 6 polypeptide 
chains of Torpedo calif omica have been determined (Noda, 1982; 
1983a; 1983b; Claudio et al. > 1983). The a-chain precursor of nAChR
from Torpedo marmorata has also been sequenced (Devillers-Thiery 
et al., 1983; Sumikawa et al., 1982).
The sequences of each chain show a high degree of homology 
(~ 40%). The a and 6 chains being more similar to each other them 
to Y'and 6 which in turn show more homology to each other than to a 
or 3. These results suggest that the genes for the four polypeptide 
chains may have originated from a pair of (and initially one) 
common ancestral genes (Raftery et al., 1980).
Once Torpedo nAChR subunit cDNA was available, it was used to
probe libraries prepared from human (Noda et al., 1983c), bovine 
(Noda et al., 1983c), chicken (Ballivet et al., 1982) and mouse 
muscle cell lines (Merlie et al., 1984).
Comparison of the a-subunit sequences from different species 
has shown that the AChR is highly conserved throughout evolution. 
Noda et al. (1983c) showed 97% homology between a-chains of human
and calf receptor and 80 - 81% homology between human and Torpedo °-
chains-. It was proposed that the a-subunit has evolved more slowly 
than the other subunits and that the pentameric structure a ^ Y 5 was 
established 550 - 690 million years ago (Kubo et al. 3 1985).
Using similar techniques a fifth polypeptide chain called e has 
recently been isolated from calf muscle (Takai et al.3 1985). The 
actual role of this e-subunit is not known but it has been 
suggested that it may replace the y-subunit at certain stages of 
muscle development (Takai et al. 3 1985).
1.2.3 Post-translational modifications
In Torpedo electroplaques.approximately 2.4% of the total 
messenger RNA (mRNA) codes for the nAChR (Mendez et al., 1980). As
mentioned above, translation of this mRNA results in precursors of
each subunit. These precursors contain a leader sequence of 17 - 24
amino acids which are mainly hydrophobic and are absent in the
mature subunit (Anderson and Blobel, 1981), suggesting that post-
transl'ational modification occurs. The requirement of cellular
components for the biosynthesis of functional nAChR was
demonstrated by the translation of mRNA isolated from Torpedo in
either a cell-free system (Mendez et al., 1980; Anderson and
Blobel, 1981; Sumikawa et al., 1981) or a Xenopus oocyte system
(Sumikawa et al. > 1981; Barnard et al., 1982; Mishina et al.,
1984). In the cell-free systems, although the individual subunits
for the receptors were identified,no receptor activity was
125observed, as shown by the lack of [ I ] a-BGT binding (Anderson 
and Blobel, 1981; Sumikawa et al., 1981). In contrast, when mRNA 
(either isolated from cells or synthesised in vitro using a cDNA 
template) was injected into oocytes, nAChR was synthesised, 
post-translational processing was carried out and functional 
receptors were inserted in the oocyte membrane (Sumikawa et al., 
1981). Following translation the native polypeptides are further 
processed (see Hucho, 1986). The four subunits are glycosylated 
(Mattson and Heilbronn, 1975; Raftery et al., 1976) and recent 
studies using site-directed mutagenesis (Mishina et al., 1985) have 
suggested that the N-glycosylation site at asparagine residue 141 
on the a-subunit is important for the assembly and function of the 
receptor. There is also evidence that all four subunits are 
phosphorylated (Vandlen et al., 1979), covalently linked to fatty 
acids (Olson et al., 1984) and methylated (Flynn et al., 1982;
21.
Nuske, 1986). However, the exact roles of these modifications
relating to receptor function have yet to be defined.
1.2.4 The ACh binding site
Although the four subunits show a large degree of sequence 
homology, they are not identical. It is only the a-subunits which 
carry a high affinity binding site for ACh, d-tubocurarine and
a-BGT (Karlin et at., 1986).
Identification of the ACh binding site was carried out using 
the sulphydryl affinity labelling reagents bromoacetylcholine 
(Br-ACh; Silman and Karlin, 1969) and 4-(N-maleimido)-benzyl tri- 
methylammonium iodide (MBTA; Reiter et at., 1972). These ligands 
bind covalently to SH groups at or near to the ACh site after 
reduction of sulphide bonds with dithiothreitol and hence prevent 
the binding of a-BGT. However, the two a-subunits are not equiva­
lent, one site on the receptor is easily labelled with the affinity 
ligands (Dalmle et al., 1978; Karlin, 1980; Wolosin 
et al., 1980) but high concentrations of affinity ligands and 
reducing agents are required to label the second site (Wolosin 
et al., 1980; Walker et al., 1984b). Kinetic binding studies have 
shown that a-BGT binds equally to each subunit (Lee, 1979) whereas 
d-tubocurarine shows a 300 fold difference in affinity for the two 
sites (Neubig and Cohen, 1979). This may be a result of differences 
in the post - translational modifications of the two subunits, 
alternatively, it may be a reflection of the different environ­
ments of the subunits within the receptor complex (Ratnam 
et al., 1986). Indeed recent evidence (Ratnam et al., 1986) has 






Fig. 1.3. Model of the predicted transmembrane organisation of the
a-subunit of the nAChR (Guy, 1984; Finer-Moore and Stroud,1984). 
Counting from the N-terminus the membrane spanning regions 
were named Ml, M2, M3, MA (or M5) and M4. The regions Ml,
2, 3, 4 are hydrophobic whereas MA is amphipathic (hydro- 
phobic groups along one face and hydrophilic groups along 
the other face of the helix).
Recent evidence (Mishina et al. t 1985) has shown that an 
N-glycosylation site (nl41) is important for the assembly 
and the function of the receptor.
In the a-subunit, the ACh binding site has been shown to 
be close to cysteine(192) which forms a disulphide bond 
with cysteine (193) (Kao et at. , 1984).
other; the one which is least glycosylated showing higher affinity 
for d-tubocurarine.
From analysis of the amino acid sequence of the a-subunit 
Numa et at,, (1984) proposed that the important disulphide bond 
present in the ACh binding site was the bridge formed between cys 
128 and cys 142. After this suggestion various models of the ACh 
binding site were proposed (e.g. White, 1985). However, studies by 
Kao et al. 3 (1984) revealed that it is the disulphide bond between 
the adjacent cysteine residues 192 and 193 which binds the affinity 
ligand MBTA. Similar experiments have shown that a-BGT and d-tubo­
curarine bind to fragments of the a-subunit which contain the cys 
192 and cys 193 residues (Wilson et al. s 1985; Neumann et al., 
1986). There is therefore increasing evidence that the N-terminal 
region containing cys 192 and cys 193 is the area to which ACh and 
competitive antagonists bind (see Fig. 1.3).
1.2.5 Models of the tertiary structure
The exact tertiary structure of the nAChR is still unknown 
because crystallisation and X-ray diffraction analysis of the 
receptor has not yet been possible. However, from the biochemical 
and biophysical information obtained so far, predictions of the 
arrangement of the a-polypeptide chain have been made (Noda 
et al. 3 1983c; Claudio et al. 9 1983; Devillers-Thiery et al.} 1983; 
Finer-Moore and Stroud, 1984; Gury, 1984).
Using Fourier and hydrophobicity analysis, Finer-Moore and 
Stroud (1984), and Guy (1984) predicted that each subunit contained 








Fig. 1.4. 3-D model of the nAChR from Torpedo calif omica (from
Lindstrom et al., 1984; Hucho, 1986).
The five polypeptide chains (a 8 y 6 ) span the membrane, 
each bearing oligosaccharide chains on the outer surface 
(zig-zag lines). However, the exact subunit arrangement 
is unknown (either the B or y subunit lies between the 
two a subunits). In Torpedo the receptor occurs in the 
light form (a^B Y <5 ) or as a heavy-form dimer resulting 
from the association of two light forms by 6 - 6 disulphide 
bridge. The receptors are cross-linked to membrane 
structural proteins (M.W. 43,000) which may link the 
receptor to the cytoskeleton.
The N-terminus of each polypeptide is on the extracellular 
surface and the C-terminus is probably intracellular, the 
polypeptide chain passing the membrane five times 
(see Fig. 1.3).
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helices (Fig. 1.3).These workers suggested that the MA region forms 
the wall of the proposed ion channel.
Monoclonal antibodies raised to specific domains of the 
receptor subunits have been used to verify the proposed secondary 
structure. Using such techniques Lindstrom et al. (1984) and 
Young et at. , (1985) showed that the C-terminus of the subunits 
was on the cytoplasmic side of the membrane.
However, although the model of Finer-Moore and Stroud and also 
Guy is widely accepted, the arrangement of the polypeptide chains 
and the number of membrane spanning regions is still controversial; 
recent immunological data suggest five (Young et at. , 1985) and 
even seven (Neumann et at., 1984; Criado et at., 1985) membrane 
spanning domains.
Other structural predictions have been the number and location 
of asparagine-linked glycosylation sites and the location of 
cys-cys disulphide bonds near the ACh binding site (Fig. 1.3).
Using all the information available, a 3-D model of the nAChR 
complex in the membrane bilayer has been proposed (see Fig. 1.4).
1.2.6 Biochemical evidence for a nAChR ionophore
Evidence for the ionophore being an integral part of the penta- 
meric a^3 Y <5 structure was obtained by experiments in which the 
purified AChR was reconstituted into vesicles (reviewed by McNamee
and Ochoa, 1982; Anholt et at., 1983). The function of the receptor
22can be assayed by either measuring agonist-induced influx of Na 
into the vesicles, or by measuring the opening and closing of the 
channels in individual receptors using patch-clamp techniques 
(Suarez-Isla et at., 1983).
Further evidence for an AChR ionophore was provided by the 
expression of functional receptor from cloned cDNAs in Xenopus 
oocytes (Mishina et al., 1984). Comparison of the channel 
activities of Torpedo and calf receptors (expressed on the surface 
of oocytes) showed that the response is species specific; the 
amplitude is the same but the response is longer for the calf nAChR 
(Sakmann et al., 1985). By taking a, 0, y subunit specific mRNA 
from Torpedo and 6-subunit specific mRNA from calf to form hybrid 
mRNA, Sakmann and co-workers showed that the resulting channel 
properties of the expressed receptor were characteristic of the 
calf type receptor. These results suggest that the 6 subunit plays 
a specific role in the gating of the ion channel.
These results, together with the predicted folding of the 
receptor polypeptides within the plasma membrane (see Figs. 1.3 and 
1.4) and the 3-D electron density image of the receptor (see Fig. 
1 .2 ) provide substantial evidence for the ionophore being an 
integral part of the receptor.
1.2.7 The binding sites for noncompetititve antagonists
The sites to which noncompetitive antagonists bind are still 
unknown and may be as diverse as their structures. A single high 
affinity binding site for noncompetitive antagonists per nAChR 
molecule has been suggested which is characterised by its 
sensitivity to HTX and may be related to the ion-channel 
(Heidmann et al., 1983; Oswald et al., 1983; Haring and Kloog,
1984). There are also low affinity binding sites for noncompetitive 
antagonists which are insensitive to HTX and possibly located away 
from the channel at the protein-lipid interface (Heidmann et al.,
1983). To gain more information about the binding sites for non­
competitive antagonists and the gating mechanism of the receptor 
ionophore, binding experiments have been carried out using photo­
affinity labelling. Using this technique the azido derivative of 
the local anaesthetic trimethisoquin was shown to preferentially 
bind to the 6 subunit of the receptor (Saitoh et at., 1980). Later 
studies using unmodified noncompetitive antagonists as photo­
affinity labels showed labelling of a, 3 and 6 subunits and using 
3 3 +
[ H]triphenylmethylphosphonium ( [ H]TPMP ) the binding was shown 
to be in the M2 region of the proposed arrangement of the poly­
peptide chain (see Fig. 1.3; Hucho, 1986). This area is not in the 
proposed channel-forming MA segment.
Hucho (1986) suggests that the region labelled by [ ^ H]TPMP+ may 
form part of the ion-channel which is consistent with the work of 
Taylor who has shown that noncompetitive antagonists bind at a site
4.8 nm away from the agonist binding site (see Fig. 1.2; Colquhoun,
1986).
1.2.8 Comparison of the nAChR from Torpedo and vertebrate muscle
Pharmacologically, the nAChR isolated from electric fish and 
vertebrate muscle show no major differences, they are both excited 
by ACh and specifically blocked by a-BGT (Changeux, 1981). Electro- 
physiological studies have also shown that the two types of recep­
tors are similar (Peper et at., 1982). The structure of the 
Torpedo nAChR has also been shown to be very similar to the 
receptor from vertebrate muscle using immunological techniques. 
Antisera and monoclonal antibodies raised against Torpedo nAChR 
cross react with antigenic determinants corresponding to the a, 6 ,
and <5 chains in rat, bovine and human muscle (Lindstrom et at., 
1978, 1979). The primary structures and molecular masses of the 
subunits are also similar but not identical (Kubo et at. 3 1985; 
Einiarson et at., 1982). The observed similarities between the two 
receptors is not surprising because electroplaque cells are evolved 
from embryonic striated muscle cells.
1.3 EVIDENCE FOR NEURONAL nAChR
In 1934, Dale proposed that ACh might act as a transmitter 
in the CNS, although there was no direct evidence. This was 
provided soon after by the identification of ACh and acetylcholin­
esterase in various regions of the CNS (see Krnjevic, 1975).
1.3.1 Electrophysiological studies
The existence of nAChR in the mammalian CNS has since been 
demonstrated by measurement of the excitatory responses of neurones 
following iontophoresis of ACh or nicotinic agonists (see Krnjevic, 
1975; Phillis, 1976). The excitatory action of nicotine has been 
recorded in most regions of the CNS but it is the Renshaw cell (in 
the spinal cord) which has often been the choice of study because 
it is a large and easily identifiable neurone. The characteristic 
feature of the nicotinic response is a quick excitation which is 
rapidly reversible and is prevented by ganglionic blocking agents 
(Krnjevic, 1975). It was also found that d-tubocurarine and related 
compounds were not useful nicotinic antagonists in the CNS because 
they excite many neurons.
More recent electrophysiological evidence for central nAChR 
displaying ganglionic pharmacology has been provided by McLennan 
and Hicks (1975), Lichtensteiger et at.. (1982) and Clarke et at. 
(1985b).
1.3.2 The use of a-BGT as a probe for neuronal nAChR
a-BGT has been an invaluable probe for the study of the 
nAChR from skeletal muscle and Torpedo electric organ. In the 
search for a central nAChR, a-BGT was therefore initially used as a
ligand. However, the suitability of a-BGT as a probe for a neuronal
nAChR has been questioned (Oswald and Freeman, 1981).
Electrophysiological studies showed that a-BGT can block
cholinergic retinotectal transmission in the toad (Freeman, 1977),
goldfish (Freeman et at., 1980) and frog sympathetic neurones
(Marshall, 1981). In contrast, a-BGT had no effect on transmission
in rat retinotract systems (Schmidt and Freeman, 1980), rat
cervical ganglion (Brown and Fumagalli, 1977) or chick ciliary
ganglion (Carbonetto et at., 1978; Kouvelas et at., 1979; Ravin and
Berg, 1979). a-BGT also failed to block synaptic transmission at
nicotinic cholinergic synapses in the frog spinal cord (Miledi and
Szczepaniak, 1975) and in Renshaw cells of the cat spinal cord
(Duggan et at., 1976).
125However, [ I]a-BGT binds with high affinity to rat brain
membranes (Schmidt et at., 1980) and the binding is saturable and
displaced by nicotinic agonists, but unlike the binding to
Torpedo or muscle nAChR it is more readily reversible (Schmidt
et at., 1980). The physiological relevance of a-BGT binding sites
has been questioned because it was found that some neurones contain
both a-BGT binding sites that are not functional nAChR,and,nAChR
that are activated by ACh but do not bind a-BGT (Patrick and
125Stallcup, 1977; Jacob and Berg, 1983). [ I]a-BGT has also been
shown to bind to structures which lack any cholinergic innervation
(Hunt and Schmidt, 1979), and to bind to extrasynaptic structures
(Ninkovic and Hunt, 1983; Loring et at., 1985).
1.3.3 Purification of an a-BGT binding component
Purification of an a-BGT binding protein from rat brain has
been difficult because of the low amount of binding sites (1.4 - 6
pmoles/g wet wt; see Schmidt et at., 1980) compared with the
relatively high amounts obtained from electric organs (e.g. from
125Torpedo marmorata 1720 pmoles [ I ]a-BGT sites/g wet wt; Eldefrawi 
and Eldefrawi, 1973). Nevertheless, using a-BGT as an affinity 
ligand early studies reported the purification of a-BGT binding 
components from goldfish brain (Oswald and Freeman, 1979), chick 
retina (Betz, 1981), chick optic lobe (Norman et at., 1982), mouse 
brain (Seto et at., 1981) and rat brain (Wonnacott et at., 1982).
In common with the peripheral nAChR, the brain a-BGT binding 
proteins are glycoproteins, they are soluble in non-ionic deter­
gents and there is indirect evidence that they bind the affinity 
alkylating agents MBTA and Br-ACh (Lukas and Bennett, 1980). These 
properties were initially taken as confirmation of their identity 
as the central nAChR. However, there were some major differences 
such as the sedimentation coefficient, the isoelectric point, 
subunit composition and the affinity for a-BGT (see Wonnacott 
et at., 1982). The a-BGT binding proteins were shown to be 
composed of one type of subunit (Seto et at., 1980; Norman 
et at., 1982; Betz et at., 1982). However, more recently Conti- 
Tronconi et at. (1985) have reported the purification of an a-BGT 
binding protein from chick optic lobe which contained three sub­
units with apparent molecular weights 48,000, 56,000 and 69,000, 
although the stoichiometry is unknown. N-terminal amino-acid 
sequencing showed that the 48,000 molecular weight component was 
highly homologous with the a-subunit of electric organ and muscle 
receptors. Unfortunately,sequencing of the other subunits was not 
possible because of N-terminal blockage. However, the 58,000
molecular weight subunit was also shown to resemble the a-subunit 
of the peripheral type receptor by its ability to be labelled with 
Br-ACh and cross-linked to a-BTX. All the subunits cross reacted 
with monoclonal antibodies directed against chick muscle receptor.
Further evidence for the brain a-BGT binding protein being 
related, but not identical to nAChR at the neuromuscular junction, 
was provided in the same year by Kemp et at. (1985) who showed 
that the a-BGT binding protein from rat brain was composed of three 
subunits of apparent molecular weights of 49,000, 53,500 and 
55,000. Two a-BGT binding sites were identified and it was the
55.000 molecular weight protein which bound the affinity ligand 
[3H ] MBTA.
These results are consistent with those of Conti-Tronconi 
et at. (1985) in that it is the subunit of molecular weight around
55.000 which has characteristics of the a-subunit from Torpedo or 
muscle nAChRs. This neuronal a-BGT binding subunit is also of a 
molecular weight similar to the single subunits originally isolated 
by Seto et at. (1980), Norman et at. (1982) and Betz et at.
(1982). The purification of additional subunits by the more recent 
studies may be a result of improvements in receptor purification 
techniques and the use of protease inhibitors (Conti-Tronconi
et at., 1985).
To compare the neuronal a-BGT binding sites with nAChR isolated 
from Torpedo or muscle, several immunological studies have been 
carried out. Cross reactivity between antisera to nAChR from 
Torpedo with the a-BGT binding component of rat brain has been 
shown (Block and Billiar, 1979; Wonnacott et at., 1982; Mills and 
Wonnacott, 1984). Antisera to receptor from denervated cat muscle
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and two monoclonal antibodies to receptors from chick muscle have 
also been shown to cross react to an a-BGT binding protein from 
chick brain (Norman et at., 1982; Mehraben et at., 1984). However, 
there have also been reports of no interaction between the 
a-bungarotoxin binding component purified from rat brain and 
antisera against nAChR from Torpedo (Morley et at., 1983).
1.3.4 Purification of other ligand binding proteins
Evidence for the existence of at least two distinct types of 
neuronal nAChR has recently been provided (Schneider et at. , 1985; 
Wonnacott, 1986; Whiting and Lindstrom, 1986). Using o-toxin 
affinity purification, high affinity [ H ] nicotine binding sites 
have been separated from a-BGT binding proteins in rat brain 
(Wonnacott, 1986), and by similar techniques high affinity [ h] ACh 
binding sites have been purified from chick optic lobe which are 
distinct from the a-BGT binding proteins (Schneider et at., 1985). 
Information about the subunit composition of the agonist binding 
components is not yet available although Whiting and Lindstrom (1986) have 
used monoclonal antibody affinity chromatography to purify a neuronal 
nAChR which is composed of two subunits, apparent molecular weights
48,000 and 59,000. This protein shows little structural homology to 
muscle nAChR but appears to be related to the high affinity [ H] 
nicotine binding sites in brain. The binding of [ H]nicotine is 
displaced by antibodies raised against the purified receptors and 
monoclonal antibodies to the purified receptor label brain sections
3
with the same pattern as [ Hjnicotine (Whiting and Lindstrom,
1986).
In the recent search for neuronal nAChRs, studies have been 
carried out using PC-12 cells, a tumour cell line derived from rat 
adrenal medulla. These cells have a-BGT binding sites which are not 
functional nAChR (Hall, 1986). Using cloning techniques, a cDNA 
clone was obtained from PC-12 cells which codes for a protein that 
is related (47% homology) to ,but different from, the a-subunit from 
muscle receptor (Boulter et at., 1986). Evidence for the cDNA clone 
encoding a neuronal type receptor was obtained by hybridisation 
studies. The clone did not bind to mRNA in normal or denervated 
muscle but hybridised to specific brain areas in the rat and to 
bovine adrenal medulla (Boulter et at., 1986). A large amount of 
labelling was also found in the area known as the medial habenula, 
an area to which nicotine and ACh,but not a-BGT bind (Clarke 
et at., 1985a). These results suggest that the PO-12 clone encodes 
a subunit which is distinct from the muscle nAChR a-subunit. 
Although the muscle a-subunit and the PC-12 subunit are probably 
products of two separate genes there are a number of similarities 
such as the presence of the four extracellular cysteine residues and 
the four hydrophobic regions and one amphipathic region. In view of 
these similarities one might expect the functioning of the 
receptors to also be comparable.
1.3.5 Comparison of the binding of radiolabelled nicotinic ligands
in rodent brain
The nicotinic ligands [125l]a-BGT, [3H]nicotine and [3H]ACh 
have been shown to specifically bind to rodent brain (Clarke 
et at., 1985a). Comparison of the regional distribution of binding 
of each ligand and the displacement of the binding by a range of
unlabelled cholinergic drugs has provided further information about 
central nAChRs. In view of the problems with ot-BTX as a probe for 
neuronal nAChR (see above) more recent studies have used tritiated 
nicotine and acetylcholine of high specific activity to study 
central agonist binding sites.
3
a) [ Hjnicotine
Saturable binding of [ H ] nicotine to rodent brain has been 
demonstrated and derivation of kinetic constants have yielded 
values ranging from 1 - 5 0  nM,consistent with a high affinity 
binding site (Yoshida and Imura, 1979; Romano and Goldstein, 1980; 
Marks and Collins, 1982; Costa and Murphy, 1983). There have also
3
been reports of two [ Hjnicotine binding sites, one of high and one 
of low affinity (Romano and Goldstein, 1980; Shershen et al., 1981; 
Yoshida et at., 1982; Costa and Murphy, 1983; Sloan et at., 1984; 
London et at., 1985a),although the specificity of the low affinity 
site has been questioned because it is often only observed when 
binding is carried out at 4°C (Marks and Collins, 1982) and it is 
not observed in the presence of protease inhibitors (Lippiello and 
Fernandes, 1986).
3
The high affinity [ Hjnicotine binding site is stereoselective, 
displaying a preference for the naturally occurring (-)-isomer (see 
Wonnacott, 1986). Recent evidence (Sloan et at., 1985; Abood 
et at., 1985) suggests that the two enantiomers of nicotine may act 
preferentially at different sites. It has therefore been proposed 
(Sloan et at., 1985) that (-)-[ Hjnicotine should be used in 
binding studies to avoid any spurious effects caused by the 
(+)-isomer.
3
High affinity [ Hjnicotine binding is displaced by cholinergic 
agonists (e.g. cytisine, DMPP and lobeline), but high concen­
trations (> pM) of the well established nicotinic antagonists (e.g. 
hexamethonium, mecamylamine) are required to displace the binding
(Romana and Goldstein, 1980; Marks and Collins, 1982; Costa and
125
Murphy, 1983). Although nicotine is able to displace [ l]a-BGT
3
binding, a-BGT is ineffective at displacing [ Hjnicotine binding 
(Marks and Collins, 1982; Rapier et at., 1985). The failure of many 
nicotinic antagonists to compete for the high affinity [ H Jnicotine 
binding site may be a result of the artificial situation, where the 
receptors are exposed to agonists for long periods and the receptor 
is converted to a desensitised form (Clarke et at,, 1985a). There
3
are however two antagonists which displace the high affinity [ Hj
nicotine binding: NSTX and DH0E. The ganglionic antagonist NSTX is
totally specific for the high affinity [ Hjnicotine site (Hayashi
et at,, 1984; Rapier et at., 1985; Yamada et at., 1985) and does 
125
not inhibit [ Ija-BGT binding (Rapier et at., 1985). The other
3
antagonist DH3E, is effective at displacing high affinity [ H J
nicotine binding (Clarke et at., 1984; Wonnacott, 1987) as well as 
125
[ IJa-BGT binding (Schmidt, 1977; Wonnacott, 1987).
b) [3HjACh
Characterisation of central nicotinic receptors has also
3
been studied by measurement of [ HjACh binding to rat brain 
membranes in the presence of excess atropine to block muscarinic 
receptors (Schwartz et at., 1982). [ HjACh binds to a single high 
affinity nicotinic receptor; the binding is displaced by 
cholinergic agonists such as nicotine and cytisine and displays
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stereoselectivity for (-)-nicotine (Schwartz et at., 1982). As
3 3observed for the [ Hjnicotine binding site, the [ HjACh recognition
site shows low affinity for most nicotinic antagonists except DI^E
(Schwartz and Keller, 1983).
More recently both high affinity and low affinity nicotinic
3
binding of [ H ]ACh to rat brain membranes has been demonstrated 
(Reulecke and Hucho, 1985), consistent with the reported high and
3
low affinity binding sites for [ H Jnicotine.
c) Other radiolabelled ligands
3
Williams and Robinson (1984) recently reported that [ H]
DHBE binds specifically to rat brain tissue and two binding sites
are identifiable, one of high affinity and one of slightly lower
affinity. The binding of this radiolabelled antagonist was
125displaced by nicotinic agonists but as in the case of [ I ]a-BGT,
3 3[ Hjnicotine and [ HjACh binding, nicotinic ganglionic antagonists
(mecamylamine, hexamethonium, pempidine) were ineffective at
displacing bound ligand. It was concluded that [ HJDHBE bound to a
nicotinic recognition site in the brain which was neuromuscular
rather than ganglionic in nature. This interpretation may be naive
particularly in the light of the reported equipotency of DH3E at
cat ganglia and muscle (Megirian et al., 1955).
[ H jTubocurarine has been shown to specifically bind to rat
brain membranes (Nordberg and Larsson, 1980) and display's similar
3binding constants and regional distribution binding as [ Hjnicotine 
(Larsson and Nordberg, 1985). However, the use of other radiolab­
elled antagonists to label central nicotinic sites has not yet been 
possible.
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d) Comparison of the regional distribution of radiolabelled 
ligand binding
Although [^Hjnicotine, [^HjACh and ["^^iJa-BGT bind to many
brain areas,a lack of correlation between the distribution of
agonist and a-BGT binding sites has been demonstrated (Marks and
Collins, 1982; Schwartz et al., 1982; Clarke et at., 1985a).There
is therefore substantial evidence suggesting that a-BGT and
nicotinic agonists do not necessarily label the same molecules.
This conclusion is supported by the recent purification of two
distinct proteins from rat brain (Wonnacott, 1986), one binding 
125 3
[ iJa-BGT and one which binds [ Hjnicotine with high affinity.
The evidence to date is therefore in favour of there being two
distinct agonist binding sites in rat brain and that a-BGT binds to
0
only one site which is possibly the low affinity [ Hjnicotine 
binding site (Wonnacott, 1986).
The binding of radiolabelled nicotinic ligands to rat brain 
membranes provides evidence for the presence of central nAChR. 
However, these studies give no information about the functioning of 
the receptors. Alternative studies have therefore been carried out 
to study the action of nicotine in the CNS.
1.3.6 The action of nicotine in the CNS
Many of the early side effects observed by people beginning
to smoke such as vomiting and irritability, may be attributed to
the central actions of nicotine(Ashton and Stepney, 1983). These
effects have been studied in the laboratory by the intravenous
injection of nicotine into experimental animals. Early studies 
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using [ C J nicotine showed that high levels of nicotine rapidly
appeared in the brain (reviewed by Aceto and Martin, 1982).
Nicotine stimulates all areas of the CNS producing increased levels 
of behavioural activity and may produce tremors and convulsions 
(Caulfield and Higgins, 1983; Nordberg and Sundwall, 1983). It is 
also capable of stimulating the vomiting and respiratory centres of 
the brainstem (Beleslin et at., 1983) and stimulates the hypo­
thalamus to release antidiuretic hormone resulting in the retention 
of fluid (Voile and Koelle, 1975). Other central effects include 
the improvement of learning and memory processes (Nordberg and 
Bergh, 1985) and the release of a range of neurotransmitters 
(reviewed by Aceto and Martin, 1982; Balfour, 1982).
The action of nicotine in the CNS is typically blocked by 
ganglionic antagonists (e.g. mecamylamine) which also penetrate 
centrally (Clarke et at. , 1985). There is therefore evidence for 
the presence of nAChR within the CNS with characteristics similar 
to the Cg nAChR. However, the functional significance of the 
central nAChR is not well understood.
The neurotransmitter releasing action of nicotine provides a 
system for the study of a ’functional' nAChR. Early studies by 
Westfall (1974a) showed that nicotine could evoke the release of 
noradrenaline from hypothalamic slices and dopamine (DA) from 
striatal brain slices, suggesting that nicotine had a direct effect 
on the nerve terminal.
The next section describes the evidence for the nicotinic 
regulation of transmitter release in the CNS and the experimental 
systems used to study a functional receptor.
1.4 PRESYNAPTIC REGULATION OF TRANSMITTER RELEASE
1.4.1 Presynaptic receptors
In 1961, Koelle showed that in sympathetic ganglia ACh 
facilitated its own release by acting at receptors on the terminals 
from vjhich it was released (Koelle, 1961). This demonstration 
provided the first evidence for functional presynaptic receptors. 
Since this early observation many different types of presynaptic 
receptors have been described (reviewed by Vizi, 1979; Langer,
1981; Starke, 1981; Chesselet, 1984).
Presynaptic receptors can be divided into two groups 
i) Autoreceptors; receptors which respond to the neuro­
transmitter released from the nerve terminal; and, 
ii) Heteroreceptors; receptors which are activated by neuro­
transmitters other than the native neurotransmitter 
released from the nerve terminal.
By definition, a presynaptic receptor is one which modulates 
neurotransmitter release and/or neurotransmitter synthesis (Lehmann 
and Langer, 1983). However, presynaptic receptors may not always 
be postsynaptic to another nerve cell e.g. in the striatum there is 
little evidence for axo-axonic synapses and it has been suggested 
that the interaction between ACh and DA terminals could occur by 
non-synaptic communication (see Bonanno et at., 1985).
Presynaptic receptors have also been categorised according to 
whether they operate mainly under a) resting as well as depolar­
ising conditions: Type I receptor-effector complexes (REC) or b) 
depolarising conditions: Type II REC (Lehmannand Langer, 1983).
This classification may also be used for receptors in addition to 
those on nerve terminals.
a) Type I REC
'' When these are activated a specific ion conductance is 
changed irrespective of the membrane's potential. They are present 
in muscle endplates, neuronal cell bodies and nerve terminals.
b) Type II REC
These typically act to regulate the conductance of ion 
channels which are opened in response to depolarisation (voltage- 
dependent ion-channels). In vitro depolarisation may be achieved by 
either field stimulation or by application of a high concentration 
of K . Type II REC are located on nerve terminals, cell bodies, 
smooth muscle and glands, and can modulate neurotransmitter 
release, rhythmic firing patterns in neurones and the force of 
muscle contraction.
Autoreceptors
The regulation of catecholamine release by presynaptic 
autoreceptors has received most attention (reviewed by Langer,
1981). The release of noradrenaline is modulated by inhibitory 
a^-adrenoceptors and facilitatory 3-adrenoceptors in a range of 
tissues in both the PNS and CNS. The release of DA in the CNS is 
subject to inhibition via presynaptic DA receptors.
In contrast, the presence of cholinergic autoreceptors is less 
well documented. In the PNS there is evidence for inhibitory 
muscarinic and facilitatory nicotinic autoreceptors in the
myenteric plexus (Briggs and Cooper, 1983). There is also evidence 
for inhibitory presynaptic muscarinic receptors in Torpedo electric 
organ (Dowdall et at., 1982). Recently, facilitatory nicotinic 
autoreceptors (Rowell and Winkler, 1984; Moss and Wonnacott, 1985; 
Beani'et al., 1985) and inhibitory muscarinic autoreceptors (de 
Belleroche and Gardiner, 1982; Raiteri et al. y 1984; Meyer and 
Otero, 1985) have also been shown to exist in the CNS. Of 
particular interest is the reported nicotinic regulation of ACh 
release in the hippocampus (Moss and Wonnacott, 1985). This will be 
considered in greater detail in Chapter 5.
Hetereoreceptors
The modulation of neurotransmitter release by hetereo­
receptors has also been extensively studied (reviewed by Starke, 
1981; Langer, 1981; Chesselet, 1984).
The release of DA in the area of the brain known as the 
striatum has been shown to be regulated by a range of 
neurotransmitters. However, in this thesis attention will be mainly 
focused on the evidence for cholinergic modulation of DA release.
1.4.2 The nigro-striatal pathway
The nigro-striatal pathway is a neuronal route formed 
between the substantia nigra and the striatum (Fig. 1.5). The 
striatum is made up of the caudate nucleus and putamen, and 
together with the globus pallidus, subthalamic nucleus and 
substantia-nigra the complex known as the 'Basal ganglia' is formed 
(reviewed by Heimer et al., 1985). Medically, the basal ganglia has 
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Fig. 1.5. Dopamine pathways in rat brain showing the 
Nigro-striatal tract.
disorders such as Parkinson's disease, Tardive dyskinesia and 
Huntington's chorea. The release of neurotransmitters and their 
regulation within the basal ganglia has therefore been an area of 
particular research.
The major neurotransmitter in the nigro-striatal pathway has 
been shown using histochemical and fluorescence techniques to be DA 
(Anden et at., 1964). The striatum therefore contains a dense 
network of dopaminergic nerve terminals. The striatum also receives 
inputs from several other regions of the brain (see Graybiel and 
Ragsdale, 1983) and is therefore rich in many different neuro­
transmitters. Another major transmitter in the striatum is ACh, 
which has been shown to originate from cholinergic interneurones 
(McGeer et at., 1975) which are distributed throughout the 
striatum.
DA-ACh interactions in the striatum are well documented (Lehmann 
and Langer, 1983) and there is substantial evidence that DA plays a 
role in the regulation of ACh release and likewise ACh plays a 
significant role in the regulation of DA release.
1.4.3 Experimental procedures used to study the release of DA
The synthesis of DA and the regulation of its release from
the nerve terminal are summarised in Figs. 1.6 and 1.7.
To study DA uptake and modulation of its release from the nerve
terminal, striatal DA pools have been labelled directly using 
14 3
either [ C ] or [ H]DA, taking advantage of the high affinity uptake
O
process (Holz and Coyle, 1974). Alternatively, the precursor [ H] 
tyrosine has been used,in which case [ H]DA is synthesised within 
the terminal.
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(a) Tyrosine hydroxylase 
(E.C. 1.14.6.2)
(b) Aromatic L-amino acid decarboxylase 
(E.C. 4.1.1.28)
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Fig. 1.7. Regulation of the release of DA from the nerve 
terminal.
DA is synthesised from tyrosine (via L-Dopa) which 
is either stored in synaptic vesicles (1 ) or 
remains as a cytoplasmic pool. Upon arrival of 
the action potential, DA is either released 
from the cytoplasm (2 ), being metabolized by 
mitochondrial MAO to form DOPAC,or released 
from synaptic vesicles (3).
In the synaptic cleft DA either activates pre­
synaptic autoreceptors (4), is taken up into 
the presynaptic terminal (5), metabolised 
by the combined action of MAO and COMT, to 
form 3-methoxytyramine (MT) and HVA (6 ) or 
interacts with the postsynaptic DA receptors (7)
MIT - mitochondrion 
SV - synaptic vesicle
->HVA
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Fig. 1.7.Regulation of the release of DA from the nerve 
terminal.
a) Measurement of released transmitter
Two main types of experimental procedures have been used to 
monitor the efflux of radiolabelled transmitter in response to 
stimulation; i) static incubation, and ii) perfusion (superfusion). 
Static incubation has been employed by several groups (e.g.
Futerman et at,, 1982; Connelly and Littleton, 1983) but the method 
has been criticised because it is not possible to completely 
prevent the reuptake by the tissue of the released transmitter 
(Raiteri et at,, 1974); this makes the interpretation of the 
release data difficult. In preference, the method of perfusion is 
usually now used. Perfusion involves the continuous washing of the 
tissue (either preloaded with radiolabel, e.g. de Belleroche and 
Bradford, 1978; Lehmann and Langer, 1982, or the continuous 
perfusion with radiolabel, e.g. Giorguieff et at., 1976, 1977,
1979) and the collection of serial fractions of the effluent. 
Administration of stimulating and blocking agents into the main 
flow is relatively easy and reuptake of the released transmitter is 
less likely than in the static incubation system. Perfusion studies 
have been carried out in situ (e.g. Giorguieff et at., 1976, where 
perfusion of cat striata was carried out through a push-pull 
cannula) or in vitro using a) slice preparation (e.g. Giorguieff 
et at., 1976; Lehmann and Langer, 1982) or b) a synaptosomal 
preparation (e.g. de Belleroche and Bradford, 1978; Mills and 
Wonnacott, 1984).
b) Slice preparations
Many studies using brain slice preparations have been 
carried out after the work of Mcllwain;(1961) who developed
a technique of slicing the brain to produce preparations which were 
viable for several hours. Brain slices can be prepared either by 
hand or mechanically and ideally should not be thicker than 
0.35 mm. They are highly organised structures containing both 
neuronal and non-neuronal cells. They have several advantages, 
including their ability to be electrically stimulated and be used 
in electrophysiological studies. The application of brain slices to 
cholinergic biology has been reviewed by Weiler et al. (1982). 
Their use in the study of the cholinergic modulation of DA release 
in the striatum is summarised in Table 1.2.
c) Synaptosomal preparations
When brain tissue is homogenised, presynaptic nerve termin­
als are detached and form sealed structures known as "synapto- 
somes". These subcellular particles were originally isolated by 
density gradient centrifugation techniques (Gray and Whittaker,
1962; De Robertis et al., 1962).
Synaptosomes have several morphological characteristics; they 
appear in section as membrane-bounded oval profiles about 0.5 - 
2 pm in diameter containing numerous vesicles, small mitochondria 
and in many cases an attached postsynaptic membrane (reviewed by 
Jones, 1975; Whittaker, 1984). Synaptosomes are of particular value 
because they survive the homogenisation and centrifugation 
procedures and remain in iso-osmotic medium as active metabolic 
units for several hours (Bradford et al., 1975). Normal ionic 
gradients are maintained across the membrane and the synaptosomes 
display the ability to synthesise and store transmitter substances.
A synaptosomal preparation is therefore particularly useful in the
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study of presynaptic neurochemical events.
There are several advantages and disadvantages in using either 
a slice or synaptosomal preparation for the study of the 
presynaptic regulation of transmitter release. These will be 
discussed later (p.181 ).
1.4.4 Presynaptic modulation of DA release in the striatum
a) Autoreceptors
The activation of DA autoreceptors results in an inhibition 
of the released DA. These autoreceptors typically act under 
depolarising (either electrical or K+-evoked) conditions (e.g.
Arbi11a and Langer, 1984) and are therefore Type II REC (after 
Lehmann and Langer, 1983). The mechanism by which they act has 
recently been shown to involve the inhibition of tyrosine 
hydroxylase activity (El Mestikawy et at., 1986).
b) Cholinergic heteroreceptors
Early evidence for the regulation of DA release from the 
striatum by ACh was provided by Besson et at. (1969) who
demonstrated that at a low concentration ACh (10 nM) stimulated the
3 3release of [ H]DA synthesised from [ H]tyrosine in the isolated
striatum. Since then there have been many similar demonstrations
(see Table 1.2). However, the type of response (either facilitatory
or inhibitory) caused by either nicotinic or muscarinic agents was
controversial. It was generally found that nicotinic agents
enhanced DA release in either stimulated or unstimulated tissue
(e.g. Sakurai et at., 1982). Facilitatory nicotinic receptors are
therefore clearly present on the dopaminergic nerve terminals and
Table 1.2. Summary of the evidence for the cholinergic modulation of DA release in the striatum using perfusion techniques 
Enhancement by agonist of either basal or stimulated release (t), reduction (+) and no effect (x).
Level of antagonism, complete (/), partial (''■') or ineffective (X)
Preparation







SLICE Basal Nicotine (5 mM) Hexamethonium (9.3 pM) Westfall (1974a)
Basal Nicotine (100-1000 pM) 
DMPP (50-750 m M)
+
Hexamethonium (10 pM)
ND Westfall et al. (1983a)
Basal ACh (10 mM) Mecamylamine (10 pM) Giorguieff et al. (1976)
Basal ACh (10 pM) + Pempidine (10 pM) Giorguieff et al. (1977)
Basal Nicotine (1 pM) + Pempidine (10 pM) 
d-tubocurarine (5 pM)
/ Giorguieff-Chesselet et al. 
(1979)
Basal Nicotine (1 mM) + ND Arqueros et al. (1978)
Basal
Basal




Hexamethonium (0.3 mM) X
ND
Marien et al. (1983) 
Arbuthnott et al. (1984)
SYNAPTOSOMAL K+ (56 mM) ACh (0.3 mM) t Hexamethonium (0.2 mM) 
a-BGT (0.188 pM)
de Belleroche and Bradford 
(1978)
Basal Nicotine (200-500 pM) 
ACh (500 pM)










Sakurai et al. (1982)
■' K+ (25 mM) Lobeline (50 pM) t ND Sakurai et al. (1982)
Basal Nicotine (100 pM) t Mecamylamine (100 pM) / Mills and Wonnacott (1984)
PUSH-PULL CANNULA Basal ACh (10 jpiM) t Hexamethonium (IO^aaM) 
Mecamylamine (10y4M)
Giorguieff et al. (1976)
Table 1.2 (continued)
Preparation







SLICE Nicotine (5 mM) ACh (10 pM) i ND Westfall (1974a)
K+ (50 mM) ACh (1-10 pM) + ND Westfall (1974b)
» Electrical ACh (1-100 pM) ND Westfall (1974b)
» Basal ACh (10 pM) ♦ Atropine (1 pM) Giorguieff et al.
Scopolamine (1 pM) (1977)
" Basal Oxotremorine (lOpM) t Atropine (1 pM) V Giorguieff et al. (1977)
Electrical Oxotremorine (1.8-10 pM) t Atropine (0.1 pM) / Lehmannand Langer (1982)
SYNAPTOSOMAL K+ (56 mM) ACh (0.3 mM) + Atropine (0.129 mM) de Belleroche and Bradford
(1978)
Basal Oxotremorine (20 pM) X Sakurai et al. (1982)
K+ Oxotremorine (50 pM) X Sakurai et al. (1982)
K+ (15 mM) ACh (10 pM) t Atropine (0.1 pM) / Raiteri et al. (1982)
can be classified as 'Type I REC' (after Lehmann and Langer, 1983). 
ACh evoked transmitter release was partially blocked by 
mecamylamine, pempidine, hexamethonium, a-BGT and d-tubocurarine 
(Giorguieff et at., 1976; de Belleroche and Bradford, 1978; 
Sakurai' et at., 1982) whereas nicotine evoked release was 
completely blocked by pempidine, and mecamylamine (Giorguieff- 
Chesselet et at., 1979; Mills and Wonnaeott, 1984) and partially 
blocked by hexamethonium (Westfall, 1974a).
The inability of nicotinic antagonists to completely block the 
release evoked by ACh suggested the possibility of facilitatory 
muscarinic receptors on dopaminergic nerve terminals. The reported 
action of muscarinic agonists on the release of DA is mixed 
(Westfall, 1974a,b; de Belleroche and Bradford, 1978; Giorguieff 
et at., 1976) and the differences are dependent upon the 
experimental conditions employed. Westfall (1974a,b), and de 
Belleroche and Bradford (1978), looked at the effect of ACh on 
stimulated release of transmitter from striatal slices and both 
reported that muscarinic receptors were inhibitory. In contrast, 
Giorguieff et at. (1977) reported that ACh evoked the release of
3
[ H]DA from unstimulated slices and that this was partially blocked 
by the muscarinic antagonists atropine and scopolamine, suggesting 
that muscarinic receptors were facilitatory. More recent studies
have shown that activation of muscarinic heteroreceptors by ACh
+ 3potentiates stimulated (electrical or K evoked) release of [ H]DA
(Lehmannand Langer, 1982; Raiteri et at., 1982). Muscarinic hetero­
receptors therefore fall into the category of 'Type II REC'. The 
facilitatory effect of ACh on [ H]DA release was also shown to be 
dependent upon the concentration of K+ used to depolarise the nerve
endings. Raiteri et al. (1984) reported an optimum concentration of 
15 mM should be used. This may explain the discrepancies in the 
literature concerning the influence of ACh on DA release (mentioned 
above), where high concentrations of K+ (56 mM) were used by de 
Belleroche and Bradford (1978) and a high depolarising nicotine 
concentration (5 mM) by Westfall (1974a). Besides enhancing 
stimulated [ H ]DA release, muscarinic agents have also been shown 
to increase the basal (spontaneous) release of newly synthesised 
pH ]DA (Giorguieff et al., 1977). This contradicts the classifi­
cation of these receptors as type II REC and emphasises the 
limitations of this general classification. That muscarinic 
heter oreceptors may be stimulated by endogenous levels of ACh was 
shown by the reduction of evoked release of DA when muscarinic 
antagonists in addition to anticholinesterases were present (Lehmann 
and Langer, 1982). In this type of experiment, electrical 
stimulation evokes the release of transmitter from all nerve 
terminals and therefore it is not surprising that the levels of ACh 
reach a level which will activate muscarinic receptors. However, 
under similar conditions activation of nicotinic receptors was 
inferred not to occur by the lack of effect of d-tubocurarine on 
evoked release (Lehmannand Langer, 1982), although antagonism of 
nicotinic responses in the CNS by d-tuboburarine has not been 
convincingly demonstrated (Krnjevic, 1975).
There are therefore several problems in studying muscarinic and 
nicotinic events separately, using ACh as an agonist, and a 
heterogeneous population of nerve terminals. For example, when 
atropine is used as a muscarinic antagonist both muscarinic 
heteroreceptors on dopaminergic nerve terminals and inhibitory
muscarinic autoreceptors on cholinergic nerve terminals will be 
blocked. This will lead to an increase in the concentration of ACh 
which will activate nicotinic receptors on dopaminergic nerve 
terminals leading to an increase in DA release. To completely block 
the action of ACh it is therefore necessary to have both nicotinic 
and muscarinic antagonists present (Giorguieff et al., 1977).
Overall, the results from both types of release study in vitro 
(synaptosomal and slice) have been similar (see Table 1.2). From 
the experiments in situ there is also evidence for a nicotinic 
facilitatory mechanism (Giorguieff et al., 1976) although a 
muscarinic involvement has yet to be demonstrated. There is however 
indirect evidence for a muscarinic effect as muscarinic agents have 
been shown to increase DA turnover in the striatum (Westerlink and 
Korff, 1976).
Although the use of a synaptosomal preparation strongly 
suggests that the regulatory cholinergic receptors are present on 
the dopaminergic nerve terminals, in a slice preparation where 
there are many neuronal interconnections, the exact location of the 
receptors is less clear. Perfusion in the presence of TTX, a 
specific inhibitor of the voltage sensitive sodium channel 
(discussed later in Section 3.3.4c) showed that the action of 
cholinergic agents was independent of the activity of the nerve 
(Giorguieff et al., 1977) and suggested that the cholinergic 
receptors modulating DA release in a slice preparation were 
situated at the nerve terminal.
Further evidence for a presynaptic location of nicotinic
receptors on dopaminergic nerve terminals was shown by measurement
125of a reduction in [ I ]a-BGT binding sites in the striatum
following 6-hydroxydopamine-induced lesions of the nigro-striatal
3
pathway (de Belleroche et al., 1979). More recent studies using [ H]
3
ACh (Schwartz et al., 1984) and [ Hjnicotine (Clarke and Pert,
1985) as binding ligands have confirmed this finding. Although a
decrease in muscarinic sites has also been shown using a similar
/
approach, the evidence for a presynaptic location is less
convincing (Chesselet, 1984).
To summarise, it has been shown that both muscarinic and
nicotinic cholinergic receptors are present on dopaminergic nerve
terminals in the striatum and they play a facilitatory role in the
regulation of DA release. The nicotinic regulation of DA release
therefore provides a system to study functional nAChR. However, the
pharmacology of this regulation is not clear; both C_ and C1(_o 10
nicotinic antagonists have been reported to inhibit the action of 
nicotinic heteroreceptors (see Table 1.2).
The aim of this project was to develop a perfusion system which 
could be used to study the nicotinic regulation of striatal DA 
release in more detail. A synaptosomal preparation was chosen 
instead of a slice preparation so that the regulation of 
transmitter release at the nerve terminal could be studied without 
the possible involvement of striatal interneurones. To monitor the 
release of DA the striatal synaptosomes were preloaded with [ H]DA.
[ H ]Tyrosine was not used because this would require isolation of the DA 
from the perfusate.
The following chapter describes the characterisation of the 
striatal synaptosomal preparation and the optimisation of the DA 
uptake conditions. The subsequent chapter then summarises the 
development of a sensitive perfusion system in which synaptosomes
may be repeatedly stimulated using micromolar concentrations of
nicotinic agonists. The revised system was then used to study the
+ 3effect of nicotinic antagonists on agonist and K -evoked [ H ]DA 
release. Finally, for comparison the nicotinic autoreceptor present 
on c h o l i n e r g i c  hippocampal nerve terminals was studied by the 
perfusion of hippocampal synaptosomes preloaded with ['"'H Jcholine.
MATERIALS
Chemicals
Unless otherwise stated below, all general reagents were 
supplied by either BDH (Poole, Dorset, U.K.), Fisons (Loughborough, 
Leicestershire, U.K.) or Sigma Chemical Company Ltd. (Poole,
Dorset, U.K.).
Lobeline hydrochloride, l-l-dimethyl-4-phenylpiperazinium and 
diphenylborate-ethanolamine were from Aldrich Chemical Co. Ltd. 
(Gillingham, Dorset, U.K.).
Cytisine was from Koch-Light Laboratories Ltd. (Colnbrook,
Berks, U.K.).
Tetraoctylammonium bromide was obtained from Fluorochem Ltd. 
(Glossop, Derbyshire, U.K.).
(-)-Nicotine hydrogen (+)-tartrate was from BDH (Poole, Dorset, 
U.K.).
a-Bungarotoxin was obtained from Boehringer Corporation (Lewes, 
Sussex, U.K.).
Acetylcholine chloride, carbamylcholine chloride, choline 
chloride, decamethonium bromide, 3,4-dihydroxyphenylethylamine 
hydrochloride (dopamine), homovanillic acid, hexamethonium bromide, 
lactate dehydrogenase (E.C. 1.1.1.27), L-nicotine, oxotremorine, 
pargyline, tetrodotoxin, D-tubocurarine chloride and veratridine 
were from Sigma Chemical Company Ltd. (Poole, Dorset, U.K.).
Drugs which were gifts
Chlorisondamine from Dr. I. Stolerman, Institute of Psychiatry, 
(London, U.K.).
Dihydro-g-erythroidine hydrobromide from Dr. Benifeld, Merck, Sharp
and Dohme Research Lab. (Hertfordshire, U.K.).
Ketamine from Parke, Davis and Co. (Cambridge, U.K.).
Mecamylamine hydrochloride from Dr. Caulfield, Glaxo Group Research 
Ltd. (Greenford, U.K.).
Neosui/ugatoxin from Professor T. Kosuge, Shizuoka College of 
Pharmacological Sciences, (Shizuokay, Japan).
(+)-Nicotine di (-)-tartrate from Dr. R. Barlow, University of 
Bristol (Bristol, U.K.).
Nomifensine maleate from Dr. Schone, Hoechst (Frankfurt, Germany). 
Pempidine tartrate from Mrs. Adams, May and Baker Ltd. (Dagenham, 
Essex, U.K.).
Perhydrohistrionicotoxin from Dr. E.X.Albuquerque, University of 
Maryland (Baltimore, U.S.A.).
Stock Solutions
Dihydro-B-erythroidine hydrobromide (25 mg) was dissolved in 
1.82 ml ethanol (95%) to give a final concentration of 50 mM. This 
solution was stored at 4°C.
Veratridine was dissolved in 50% ethanol to give a final
concentration of 20 mM and stored at 4°C.
Ketamine was dissolved in water to give a concentration of 10 mM 
and stored at 4°C (Maleque et at., 1981).
Tetrodotoxin (TTX, 1 mg + 5 mg sodium acetate) was carefully 
dissolved in water to form a 1 mM solution. Aliquots (100 pi) were
stored at -80°C until required.
a-Bungarotoxin (a-BGT, 1 mg) was dissolved in the appropriate 
buffer to a concentration of 1 pM and stored at -20°C in 100 yl 
aliquots.
Pure crystalline neosurugatoxin (250 Mg) was dissolved in 0.12 
ml dimethylsulphoxide and diluted with 2.88 ml water to give a 0.1 
mM solution (Kosuge et at., 1982). Aliquots (50 Ml) were stored at 
-80°C until required.
Perhydrohistrionicotoxin dissolved in 0.1 ml ethanol to 10 mM 
was stored in 20 Ml aliquots at -80°C.
Storage and dilution of Pharmacological agents for perfusion 
experiments
All drugs were stored at 4°C (unless otherwise stated). Each 
drug was dissolved in perfusion medium (p.135 ) and the pH adjusted 
to 7.4 if necessary. Concentration ranges of drugs were obtained by 





[7,8- H] Dopamine (46 Ci/mmol) was obtained from Amersham 
International (Amersham, Bucks, U.K.). It was diluted 1:1 with
2.5 mM ascorbic acid and stored at -20°C in 50 yl aliquots.
[^HjCholine
Methyl-pHJcholine chloride (78 Ci/mmol) was supplied by 
Amersham International (Amersham, Bucks, U.K.). It was diluted 1:1 
with 20 pM choline chloride and stored at -20°C in 100 pi aliquots.
[^HjNicotine
(+/-) N-methyl-pH]nicotine (73.7 Ci/mmol) was purchased from 
NEN Radiochemicals Ltd. (Southampton, Hants, U.K.) and stored in
ethanol at -20°C.
[■*■^ 1 ] a-Bungarotoxin
a-Bungarotoxin (a-BGT) was iodinated in the laboratory
following the method of Wonnacott et al., (1980), using 
125
carrier-free Na [ I] obtained from Amersham International
(Amersham, Bucks,U.K.). Using this method about 80% of the
125iodinated toxin was the mono derivative. [ I]a-BGT was stored at 
4°C for not longer than 3 weeks.
Other Materials
Glass fibre filters were from Whatman Biochemicals Ltd. 
(Maidstone, Kent, U.K.). Aqua Luma was from LUMAC B.V., (Ad 
Schaesberg, The Netherlands). Optiphase Safe was from LKB 
Instruments (South Croydon, Surrey, U.K.). Picofluor TM30 and 
Emulsifier 299TM were from Packard Instruments Ltd. (Pangbourne, 
Berks, U.K.). Perfusion apparatus (see p.136).
CHAPTER 2 
PREPARATION AND CHARACTERISATION OF 
RAT BRAIN STRIATAL SYNAPTOSOMES
2.1 INTRODUCTION
Traditional methods for preparing synaptosomes take almost 3 h 
(Gray and Whittaker, 1962) although many modified procedures have 
since been described (reviewed by Jones, 1975; Gibson and Blass, 
1982);' The method used in the work described in this thesis was 
based on that of de Belleroche and Bradford (1980) which takes 
approximately lV2 h. However, the procedure was modified (as 
reported in Section 2.2.1) so that the process consisted of just 
one high speed centrifugation step (1 h) followed by a low speed 
wash (7 min). The purity of the synaptosomal fraction was assessed 
by electron microscopy using both negative and positive staining 
techniques. To determine the integrity of the synaptosomal 
preparation the cytoplasmic enzyme marker lactate dehydrogenase
3
(E.C. 1.1.1.27) was assayed and the high affinity uptake of [ H]DA 
was measured,confirming the presence of dopaminergic nerve endings.
3
The conditions for loading the striatal synaptosomes with [ HjDA 
were then studied to ensure optimum usage of tissue, radiolabel and 
time.
3 125The subcellular distribution of [ H ]nicotine and [ l]a-BGT
binding sites was also determined to demonstrate that nicotinic
binding sites are enriched in striatal nerve terminal preparations.
2.2 METHODS
2.2.1 Preparation of synaptosomes
Male Wistar rats weighing 150-200g were killed by decapitation. 
The brains were rapidly removed and placed on filter paper moistened 
with ice cold 0.32 M sucrose, pH 7.4. The striata were dissected out 
following the method of Glowinski and Iversen (1966; Fig 2.1). Striata 
from 2 rats (70-90 mg wet wt) were homogenised in 0.32 M sucrose, pH 
7.4, 10% (w/v), in a precooled glass-teflon homogeniser (clearance 
0.31 mm) by 12 up and down strokes at 200 rpm in a time of 30 s. The 
homogenate was diluted with 0.32 M sucrose to approximately 4 ml and 
layered onto two discontinuous sucrose gradients prepared from 1.2 M 
sucrose (2 ml) overlaid with 0.8 M sucrose (2 ml) The gradients were 
centrifuged in a Beckman L5-50B ultracentrifuge equipped with a SW50.1 
rotor, at 100,000 g for 1 h at 4°C. After centrifugation the band at 
the 0.8 M/1.2 M sucrose interface (Fig 2.3, p. 78 ) was removed using a 
Pasteur pipette and slowly diluted (to avoid lysis of the 
synaptosomes) with an equal volume of perfusion medium (p.135). The 
diluted synaptosomal preparation was centrifuged in an MSE bench 
centrifuge at 1,000 <7 for 7 min at room temperature and the resulting 
pellet resuspended in perfusion medium, (1 ml medium/100 mg wet wt. 
original tissue).
2.2.2. Preparation of subcellular fractions for electron microscopy
a) Positive staining
Striata from 3 rat brains were homogenised and fractionated as
described above. The 2 gradient bands (P and PL see Fig. 2.3) and the
a b
pellet (P ) were gradually diluted with 0.32 M sucrose followed by 






JL. Diagrammatic representation of the dissection 
procedure for rat brain following the method of 
Glowinski and Iversen (1966). Dotted line 
(A) indicates the position of section to 
reveal the striata. The hippocampus was 
dissected by pulling away the cerebral cortex 
from the mid line (B).
Opposite are photographs showing the dissection 






i. Whole rat brain
iii. Side view of rat brain
ii. Sectioned rat brain showing s tr ia ta
iv. Dissected brain showing hippocampus on one side
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fixed in 4% (v/v) glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 
7.2) at 4°C overmight. Samples (approximately 3 mm3 ) were washed twice 
in the cacodylatee buffer and then post fixed in 1% (v/v) osmium 
tetroxide in 0.1 M cacodylate buffer (pH 7.2) for 1 h at room 
temperature. The samples were washed with distilled water followed by 
the addition of eeither 2% aqueous uranyl acetate or 1% tannic acid, 
buffered in 0.1 M  cacodylate, for lh in the dark at 4°C. After a 
further wash witbi distilled water, the specim.ens were dehydrated by 
passage through a  graded series of acetone: water mixtures (30% - 100% 
acetone). The dehiydrated pellets were transferred to 50% (v/v) Taab 
embedding resin iin acetone and left overnight at room temperature.
The samples were impregnated with 100% resin (two changes) over 48h 
and embedded at 650 °C for the following 48h. Ultrathin sections were 
cut using an LKB ultramicrotome equipped with a glass knife and the 
sections were col.lected on copper grids. Finally, the specimens were 
stained with uran’yl acetate followed by Reynolds lead citrate (2% 
aqueous) and examiined with a Jeol 100 CX electron microscope at 80 kV.
b) Negative sttaining
The band issolated from the sucrose gradient at the 0.8/1.2 M 
sucrose interface (Fig. 2.3) was removed and gradually diluted with 2 
volumes of 0.32 M sucrose (pH 7.4) followed by centrifugation at
1,000 g for 7 min at room temperature. The resulting pellet was 
resuspended in 2 wolumes of 0.32 M sucrose (pH 7.4).
A drop of the suspension was placed on a copper, pioloform-coated 
grid and the grid then removed from the suspension. Excess fluid was 
drawn off the grid! with a filter paper, and the grid dried under a 
lamp for 10 min. A\ drop of 2-5% (w/v) ammonium molybdate solution was
placed on the grid and the grid removed and dried as before. The 
sample was then visualised under the electron microscope as in 
positive staining.
2.2.3 Measurement of Lactate dehydrogenase (E.C.1.1.1.27) activity
Lactate dehydrogenase (LDH) can be used as a cytoplasmic marker 
(Johnson and Whittaker, 1963) and is frequently used to measure the 
integrity of a synaptosome preparation by initially measuring the free 
LDH activity and then the total activity after rupture of the 
synaptosomes with Triton X-100. Enzyme activity was assayed by 
measuring the oxidation of NADH^ in the presence of pyruvate:
Pyruvate + NADH + H+ LDl i , Lactate + NAD+
By monitoring the rate of change of absorbance at 340 nm the LDH 
activity can be calculated as follows:
Mmol pyruvate reduced/min/mg protein
AA vol. in cuvette 1
-  ■— ' —  ■ ^  . i i  x  ---- —
E x 1 vol. in sample protein concentration 
where AA = change in absorbance/min
3
E = molar absorption coefficient (6.22 x 10 )
1 = length of light path (1 cm)
The occluded LDH activity was calculated as the difference between 
the total and free LDH activities.
The method used was that of Johnson (1960) with the modification 
by Marchbanks (1967). All reagents used for the assay were freshly 
prepared. In a 3 ml cuvette was placed 0.15 M Tris-HCl buffer pH 7.4,
(2.6 ml),2 mM NADH (0.1 ml) and a sample (25 Ml) from the sucrose 
density gradient. The cuvette was placed in a Pye Unicam SP6-450 
spectrophotometer equipped with a chart recorder and the reaction was 
initiated by the addition of 10 mM pyruvate (0.1 ml) followed by rapid 
mixing'. Free LDH activity was measured for at least 1 min after which 
the total activity was measured by the addition of 0.1 ml 10% (v/v) 
Triton X-100 to the assay mixture. All assays were carried out in 
duplicate and the results averaged.
2.2.4 Determination of Protein
Protein was assayed by the method of Lowry et al. (1951). 
Standard curves were constructed using a freshly prepared solution of 
bovine serum albumin (BSA) over the concentration range 0-250 Mg/ml. 
BSA standards (200 yl) or unknown (200 yl synaptosome preparation 
diluted 1/40 with distilled water) were incubated with 1.0 ml alkaline 
cupric tartrate, freshly prepared by diluting 1 vol. of 1% (w/v) 
sodium, potassium tartrate and 1 vol. of 0.5% (w/v) CuSO^.SH^O with 50 
vols. of 2% (w/v) Na^CO^ in 0.1M NaOH. After incubation for 10 min at 
room temperature, Folin-Ciocalteau1s reagent (0.1 ml) diluted 1:1 with 
water was added to each sample and the colour allowed to develop for 
30 min. Blanks contained distilled water in place of protein. The 
absorbance was read at 750 nm in a Pye Unicam SP 8-100 spectro­
photometer.
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2.2.5 Binding of [ I]aBGT and [ H]nicotine to rat brain membranes
a) Preparation of rat brain P ,^ membranes
Brains were dissected, minus cerebellum, from male Wistar rats 
(200 g) and stored at -80°C. Frozen tissue, approximately 6 g, was
69 .
allowed to thaw in 0.32 M sucrose, pH 7.4, containing 1 mM EDTA, 0.01% 
(w/v) sodium azide and 0.1 mM phenylmethylsulphonylfluoride (PMSF). A 
10% (w/v) homogenate in 0.32 M sucrose was prepared using a Teflon 
homogeniser (Aldridge et at., 1960), 6 strokes at 800 rpm in 15 s. The 
homogenate was centrifuged at 1,000 g for 10 min at 4°C. The super­
natant was removed and placed on ice. The pellets were resuspended in 
0.32 M sucrose to approximately half the original volume and recentri­
fuged at 1,000 g- for 10 min at 4°C. The combined supernatants were 
centrifuged at 20,000 g for 30 min at 4°C. Using a Pasteur pipette the 
final pellet (?2  ^ was resuspended in 50 mM - phosphate buffer, pH 7.4, 
containing 1 mM EDTA, 0.1 mM PMSF and 0.01% (w/v) sodium azide, 2 ml/g 
original wet wt. The final suspension was filtered through muslin and 
the filtrate stored at 4°C. The approximate protein concentration was 
10 mg/ml as determined using the method of Lowry et at. (1951),
(p. 6 8 ).
b) Preparation of striatal synaptosomal membranes
Synaptosomal membranes were prepared from striata which had 
been stored at -80°C. Tissue, from 6 rats, was allowed to thaw in 
0.32 M sucrose, pH 7.4, at 4°C for 20 min. A 10% (w/v) homogenate was 
prepared and subjected to isopycnic density gradient centrifugation as 
described in Section 2.2.1 (p. 63 ). The tissue at the 0.8/1.2 M inter­
face was removed and diluted with an equal volume of 50 mM sodium 
phosphate buffer, pH 7.4, (see "Preparation of rat brain P^ 
membranes"). The diluted membranes were centrifuged at 1,000 g for 7 
min at room temperature and the resulting pellet resuspended in the 
phosphate buffer allowing 1 ml/100 mg wet wt. original tissue. The 
final protein concentration was 2-2.5 mg/ml.
12 5c) Measurement of [ I jot -BGT binding sites
125[ I]a- BGT binding to rat brain membranes was assayed by the
method of Schmidt (1977). Membrane preparations were diluted with
50 mM phosphate, pH 7.4, containing 1 mM EDTA, 0.01% (w/v) sodium
azide 4nd 0.1% (w/v) PMSF, to give a protein concentration of 0.5 -
2 mg/ml. Samples (500 yl) of the diluted tissue were incubated with 
125[ I]a-BGT (see "Materials”), 5 nM, unless otherwise stated in Eppen-
dorf tubes for 60 min at 22°C. Non-specific binding was determined by
incubation of the membranes in the presence and absence of 0.5 yM
a-BGT and the specific binding was defined as the difference between
the total and non specific binding. Bound radioligand was separated by
dilution of the samples with 1 ml phosphate -buffered saline (PBS), pH
7.4 containing 10 mM potassium phosphate, 150 mM sodium chloride and
0.01% (w/v) sodium azide. The diluted samples were centrifuged in a
MSE Microcentaur bench centrifuge at 10,000 g for 2 min. The
supernatant was removed using a Pasteur pipette and the pellet washed
by resuspension in 1.5 ml ice cold PBS, followed by centrifugation at
10,000 g for 2 min. Pellets were counted for radioactivity (p. 74 ).
All assays were carried out in triplicate and blanks contained 50 mM
125phosphate, pH 7.4, in place of sample. The binding of [ I ]a-BGT was 
measured over the concentration range 0.2 - 10 nM.
3
d) Measurement of [ H ]nicotine binding sites
3
The binding of [ H ]nicotine to rat brain membranes was carried 
out as described by Romano and Goldstein (1980). The membrane 
preparations were diluted with 20 mM HEPES buffer, pH 7.5, containing 
118 mM NaCl, 48 mM KC1, 2.5 mM CaC1.2H20 and 1.2 mM MgS04 .7H20. The P2 
membranes were diluted to 1.3 - 2.6 mg protein/ml. The striatal
synaptosomal membranes were diluted to 0.5 - 0.6 mg protein/ml because 
of the low amount of tissue available.
Samples (250 \i 1) of the diluted membranes were incubated with 40
3
nM [ H ](+/-)-nicotine for 60 min at 22°C in the presence and absence 
of 100 pM (-)-nicotine. After the incubation period 2 ml of ice cold 
50 mM HEPES buffer, pH 7.5,were added to the membranes. Bound 
radioligand was immediately separated by filtration under vacuum 
through Whatman GFC filters (2.5 cm), presoaked in 0.1% (w/v) 
poly-L-lysine for 3h to reduce the non-specific binding of nicotine to 
filters (Romano and Goldstein, 1980). The sample tubes and filters 
were washed with 3 ml HEPES buffer at 4°C. The radioactivity remaining 
on the filters was counted (p.74 ). All assays were carried out in 
triplicate and blanks contained assay buffer in place of sample. [ H] 
Nicotine binding to P^ membranes was measured over the concentration 
range 3-100 nM and to synaptosomal membranes over the range 1-120 nM.
2.2.6 Analysis of the uptake of DA by striatal synaptosomes
Experiments were carried out to study DA uptake by striatal 
synaptosomes following the methods described by Schoemaker and 
Nickolson, (1983). Radiolabelled DA of high specific activity (46
3
Ci/mmol, [7, 8- H ] DA, diluted as described in the "Materials" to give
5
10 dpm/pmole) was used to label the synaptosomal transmitter pools.
a) Uptake kinetics
Samples (1 ml) of synaptosomes diluted with perfusion medium to 
give a protein concentration of approximately 1 mg/ml were
3
preincubated in Eppendorf tubes at 37°C for 10 min before [ H ] DA 
(diluted with unlabelled DA) was added. The uptake of DA was studied
over the concentration range 0.01 - 10 pM. The initial uptake was
taken as that which occurred in the first minute of incubation at 37°C;
for each DA concentration the initial uptake was measured in
duplicate and the results averaged.
/k 50 pi sample was removed and counted to give the total
radioactivity present in the suspension. The remaining synaptosomes
were separated from the medium by filtration under vacuum through
glass fibre filters (Whatman GF/F) using a Millipore manifold unit.
Each filter was washed with 10 ml ice cold medium, washing being
completed in approximately 3 s. Non-specific uptake was determined by
including the DA uptake inhibitor nomifensine (50 pM) in the medium.
Non-specific uptake was also measured at 4°C and time zero with
filtration and washing immediately following the addition of DA. The
sodium dependency of the DA uptake was tested by incubation in sodium
depleted medium (p.137). The radioactivity in each sample was counted
(p.73 ) and the uptake calculated. Values were corrected for non-
-1 -1specific uptake and expressed as pmoles DA.mg protein . min
b) Time course for the uptake of DA
Synaptosomes resuspended in perfusion medium (p.135) were
3
preincubated at 37°C for 10 min prior to the addition of [ H ] DA, 
final concentration 0.11 pM. The uptake was followed by removing 
samples (100 pi) from the incubating suspension at time intervals 
after the addition of the radiolabel. The synaptosomes were rapidly 
separated from the medium by vacuum filtration and washed as described 
in Section 2.2.6a. Total radioactivity in a 100 pi sample was measured 
in duplicate by counting samples on pre-wet (to account for possible 
quenching) filters. Non-specific uptake was determined by incubation
3
of the synaptosomes with [ H J DA at 4°C and sampling and washing at 
time zero (Schoemaker and Nickolson, 1983). Uptake was corrected for 
non-specific uptake and expressed as a percentage of the total 
radioactivity.
c) The effect of synaptosomal protein concentration on the uptake 
of [3H]DA
3
The uptake of [ H ] DA (0.11 pM) by striatal synaptosomes was 
measured over the protein concentration range 0 . 2 - 4  mg/ml. A 
preparation of synaptosomes was diluted with perfusion medium and 
uptake determined at each protein concentration (as described in 
Section 2.2.6a), after a 5 min incubation period with the radiolabel. 
All assays were carried out in duplicate.
2.2.7 Radioactivity counting
a) Scintillation spectrometry
i) Comparison of the counting efficiency of different 
scintillants
The counting efficiency of different scintillants was
3
determined by counting a 10 pi sample of [ H ] DA (0.1 yCi) in the 
presence of increasing amounts of perfusion medium and a constant 
volume of scintillant (5 ml; Fig. 2.2a). The scintillant 'Aqua Luma' 
was initially used because of its high counting efficiency over the 
required aqueous concentration range. In later experiments 'Optiphase 
Safe' was used because it was less expensive and of similar counting 
efficiency. A full range calibration curve for Optiphase Safe is shown 
in Fig. 2.2b. The presence of a minivial inside the main vial caused 
no additional quenching.
To ensure a high counting efficiency scintillant was added to 
aqueous samples to produce a 10% aqueous mixture.
ii) Fractions from perfusion experiments
To an 8 drop fraction (340 yl) 3 ml of Optiphase was added 
to give approximately 30% counting efficiency.
iii)Filters
Filters were placed in the bottom of a 20 ml plastic 
scintillation vial with 5 ml Optiphase Safe and counted after 24 h at 
4°C by which time the counting efficiency had reached a maximum (36%).
All samples were counted for 2 min in a Packard TriCarb spectro­
meter using external standardisation.
b) Gamma-counting
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Fig. 2.2. Liquid scintillation counting efficiency
a) Counting efficiency of various scintillants in the 
presence of increasing amounts of aqueous medium.
b) Standard curve for "Optiphase Safe".
2.3 RESULTS
2.3.1 Preparation of synaptosomes and analysis of the gradient 
fractions by electron microscopy
The one-step centrifugation method used for isolating 
synaptosomes from a crude homogenate was very quick and simple. Within 
1%, h after the death of the rats,a synaptosomal fraction was obtained 
which appeared as a distinct band in the sucrose gradient (Fig. 2.3).
Analysis of the 3 fractions (P , P, , P : Fig. 2.3) under thea b c
electron microscope, showed the characteristic morphology of the 
structures present in each band. The P& fraction consisted of electron 
dense concentric rings characteristic of myelin fragments with little 
contamination from other structures. The pellet (P ) consisted of cell 
bodies (containing large nuclei) and cell debris in addition to free 
mitochondria. The size of the cell bodies ranged from 7 - 1 3  ym.
Under low magnification the P, fraction consisted of numerousb
spherical structures, some identifiable as synaptosomes others as 
mitochondria. Analysis under high magnification (Fig. 2.4) using the 
two different staining techniques of positive and negative staining, 
showed in greater detail the morphology of the synaptosomes. Using 
negative staining (Fig. 2.4b) the synaptosome appeared as a thin- 
walled bag containing vesicles. For the positive staining two stains 
were compared; 1% tannic acid and 2% aqueous uranyl acetate. Both 
stains gave similar results although at high magnification the 
internal structures of the synaptosomes were more defined in sections 
stained with 1% tannic acid.The positively stained section revealed 
the intracellular components: mitochondria, vesicles and vacuoles.
Also attached were a few dark regions on the plasma membrane, these
Fig. 2.3. Preparation of synaptosomes
Synaptosomes were prepared from a 10% (w/v) 0.32 M 
sucrose (pH 7.4) homogenate by discontinuous sucrose 
gradient centrifugation (10,000 g for 60 min at 4°C). 
The resulting gradient bands were labelled as shown 
opposite. Because the synaptosomal band at the 0.8 -
1.2 M sucrose interface had been prepared by a one step 
centrifugation process it was called rather than the 
conventional labelling P^b (Gray and Whittaker, 1962), 
where synaptosomes are isolated from the second pellet 
(P2).
The 3 membrane fractions (P.P. and P ) were examineda b c
under the electron microscope (p.63 ). The micrographs 
showed clearly the morphology of the structures 
isolated in each band.
P& Myelin fraction (stain = 1% tannic acid)
Myelin (my) was identified by its multilamellar 
structure.
P^ Synaptosomal fraction (stain = 1% tannic acid) 
Numerous synaptosomal profiles (s) and a few 
isolated mitochondria (m) were characteristic of 
this fraction.
Pc Cell debris (stain = 2% aqueous uranyl acetate)
This fraction consisted of the cell bodies and 
unidentifiable fragments. Within the cell bodies 
were large, heavily stained nuclei (n).
Also present are mitochondria (m)











Fig. 2.4. Striatal synaptosomes viewed under the electron 
microscope (high power magnification)
a) Positively stained synaptosomes (1% tannic acid) 
containing synaptic vesicles (sv), mitochondria (m) 
and a vacuole (v).
b) Negatively stained synaptosomes visualised as thin-
walled bags.

Fig. 2.5. Distribution of LDH activity in the gradient fraction.
a) LDH activity was measured in each gradient fraction.
The free (shaded) and the total (unshaded) 
activities were determined in the absence and 
presence of Triton X-100, respectively. The occluded 
activity was calculated as the difference between 
the two activities and expressed as a percentage of 
the total value (numbers ).
b) The recovery of LDH activity in each gradient
fraction represented as a percentage of the total 
activity in the original homogenate.
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were identified as post synaptic thickenings. The approximate size of 
the synaptosomes was 0.6 - 1 pm-
2.3.2 Distribution of LDH activity in the gradient fractions
Thfe cytoplasmic marker LDH was used to measure the integrity of 
the synaptosome preparation. LDH activity was distributed throughout 
the sucrose gradient (Fig. 2.5a). The highest percentage occluded 
activity was found in the band, indicating am enrichment of sealed 
membrameous structures. The mean occluded LDH activity in this synap­
tosome band was 79.13 ± 4.88% of total activity (n = 8 , mean ± SEM). 
Over 50% of the total LDH activity was recovered in the fraction 
(Fig. 2.5b).
125 32.3.3 Binding of [ I]a—BGT and [ H ] nicotine to rat brain membranes
a) The relationship of radioligand binding and protein 
concentration
3 125
The binding of [ H]nicotine (40 nM) and [ I]a-BGT (5 nM) to
P^ membranes was shown to be linear with respect to protein
concentration (Fig. 2.6 a and b respectively). Subsequent binding
assays were carried out using protein concentrations of approximately
2 mg/ml.
b) Analysis of radioligand binding by Scatchard analysis 
The simplest model used to describe the ligand receptor
interaction assumes that a single set of ligand molecules, L, reacts 
reversibly with a single set of receptor molecules, R, to form a 
ligand receptor complex LR,
84.
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The constants k , and k , are the kinetic constants for association +1 -1
and dissociation respectively and is the equilibrium dissociation 
constant.
Alternatively, the is determined at equilibrium using the 
Scatchard equation (5). When R in equation 2 is equal to - LR where 
R^ represents the total concentration of receptors, equation 2 can be 
rearranged
[Rt - LR] [L] /[LR] = K. (3)
If LR is defined as the bound ligand (B), L as free ligand (F) and R
as the maximum number of specific receptor sites (B ). equation 3max
becomes
<B v - B) (F) / B = K (4)max d
which can be rearranged
(B - B)












































3 1232.6. Protein dependence of [ H]nicotine and [ l]a-BGT
binding to P^ membranes.
3 125
a) [ H Jnicotine (40 nM) and b) ( Ik-BGT (5 nM) were incubated
with varying amounts of membrane samples for 60 min at 22°C.
Non specific binding was measured in the presence of 100 pM
nicotine and 0.5 mM GBGT respectively.
< □ ) t.oLa] binding, ( a )non-specific, i A ) specific.
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This is the Scatchard equation (Scatchard, 1949). A plot of B/F versus
B gives either a straight line with a slope of and an intercept
with the abscissa of B , or a non-linear curve, indicating hetero-max
geneity or cooperativity of the binding sites for the ligand studied.
c) Binding of [^^i] ot-BGT to rat brain membranes
125Specific binding of [ I]a-BGT to rat brain membranes was
measured over the concentration range 0.2 - 10 nM (Fig. 2.7).
Scatchard analysis of the data gave a straight line with an apparent
K, value of 2.99 ± 0.25 nM and a B value of 67.3 ± 8.2 fmoles/mgd max
protein for the binding to membranes. For the binding to striatal
membranes K. and B values of 3.33 ± 1.07 nM and 82.2 ± 22.3 d max
fmoles/mg protein respectively were obtained. Results are expressed as 
the mean ± range of 2 experiments carried out on different membrane 
preparations.
0
d) Binding of [ Hjnicotine to rat brain membranes
3
Saturable specific binding of [ H ] (+/-) - nicotine to and
striatal membranes was shown (Figs. 2.8a and b).
For P^ membranes, Scatchard analysis of the binding data yielded a
straight line (r2 = 0.900) giving an apparent K, of 16 nM and B
d max
value of 80 fmoles/mg protein, (single determination). These data
suggest the presence of a single population of binding sites.
Because of the low amounts of striatal tissue available, initial
3binding studies were carried out using only 5 concentrations of [ H ] 
nicotine. Curvilinear Scatchard plots were obtained, suggesting either 
cooperativity or heterogeneity of binding sites. A more detailed study
3
using 10 concentrations of [ H ] nicotine also resulted in a curvi-
linear Scatchard plot (Fig. 2.8b). The data obtained were analysed
using the method of Humrich and Richardson (1983) modified for the BBC
computer by B. McCormack (Bath University). A high affinity binding
site with an apparent KJ of 1-5 nM and B of approximately 80 fmoles/d max
mg protein identified.
125 3e) Subcellular distribution of [ I]a-BGT and [ H ] nicotine
binding
i nc q
Comparison of the binding of [ I ] a-BGT (5 nM) and [ H ]
nicotine (40 nM) binding to the 3 gradient fractions (P.P. and P :a b c
Fig. 2.3) clearly demonstrated that the synaptosomal fraction con-
125 3tained a higher concentration of both [ I]a-BGT and [ H ] nicotine
binding sites (Fig. 2.9). There was also appreciable binding to the
cell debris (P ) fraction, c
3
2.3.4 Uptake of [ H ]DA by striatal synaptosomes
3
The uptake of [ H ]DA (0.05 - 1 yM) by striatal synaptosomes
(protein concentration 1 mg/ml) was saturable and inhibited by
nomifensine (50 yM; Fig. 2.10). The Michaelis constant (K ) and the
m
V for the specific uptake was determined by the direct linear plot max  ^ ^
(Eisenthal and Cornish-Bowden, 1974; Cornish-Bowden and Eisenthal,
1978). Values of 0.24 ± 0.03 yM for the K and 91.4 ± 9.5 pmoles [ 3H 1m
DA/mg protein/min for the V were obtained. Results are expressed as 
the mean ± standard error.
3
Uptake of [ H ]DA (0.11 yM) was shown to be linear for the first 2 
min (Fig. 2.11), reaching a maximum at 5 min. From this experiment an
3
uptake value of 40 - 50 pmoles [ H]DA/mg protein was obtained. The 
uptake was also shown to be proportional to the amount of protein;
125Fig. 2.7. Saturability of [ Ija-BGT binding.
membranes (a) and striatal synaptosomal membranes b)
were incubated for 60 min at 22°C with increasing
125
concentrations of [ I]a-BGT in the presence (0) or
absence (•) of 0.5 yM a-BGT. Inset represents a
Scatchard plot of the specific binding (A) from which
the apparent K, and B were calculated, d max
(a) K = 2.64 nM, B 75.3 fmoles/mg proteind max
(r2 = 0.822)
(b) = 2.26 nM, B ^ 59.9 fmoles/mg protein
(r2 = 0.815)
Fig.
B (pmol/mg x 10 )
i--------------- 1--------------- 1_________ S_________ I_________ i_________ 1_________ l .
1 2 3 4 5 6 '
125[ Ij-BGT concentration (nM)

















B (pmol/mg x 10 )
10
9 1085 6 741 2 3
125[ I]a-BGT concentration (nM)
125Fig. 2.7b. Binding of [ I]a-BGT to striatal synaptosomal membranes
o
3
Fig. 2.8. Specific binding (•) of [ H ](+/-)-nicotine to a)
membranes and b) striatal synaptosomal membranes was 
determined by incubation with increasing concentrations 
of [ H ](+/-)-nicotine in the presence and absence of 
100 pM (-)-nicotine. Scatchard analysis of the data 
(lower plots) yielded the following binding constants:
a) Straight line Scatchard (r2 = 0.900)
K, = 16 nM, B = 8 0  fmoles/mg protein d max
b) Curvilinear plot analysed by the method of Humrich 
and Richardson (1983), modified by B. McCormack 
(Bath University) for the BBC computer.
High affinity site K =1-5 nM B ? 80 fmoles/mgd max
protein.
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Fig. 2.9 Subcellular distribution of the binding of (a) [ 125I]a-BGT 
(5 nM) and (b) [ H ]nicotine (40 nM). Specific binding 
was determined as described on p.70 . Results are
expressed as the mean of two experiments. Error bars 
represent the range of results.
95.
optimal loading being achieved at a protein concentration of 2 mg/ml 
(Fig. 2.12).
The Na+- dependency of the uptake was demonstrated by incubation 
in Na+-depleted medium (p.137). At a high DA concentration of 10 yM 
only 67% of the normal uptake was observed in Na+-depleted medium. In
3
the presence of nomifensine (50 yM) 34% of the normal uptake of [ H]DA 
(10 yM) occurred. The uptake was also temperature sensitive; at 4°C 
uptake of [3H]DA (10 yM) was 17% of control (37°C) and at a lower [3h] 
DA concentration (0.11 yM) only 5% of the control value.
2.3.5 Conditions used to preload the striatal synaptosomes with 
[3H]DA
3
To achieve maximum loading of the synaptosomes with [ H]DA, 
synaptosomes were resuspended in perfusion medium to give a protein 
concentration of 2 - 4 mg/ml. After a 10 min preincubation period at 
37°C, [ H]DA was added, final concentration 0.11 yM, (10 yl of stock 
(11 yM) per ml synaptosomes). Since the data shown in Fig. 2.11 
indicate that maximum uptake is achieved in only 5 min and thereafter
3
a gradual decline occurs, incubation with [ H]DA was continued for 
5 min.
2.3.6 The effect of washing by centrifugation on synaptosomal 
integrity
3A method for removing [ H ]DA which had not been taken up by the 
striatal synaptosomes was required to reduce the washout period in the 
perfusion experiments (p. 117 ). The effect of washing the preloaded 
synaptosomes by centrifugation was determined as described below.
Fig, 2.10, (Jptake of DA by striatal synaptosomes
a) After 10 min preincubation (37°C) samples of 
striatal synaptosomes (1 mg protein/ml) were 
incubated with a range of DA concentrations. 
Uptake was determined by filtration (*), non­
specific uptake was measured in the presence of 
nomifensine (50 yM, a ).
b) Specific uptake was analysed using the direct
linear plot. A K value of 0.24 yM (standard m
error ± 0.03) and a V of 91.4 ± 9.5 pmoles/mgmax
protein/min were obtained.
Results are from a single experiment, determinations 
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Fig. 2.11, Time course of [ H]DA uptake into striatal synaptosomes
After 10 min preincubation, (37°C),[ H]DA (0.11 yM) was added to a suspension of synaptosomes 
At time intervals, a 100 yl sample was withdrawn and uptake determined (p.72 ). Results are 

















Fig. 2.12. Effect of protein concentration on the uptake of [ H]DA 
by striatal synaptosomes.
A preparation of synaptosomes was diluted with perfusion 
medium and for each protein concentration uptake of [ HjDA 
(0.11 nM) was determined as described on p.71 , after
incubation at 37°C for 5 min with the radiolabel.













Striatal synaptosomes were prepared and loaded with [ H ]DA using
3
the optimum conditions (Section 2.3.5). The uptake of [ H]DA was 
determined as outlined on p.71 and the integrity of the preparation 
was determined by measuring the occluded LDH activity (p.67 ). The 
remaining suspension was centrifuged at 1,000 g for 7 min at 4°C and 
the resulting pellet was gently resuspended in medium to its original 
concentration. Further samples were removed for uptake and LDH deter­
minations and the washing procedure was repeated. Throughout the 
washing steps the synaptosomes were kept at 4°C to prevent further 
[^H]DA uptake.
Table 2.1. The effect of washing synaptosomes by centrifugation.
q Occluded LDH activity
Number of [ H]DA
washes uptake(%) moles/min/mg protein % total
0 54 1.04 81
1 82 1.02 91
2 85 1.00 92
The table above summarises the results obtained from a synaptosome 
preparation of protein concentration 2.75 mg/ml. The occluded LDH 
activity was retained throughout the successive washes, indicating 
that the synaptosomes remain intact and are not damaged by this 
washing procedure.
2.4 DISCUSSION
2.4.1 The synaptosomal preparation
The one-step centrifugation process was a quick and
effective method for separating cell bodies, myelin and
synaptosomes from a crude striatal homogenate, as revealed by
observation of the gradient fractions under the electron microscope
(Fig. 2.3). Using low power magnification the size of the cell
bodies present in the fraction (7 - 13 ym) agrees with the
reported size of medium sized neurones (which are the main type of
neurone in the striatum) of 10 - 20 ym in diameter (Heimer et at. 9
1985). The size of the synaptosomal fraction (P. ), viewed underb
high power magnification, of 0.6 - 1 ym also agrees with the re­
ported range in size of rat brain synaptosomes of about 0.5 - 2 ym 
(Jones, 1975; Whittaker, 1984). The synaptosomal preparation was 
visualised under the electron microscope using both positive and 
negative staining techniques. However, although negative staining 
is much quicker than positive staining and is therefore a 
useful technique to analyse the integrity of a synaptosomal 
preparation on the same day as its preparation, negative staining 
gives little information about the internal structures present 
within synaptosomes (see Fig. 2.4). In contrast, using positive 
staining techniques, the internal organelles were clearly observed, 
an important characteristic of synaptosomes (Whittaker, 1984).
Measurement of the distribution of the occluded LDH activity in 
the sucrose density gradient is also a useful method for identi­
fying the synaptosomal band. The analysis is carried out on the 
same day of preparation and can therefore be used to ensure that 
intact synaptosomes have been isolated before further studies are
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carried out using the synaptosomal preparation. The high level of 
occluded LDH activity in the fraction (Fig. 2.5) indicates the 
presence of sealed membranous structures and the result that over 
50% of the total LDH activity was found in the fraction shows 
that-it is particularly rich in synaptosomal structures. Measure­
ment of the occluded LDH activity also proved useful to 
ascertain the integrity of a synaptosomal preparation after 
repeated washing (Table 2.1). There was very little loss in the 
amount of occluded LDH activity after 2 centrifugational washes, 
which suggests that synaptosomes are stable structures, an 
important requirement for their use in perfusion experiments.
0
2.4.2 The uptake of [ H]DA by striatal synaptosomes
The striatal synaptosomes prepared by the one-step centri-
fugational method displayed high affinity uptake of [ H]DA similar
to that described by Holz and Coyle (1974). The K value obtainedm
of 0.24 yM agrees with previous reports, values ranging from 0.13 -
0.4 yM (Holz and Coyle, 1974; Synder and Coyle, 1969), the
variation probably reflecting differences in the assay conditions
employed (Copper and Carlson, 1983). Using a purified synaptosomal
preparation Holz and Coyle (1974) obtained a V value ofmax
125 pmoles DA/mg protein/min, which is slightly higher than the 
^max rePor^e(^  this thesis of 91 pmoles DA/mg protein/min 
(Section 2.3.4). This would suggest that the synaptosomes prepared 
using the one-step method are of a slightly lower purity than those 
prepared by the much longer two-step centrifugational procedure 
described by Holz and Coyle (1974).
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3
Two methods for determining the non-specific uptake of [ H ]DA 
were used: incubation with the specific uptake inhibitor nomifen­
sine (50 pM) and incubation at 4°C. In the presence of nomifensine 
more uptake occurred than at 4°C. This was particularly noticeable 
at high DA concentrations (10 pM) where the nomifensine blocked 67% 
of the total uptake whereas 83% of the total uptake was prevented 
by incubation at 4°C. At lower DA concentrations the difference 
between non-specific uptake measured by inclusion of nomifensine
3
and incubation at 4°C was less marked. At 0.1 pM [ H]DA 93% of 
uptake was blocked by 50 pM nomifensine and 95% by incubation at 
4°C. These results suggest a component of the non-specific uptake 
which is insensitive to nomifensine and may represent binding to DA 
receptors.
The Na+-dependency of the uptake was determined only at one 
concentration of [^H]DA (10 pM). Complete Na+-deficiency was not 
possible because the buffering nature of the perfusion medium 
relies upon NaHCO^/KH^PO^/CO^. Using a medium containing low Na+ 
(24.9 mM) the uptake of DA was reduced by a third, which agrees 
with the work of Holz and Coyle (1974) who demonstrated that a 
reduction in the concentration of Na+ caused a decrease in V
max
3
To preload the striatal synaptosomes with [ H] DA for the 
perfusion experiments described in Chapters 3 and 4, a concent­
ration of 0.11 pM was chosen because it was close to the estimated 
value and also at a concentration similar to that used by other 
groups (e.g. Schoemaker and Nickolson, 1983). The optimum incuba­
tion period of the radiolabel with the synaptosomes (2 - 4 mg 
protein, as defined in Section 2.3.5) of 5 min agrees with the work 
of Schoemaker and Nickolson (1983) and Bonnet et al. (1984). This
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is in contrast to the much longer incubation periods often used 
(e.g. Mills and Wonnacott, 1984).
The subcellular fractionation procedure described in this 
thesis therefore produces synaptosomes which show the character­
istic ''high affinity DA uptake of striatal dopaminergic nerve ter­
minals. These results together with the electron micrographs and 
LDH activities provide evidence in support of the use of the one- 
step method for isolating synaptosomes.
3 1252.4.3 The binding of [ H]nicotine and [ I ]a-BGT to rat brain 
membranes
Initial experiments using whole rat brain membranes were
3
carried out to reproduce published data. Specific binding of [ H]
125nicotine and [ I]a-BGT to rat brain membranes was demonstrated.
3
The straight line Scatchard plot obtained for the binding of [ H ]
nicotine to whole rat brain membranes is consistent with a
single population of binding sites. The apparent value obtained
of 16 nM agrees with the reported values for a high affinity [ H ]
nicotine binding site in rodent brain (Romano and Goldstein, 1980;
Marks and Collins, 1982; Costa and Murphy, 1983). The binding of 
125
[ Ija-BGT to membranes was also saturable and the apparent
of 2.64 nM is in agreement with previous reports (see Schmidt 
et at. 3 1980).
In contrast to the straight line Scatchard plot for the binding 
3
of [ Hjnicotine to P^ membranes, a curvilinear plot was obtained 
for the binding to striatal synaptosomal membranes (Fig. 2.8b). A 
concave curvilinear plot is indicative of either negative 
cooperativity or multiple binding sites. A similar plot was
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obtained by Yoshida and Imura (1979), who also reported high and 
0
low affinity [ H]nicotine binding sites on whole brain synaptic
3
membranes. However, there are few reports of saturation [ H]
nicotine binding studies using striatal tissue. Recently, Jenner
3et aZ.! (1986) reported a high affinity [ H ] nicotine binding site
in the striatum with an apparent K, of 7.2 nM and B of 135 fmoles/d max
mg protein. Also in agreement with the results reported in this
thesis was the presence of a low affinity site which did not
saturate (Jenner et at., 1986). The specificity of the low affinity
site has often been questioned (Marks and Collins, 1982) and
recently Lippiello and Fernandes (1986) reported that low affinity
[^Hjnicotine binding sites are not observed when protease inhibitors
are present during the preparation of the membranes. This would
explain why only high affinity [ H]nicotine binding sites were
observed for membranes (because EDTA and PMSF were present
throughout the membrane purification procedure) whereas high and
low [ H]nicotine binding sites were found using striatal membranes
(which were prepared in the absence of protease inhibitors). It is
therefore not possible to measure the low affinity [ H ]nicotine
binding site using the assay described. Nevertheless, the ability
125of nicotinic agonists to displace bound [ l]a-BGT provides
evidence for a low affinity nicotine binding site that may 
125
correspond to [ I]a-BGT binding sites (see Wonnacott, 1986).
3
The observed differences in values of high affinity [ H]
nicotine binding to striatal membranes (l-5nM) and whole rat brain
P^ membranes (16 nM) may be a result of competition by "endogenous
ligands" present at different concentrations in the membrane
125
preparations. Inhibition of both [ l]a-BGT binding (Quifc , 1982)
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3
and [ H] nicotine binding (Shershen et at., 1984; Perry et at.,
1986) to rat brain membranes by endogenous factors in brain
homogenates have been demonstrated. During the preparation of the
P, striatal membranes the tissue is washed by the density gradient 
b
centrifugation procedure and because of the low availability of
striatal tissue the striatal membranes were four times more dilute
than the P^ membranes. These differences would account for lower
amounts of endogenous ligands and hence the lower value for [ H ]
nicotine binding observed using striatal tissue. This possibility
has recently been verified in the laboratory by Wonnacott and
MacAllan (personal communication) who showed that an additional
wash of the P^ membranes, before determination of [ H jnicotine
binding, greatly reduced the value. In contrast to the
difference observed in the values of [ H]nicotine binding to P^
125membranes and striatal membranes the values for [ l]a-BGT 
binding were similar. This suggests that any endogenous ligands
3
present are possibly specific for the high affinity [ HJnicotine
125binding site rather than for the [ I]a-BGT binding site.
There are reports that the binding of a-BGT to the striatum is 
low compared with other brain regions (Marchand et at., 1979)
3
whereas regional [ H]nicotine binding studies have shown that the
3
striatum contains a high number of high affinity [ H jnicotine
binding sites compared with other regions (Jenner et at., 1986).
These regional distribution binding studies agree with the auto-
radiographical studies of Clarke et at. (1985a)and indicate that
3 -the striatum is rich in high affinity [ Hjnicotine binding sites
125 125
and low in [ I]a-BGT binding sites. Comparison of [ I J a
3
-BGT and [ H]nicotine binding to the striatal synaptosomal fraction
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(Fig. 2.9) shows that there are almost twice as many high affinity
3 125[ H Jnicotine binding sites as there are [ l]a-BGT sites. However,
3
the concentration of [ HJnicotine used (40 nM, after Romano and
Goldstein, 1980) was at a saturating concentration whereas the
125
concentration of [ Ija-BGT used (5 nM, after Schmidt, 1977) was
at a value close to the estimated K. value. The observed number ofd
125[ Ija-BGT binding sites may therefore be an underestimate. 
However, values for the binding of cholinergic ligands to
whole brain and striatal membranes are not directly comparable 
(Section 2.3.3 c and d) because of differences in the purity of the 
two membrane preparations.
1 PR Q
Comparison of the binding of [ iJa-BGT (5 nM) and [ H J
nicotine (40 nM) to the three gradient fractions (P , and P )a b c
demonstrated that the striatal synaptosomal fraction(P^) contained a
125 3higher number of both [ IJa-BGT and [ H J nicotine binding sites
125(Fig. 2.9). This enrichment of [ IJa-BGT binding in the synapto­
somal fraction is consistent with previous reports (Salvaterra and
Moore, 1973; Etervic and Bennet, 1974; Tindall et al., 1978) and
125also with the reported binding of [ IJa-BGT in synaptic regions
in rat brain (Hunt and Schmidt, 1978) and the localisation of a-BGT
conjugated to horseradish peroxidase at synaptic regions in rat
brain (Lenz and Chester, 1977). Present on the synaptosomes will be
attached a portion of the post-synaptic membrane as shown by De
Robertis et al., (1962). The binding of the radioligands may
therefore be to either presynaptic, postsynaptic or to both
125membranes. Evidence for a presynaptic location of [ iJa-BGT 
binding has been provided by de Belleroche and Bradford (1979) by 
the demonstration that destruction of the nigro-striatal pathway
108.
125with 6-hydroxydopamine reduces the number of [ i]a-BGT binding 
sites in the striatum by half.
The enrichment of [ H]nicotine binding to a synaptosomal 
preparation has also previously been demonstrated (Yoshida and
3
Imura^ 1979; Benwell and Balfour, 1985) and the binding of [ H ] 
nicotine specifically to dopaminergic nerve terminals in the 
striatum has been shown using autoradio-grap.hic and lesioning 
studies (Clarke and Pert, 1985). Using these techniques approxi- 
mately a third of the high affinity [ Hjnicotine binding sites in 
the striatum were shown to be linked to dopaminergic nerve endings 
(Clarke and Pert, 1985), providing substantial evidence for the 
possible involvement of nAChR in the regulation of DA release.
CHAPTER 3 




Many perfusion systems employing slice preparations have been 
described (e.g. Giorguieff et at. , 1976) however, relatively little 
work has been carried out using synaptosomes. The first synaptosomal 
perfusion systems were described in the early 1970's (de Belleroche 
and Bradford, 1972; Levy et at., 1973; Raiteri et at., 1974; Mulder 
et at., 1975). The common basis for such procedures was a preloading 
of synaptosomes with radiolabelled transmitter or precursor followed 
by perfusion while the synaptosomes were retained on an inert support. 
One such systems was described in 1972 by de Belleroche and Bradford 
in which the synaptosomes were sandwiched in a nylon gauze immersed in 
buffer and additions made to and samples taken from, the surrounding 
medium. However, an important prerequisite of a perfusion system is 
the prevention of reuptake and this system did not completely satisfy 
this requirement. An improved procedure was described by Levy 
et at. (1973), which used a fibre-glass filter in a Swinex filter 
unit, the synaptosomes were retained while buffer flowed through the 
filter. A variation was described by Raiteri et at., (1974), in which 
the support was a nitrocellulose filter (Millipore, 0.65 pm pore). An 
alternative perfusion apparatus was described by Mulder et at.,
(1975), in which the preloaded synaptosomes were layered onto a mini 
Sephadex column.
Numerous adaptations have been made to study the release of 
different neurotransmitters in response to varying stimuli; such 
changes have included:
i) the type of support;
ii) the flow rate;
iii) the size of the collected fraction;
iv) the period of stimulation.
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3.1.1 The period of stimulation
Perfusion studies have been carried out by several groups in 
which the period of stimulation has lasted several minutes (e.g. 
Raiteri et at., 1974; Mulder et at., 1975). Alternative studies have 
used dontinual stimulation e.g. the electrical stimulation of slices, 
Richards (1985) or K+ depolarisation, Frankhuyzen and Mulder (1982). 
Other groups have studied events over short ( <30 s) periods, e.g. 
Redburn et at., (1975), Drapeau and Blaustein (1985), Minnema and 
Michaelson (1985).
3.1.2 Calculation of release data
There are few reports of methods for calculating the release from 
repeatedly stimulated synaptosomes. It is more usual to stimulate once 
and compare the values obtained in parallel drug-treated and 
control systems (e.g. Minnema and Michaelson, 1985; Drapeau and 
Blaustein, 1983).
More studies have been carried out using perfused slice 
preparations (e.g. Ennis et at., 1981; Gillet et at., 1985; Arbilla 
and Langer, 1984; Frankhuyzen and Mulder, 1982) where the efflux is 
usually expressed as a fractional release rate, that is, the radio­
activity in each fraction divided by the total amount of radioactivity 
present in the slice at the start of the collection period. The basal 
fractional release is then subtracted to give the stimulated release 
rates. The tissue is usually stimulated twice (e.g. Ennis et at.,
1981; Arbilla and Langer, 1984) and the radioactivity released by the 
two pulses (S^ and S^) expressed as the ratio S^/S^. To study the 
effect of drugs on stimulated (K+ or electrical) release, the drug is 
introduced for a short period before the second stimulation. The
Ill.
ratios S^/S^ for both the control and drug treated slice are compared. 
The effect of the drug on the basal efflux can also be determined by 
comparison of the basal release before with the basal release 
before (Arbilla and Langer, 1984).
One of the original aims of this work was to produce a synapto­
somal perfusion system in which repetitive stimulation could be 
carried out using small pulses of stimuli followed by simple analysis 
of the released radioactivity.
3.1.3 The original perfusion system
The work described in this thesis was developed from a simple 
synaptosomal perfusion system described by Mills and Wonnacott (1984). 
Their conditions were similar to those originally described by 
Raiteri et al. (1974). The perfusion system consisted of a pyrex 
glass perfusion chamber, modified from McKernan and Campbell (personal 
communication). The chamber was cylindrical (3 cm diameter) with a 
circumferential glass ridge to support the filter disc onto which the 
preloaded synaptosomes were placed (Fig. 3.1). To perfuse medium 
through the chamber, tubing was attached above and below the filter 
support.
Modified Krebs-bicarbonate medium, pH 7.4, containing 0.01 mM 
pargyline and 2 mM ascorbic acid (Mills and Wonnacott, 1984) 
maintained at 37°C by placing the reservoir in a water bath close to 
the chamber, was pumped through each chamber using a multichannel 
peristaltic pump (Gilson Minipuls 2). The inlet flow rate was 1 ml/min 
and the outlet flow rate was 2.5 ml/min, this difference prevented any 
build up of medium on or below the filter.
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Fig. 3.1. The original perfusion chamber.
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The striatal synaptosomes were prepared (Section 2.2.1, p. 63 ) and
3
preloaded with radioactive DA by incubation with [2,5,6- H]DA 
(specific activity 6.0 Ci/mmol, final concentration 0.2 yM), for 30 
min at 37°C. Samples (1 ml,equivalent to 100 mg wet wt. of orginal 
tissue) were layered onto glass fibre filters (Whatman GF/A, 2.5 cm) 
by gentle suction and placed in the perfusion chamber. The inlet 
tubing was positioned 1 cm above the filter and perfusion was carried
out for 40 min. After this period the basal (spontaneous) release rate
0
of[ H]DA had reached a constant value.
3
The effect of drugs on [ HjDA release was tested by introducing a 
4 min pulse of test substance into the perfusion medium. To prevent 
mixingtthe pulse was separated from the perfusion medium by air gaps.
A minimum interval of 12 min perfusion with normal medium was allowed 
between each test pulse. Fractions (4 ml) of the perfusate were 
collected manually and counted for radioactivity in scintillant 
(Triton X-100/toluene, 1:2 containing 0.3% (w/v) PP0). The radio­
activity remaining on the filters at the end of the perfusion 
experiment was also measured and used to calculate the percentage of 
the total radioactivity that was released. Two chambers were run in 
parallel to allow simultaneous perfusion of both treated and control 
synaptosomes.
3
Using such a system the release of [ H]DA from striatal synapto­
somes could be evoked by nicotine in a dose-dependent manner (Mills 
and Wonnacott, 1984). The release by nicotine (100 yM) was also shown 
to be specifically blocked by the ganglionic antagonist mecamylamine 
(10 yM). However, the concentrations of agonists required to elicit a 
response in these preliminary experiments were high and it was found 












greater than 10 pM caused an increase in [ H]DA release. Additionally, 
practical difficulties were encountered,of which the major one was the 
manual collection of fractions of perfusate at the same time as 
introducing a pulse of drug.
The following section describes the successive changes that were 
made to this original system with the aim of optimising and improving 
its sensitivity and reproducibility.
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3.2 DEVELOPMENT OF THE PERFUSION SYSTEM 
3.2.1 Modifications (i)
3
Striatal synaptosomes preloaded with [ H ]DA of high specific 
activity using the optimum conditions defined in Section 2.3.5, were 
initially perfused using the original system of Mills and Wonnacott 
(1984). The only changes to the experimental procedure were the 
substitution of the original type of glass fibre filter (Whatman GF/A) 
for a GF/B grade and a reduction in the amount of protein loaded onto 
each filter (0.7 ml synaptosomes instead of 1 ml). The GF/B filter has 
a smaller particle retention size and is thicker than the GF/A grade 
(Table 3.3). The advantage of this is the retention of a greater 
number of synaptosomes, the average size of a synaptosome being 0.5 - 
2 ym (Jones, 1975; Whittaker, 1984; see also Section 2.3.1).
An early perfusion profile is shown in Fig. 3.3. The synaptosomes 
were washed with perfusion medium (modified Krebs bicarbonate medium, 
pH 7.4 containing 0.01 mM pargyline and 1 mM ascorbic acid, p.135). 
After a 40 min washout period the synaptosomes were challenged with 
two 4 ml pulses of 100 yM-nicotine, designated and S^; an interval 
of 16 min separated the pulses. In a parallel perfusion system the 
synaptosomes were continually washed with normal perfusion medium 
without exposure to nicotine. This release was taken as the basal 
release and was subtracted from that obtained in the system challenged 
with nicotine. Throughout the development of the perfusion system the 
naturally occurring nicotine isomer, (-)-nicotine was used to evoke 
transmitter release. The preliminary experiment shown in Fig. 3.3 
clearly showed that nicotine at high concentrations evoked the release 
of [ HjDA from preloaded striatal synaptosomes. The elevated 
radioactivity in response to stimulation was expressed as the total
117.
3
dpm above spontaneous efflux, which was then converted to fmoles [ H ]
DA released per mg synaptosomal protein by reference to the specific
5
activity of the radiolabelled dopamine (10 dpm/pmole) and the protein 
concentration of the synaptosome preparation. Alternatively, the peak 
of radioactivity was calculated as the percentage of the total tritium 
present on the filter immediately prior to stimulation. Because the 
monoamine oxidase (MAO) inhibitor, pargyline, and the antioxidant 
ascorbic acid were present in the perfusion medium, little degradation
3
of the released [ H]DA was expected. The tritium present in the
3perfusate was therefore taken as representing [ H]DA. This was 
confirmed in later studies (Section 3.3.3).
The initial perfusion experiments demonstrated that nicotine
3
(100 yM) could repeatedly evoke the release of [ H]DA from striatal
synaptosomes. However, apart from the practical difficulties of the
system (p.11 5), the sensitivity had not been greatly improved as high
3
concentrations of nicotine (100 yM) were required to elicit [ HjDA 
release. In an attempt to enhance the nicotinic effect the following 
changes were made.
In order to reduce the washout period, during which time the 
synaptosomes may begin to deteriorate, the preloaded synaptosomes were 
washed by resuspension in 2 volumes of perfusion medium followed by 
centrifugation in a bench centrifuge at 1,000 g for 7 min. The 
resulting pellet was gently resuspended in medium (using a Pasteur 
pipette) to its original concentration. The integrity of the syn­
aptosomes was maintained using this method (p.100). The washed 
synaptosomes were layered onto the filters (as in the previous 
procedure) but the flow rate was reduced to 0.5 ml/min, the size of 
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original system of Mills and 
Wonnacott, 1984.
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(0.7 ml, 1.4 mg protein).
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_3^ _3. Perfusion profile I, showing radioactivity released per 4 min fraction. Shaded area represents release 
above the spontaneous (unshaded) level.




fmoles [ H]DA released 
above basal/mg protein
0
fmoles [ H]DA/mg protein/ 
nmole nicotine
Evoked release (above basal) 
as percentage of radioactivity 
remaining on filter before 
stimulation
S 400 556 1.4 4.6
S2 400 404 1.0 4.0
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Fig. 3.4 Perfusion profile II.
Changes in procedure
Additional wash step of the preloaded 
synaptosomes.
Flow rate 0.5 ml/min.
Collected fraction size 1 ml.
Nicotine pulse size 1 ml (2 min).
3 3fmoles [ H]DA released fmoles [ H]DA/mg protein Evoked release (above basal) as
above basal/mg protein /nmol nicotine percentage of radioactivity
remaining on filter before
stimulation
S1 100 306 3.1 2.9
S2
n 201 2.0 3.0
S3
1 114 1.1 2.0
S4
M 137 1.4 2.9
sc
f f 126 1.3 3.5
3
Table 3.2. Release of [ HjDA by nicotine using the perfusion conditions described in Fig. 3.4.
Data presented are from a single experiment typical of six similar experiments.




that the additional wash step was included, a 40 min washout period 
was still sufficient despite the slower flow rate.
The combined effect of these changes on transmitter release is 
shown in Fig. 3.4. Nicotine (1 ml, 100 yM) clearly enhanced the efflux 
of radioactivity and the sensitivity of the revised system (as
3
indicated by fmoles [ H ]DA released/mg protein/nmole nicotine; see 
p. 138 ) had doubled. However, the concentration of agonist required to 
observe a convincing peak above the basal level was still very high 
(100 yM). The possibility that the poor resolution of the peaks was a 
consequence of mixing of the released radioactivity in the tubing was
3
investigated by injection of a 10 yl sample of [ H ]DA (0.1 yCi) 
below the filter followed by normal washing. Fractions (1 ml) were 
collected and the radioactivity measured. 97.5% of the total counts 
were recovered in one fraction, indicating that no significant mixing 
occurred.
The system described above gave satisfactory qualitative evidence 
of nicotine-induced dopamine release. However, further modifications 
were made in an attempt to improve the sensitivity and resolution.
3.2.2 Comparison of filters
Two types of filters have been used to support synaptosomes in 
perfusion chambers, i) glass fibre (Levy et al. y 1973; Collard 
et al., 1981, and Mills and Wonnacott, 1984), and ii) cellulose 
acetate/nitrate (Raiteri et al. , 1974; Minnema and Michaelson, 1985). 
The glass fibre filters have a high loading capacity and rapid flow 
rate compared with cellulose filters of a similar particle retention 
size. However, the latter type of filter has been shown to be more
Grade Retention Thickness Radioactivity remaining after Void volume
size (mm) washing sample (ml)
(ym) % total dpm
Whatman
r
GF/A 1.6 0.26 0.81 ± 0.17 ND
Glassfibre GF/B 1.0 0.68 0.39 ± 0.09 ND
< GF/F 0.7 0.42 0.41 ± 0.12 0.16 ± 0.02
\
GF/D 0.65 0.68 ND 0.18 ± 0.02
Table 3.3. Comparison 
Binding of
of filters.
[ 3H]DA to the filters was determined by placing a 10 yl sample of [ H]DA (0.1 yCi) on each
type of filter positioned in a Millipore single filtration unit and washing with 6 ml perfusion medium. 
The radioactivity remaining on the filters was counted (p.74 ) and expressed as a percentage of the 
total radioactivity. Estimation of the void volume was carried out by weighing each filter dry and then 
after soaking in water. The wet filters were placed in Eppendorf tubes and centrifuged at high speed in 
a bench centrifuge for 5 min. The excess water was removed and the filters reweighed. The difference in 




efficient in DA uptake studies using vacuum filtration, (Schoemaker 
and Nickolson, 1983).
For the perfusion of synaptosomes a filter support was required 
with a high loading capacity, low specific binding of radiolabelled 
transmitters and a rapid flow rate. The properties of a range of glass 
fibre filters were compared with those of a Millipore cellulose filter 
(0.65 pm). The results are summarised in Table 3.3.
3.2.3 Modifications (ii)
A Millipore single unit pyrex filtration apparatus (from 
Millipore, cat. no. 0XX10 22500), was investigated as a new model for 
the perfusion system. The lower part consisted of a scintered glass 
filter support, the bottom of which had been drawn out so the tubing 
could be attached and medium pumped through the chamber as in the 
previous arrangement.
The upper and lower parts of the chamber were held together by an 
aluminium spring clamp. A filter soaked in perfusion medium was firmly 
supported between the two halves. Two types of filter were compared, 
i) a cellulose acetate/nitrate (Millipore, 0.65 ym) and ii) a glass 
fibre filter (Whatman GF/F, 0.7 pm), see Table 3.3.
However, the former type of filter proved difficult to work with 
as high pressures were required to ensure rapid flow through the 
filter. The binding of [ H ] DA to the GF/F filter was comparable with 
that of the GF/B grade; because the GF/F filter had a smaller 
retention size than the GF/B it was chosen for use in all subsequent 
perfusions.
Distribution of a 1 ml drug sample through the revised system was 
determined by the perfusion of a pulse of dye (Blue dextran,
125.
Pharmacia). The sample was collected in a total of 4 (1 ml) fractions. 
However, examination of nicotine-evoked DA release showed that 
although the system gave consistent results, the sensitivity had not 
been improved.
To- study the release in greater detail using the slower flow rate
of 0.5 ml/min, a smaller volume of synaptosomes (0.4 ml) was loaded
onto the filter (to limit the possibility of reuptake of the released 
transmitter, Collard et at., 1981) and the size of pulse was reduced 
to 100 pi. This pulse was introduced into the system via a *T * 
junction tap fixed into the tubing just before entry into the chamber 
(Fig. 3.5). Administration of the drug by this method was quick and 
the response was greatly enhanced (Fig. 3.6).
The next aim was to investigate the effect of reducing the
collection volume on resolution. Fraction collectors (LKB 2112 
Redirac) were used toautomatically collect perfusate (2-8 drops) in 
plastic minivials (volume 6 ml) placed in the cassette of the fraction 
collector. The radioactivity in each vial was counted (p.74 ) using
a scintillant of high aqueous capacity.
To allow assembly of the chambers directly above the arm of the 
fraction collectors the method of the removal of perfusate was 
changed. Instead of suction through tubing below the filter, air 
pressure was applied above the filter (Figs. 3.7, 3.8 and 3.9).
However, very high air pressure was required to ensure adequate flow 
through the filter and this also disturbed the flow of the incoming 
medium. To overcome these problems the scinter was removed from the 
lower part leaving a rim to support the filters and a smaller volume 
(250 pi) of synaptosomes was used. To protect the synaptosomes from the 
impact of the drops of medium, a prefilter (Whatman GF/D, cut to
°o q o O
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Fig. 3.6. Perfusion Profile III.
Changes in procedure
New chamber with scinter and GF/F fi 
Volume of synaptosomes, 400 pi. 
Nicotine pulse size 100 \il (0.2 min). 
Entry of pulse via *T ’ junction.
3 3Pulse Total amount of fmoles [ H]DA released fmoles [ H]DA/mg protein Evoked release (above basal) 
nicotine (nmoles) above basal/mg protein /nmole nicotine as percentage of radio­
activity remaining on filter 
before stimulation
S1
10 156 15.6 2.2
S2
ft 105 10.6 1.7
S3
vt 111 11.1 1.2
S4





by nicotine using 
representative of
the perfusion conditions described in Fig. 3.6. 
3 experiments.
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1.5 cm) of high retention size and flow rate was placed over the bed 
of synaptosomes. The tube containing the incoming perfusion medium was 
brought into contact with the centre of the filter. In view of the 
improved resolution from reducing the flow rate of the medium (Fig. 
3.4), /the flow rate was further reduced to 0.175 yl/min.
With these modifications the system was more sensitive. Nicotine 
(50 yM) evoked release of the radiolabelled transmitter and this was 
clearly observed above the basal release (Fig. 3.10). In the 
experiment shown.small fractions (4 drops) were collected with the 
result that the peaks spread over only 3 to 4 fractions. However, to 
reduce the total number of samples to be counted in subsequent 
experiments larger fractions (8 drops) were collected resulting in 
peaks being spread over 5 to 6 fractions. In the experiment shown in 
Fig. 3.10 the washout period had been reduced to only 20 min and 
clearly the basal release had not settled down during this time 
period. In all subsequent experiments the wash out period was 40 min. 
The overall sensitivity of the system had been greatly improved, the 
response to nicotine having increased by a factor of 80 (see p.138 )•
Unfortunately the introduction of a drug via the *T ' junction 
required careful manipulation, and mixing often occurred leading to the 
dilution of the sample. Direct injection of the sample into the flow 
of the perfusion medium was also carried out but this lead to mixing 
and leaking at the point of injection. The administration of a 
pharmacological agent was therefore introduced as a pulse (as in the 
original experiments p.111 ). For a 100 yl pulse (flow rate 150 \il/
min) a 40 sec pulse of drug was separated by 30 sec air gaps. This 
method ensured that there was no dilution of the drug sample. A change 
in perfusion medium was also achieved by the transfer of tubing from
a:
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Fig. 3.8. The final perfusion chamber.
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Fig. 3.10. Perfusion Profile IV.
Changes to perfusion procedures 
Absence of scinter in chamber. 
Additional prefilter (GF/D).
Air pressure in upper chamber 
Automatic collection of fractions 
Volume of synaptosomes, 250 yl . 
Flow rate 175 yl/min.
(4 drops
Pulse Total amount of 
nicotine (nmoles)
2
fmoles [ H]DA released 
above basal/mg protein
3
fmoles [ H]DA/mg protein 
/nmole nicotine
Evoked release (above basal) 
as percentage of radio­
activity remaining on filter 
before stimulation
si 5 408 81.6 2
S2
5 311 62.2 2
o
Table 3.5. Release of [ HjDA by nicotine (50 nM) in Fig. 3.10.
Results shown are representative of 3 experiments.
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one bottle to the next in the water bath, an air gap separating the
two media. The introduction of air gaps caused no artifactual changes 
3
in [ H ] DA release.
3.2.4 ' The final system
a) The perfusion apparatus
The final perfusion apparatus was composed of a multichannel 
peristaltic pump to supply medium to 4 perfusion chambers, each 
supported over a fraction collector (see Fig. 3.7 and Table 3.6).
b) Perfusion Medium
The perfusion medium was a modified Krebs-Ringer-bicarbonate 











Stock solutions (xlO final concentration) were prepared and stored at 
4°C for a maximum of one month. Glucose, ascorbic acid and pargyline 
solutions were freshly prepared. Equal volumes of the stock solutions
136.
Table 3.6. Details of the perfusion apparatus.
Component Name/dimensions Supplier
Peristaltic pump




I.D . 2.00 mm 






























were mixed and distilled water added to give the required final 
concentrations. The medium was continually gassed with O^/CO^
(95%/5%). After lh gassing the pH was adjusted to 7.4 with 0.1M NaOH.
The MAO inhibitor pargyline and the antioxidant ascorbic acid were 
included to reduce degradation of DA. The KC1 concentration used was 
half that originally used by Mills and Wonnacott (1984). This was to 
reduce the total concentration of the depolarising K+ ion and to 
achieve a K+ concentration which is near the optimum of 3.9 mM for DA 
uptake (Holz and Coyle, 1974). Ca^+-free medium was prepared by 
omitting CaCl^, osmolarity being maintained by substitution with NaCl. 
Reduced Na+ medium was obtained by the replacement of NaCl with 
sucrose (237 mM).
When solutions containing elevated concentrations of KC1 (release 
studies) were used a corresponding reduction in the NaCl concentration 
was made to maintain osmolarity.
c) The final perfusion conditions (V)
3
Synaptosomes (100-250 pi) preloaded with [ H ] DA were layered 
onto Whatman GF/F filters, wetted in perfusion medium, positioned in 
the perfusion chambers. A prefilter (GF/D) was placed over the 
synaptosomes and perfusion medium (37°C) was pumped over the filters 
at a flow rate of 150 pl/min. Air pressure (20 p.s.i.) was applied 
above the filters to ensure rapid removal of the perfusate. After a 40 
min washout period, the synaptosomes were exposed to pulses (100 pi) 
of pharmacological agents, the pulse being separated from the main 
flow of medium by air bubbles. Fractions (8 drops, 340 Ul) of the 
perfusate were collected 10 min prior to the first stimulation and 
thereafter until the end of the experiment. The radioactivity in each
138.
fraction and filter was counted (p.74 ) and a perfusion profile 
constructed.
At the end of each experiment the tubing and chambers were 
thoroughly washed with distilled water. Every 4 weeks the tubing was 
replaced and the flow rate calibrated.
The details described above constituted the final system used 
throughout the rest of the study.
3.2.5 Discussion of the final system
a) Improved sensitivity
The responsiveness of each perfusion system during its 
development, expressed as fmoles [^ H ] DA released (above spontaneous 
release) /mg protein/nmole nicotine, can be used as an index of the 
sensitivity of the system. Thus the sensitivity of the final system 
was clearly greatly increased (Table 3.7), with almost a 100 fold
3
increase in the amount of [ H ] DA released per nmole nicotine.
The concentration of nicotine (100 yM) used throughout the 
development of the perfusion system was high. In later studies the 
effect of nicotine over the range 0.01 yM-1 mM was studied (p.185 ) and 
concentrations above 100 yM were found to elicit maximum [ H ] DA 
release. In perfusion system IV,the concentration of nicotine used was 
non-saturating (50 yM) and therefore the index of sensitivity is not 
directly comparable with the other systems.
b) Practical changes
The small volume of synaptosomes loaded onto each filter 
(150 yl, approx. 0.4 mg protein) allowed the number of chambers in 















I. Fig. 3.3 100 yM 1.0 4.0 1.4 0.35
II. Fig. 3.4 100 yM 0.5 2.0 3.1 1.55
III. Fig. 3.6 100 yM 0.5 0.2 15.6 78
IV. Fig. 3.10 50 yM 0.175 0.57 81.6 143
V. Final system 100 yM 0.15 0.66 69 105
Table 3.7. Development of a perfusion system.
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rats required; two rats were used for a striatal preparation and one 
rat was used for a hippocampal preparation (Section 5.2.1). Because of 
the limited availability of scintillation counters it was necessary to 
reduce the total number of samples for radioactivity counting. 
Therefore 8 drop fractions (340 yl) of perfusate were collected 
resulting in a slight reduction in the resolution of the peaks of 
released radioactivity.
c) The period of stimulation and the time interval between 
successive stimulations
The length of the period of stimulation (pulse) used in the 
final perfusion system (p.135) had been reduced from 4 min (4 ml) as 
in the original system (p.Ill) to 40 s (100 yl). Using this size of 
pulse a 20 min recovery time between successive pulses was allowed.
However, although this was an adequate recovery time using 
nicotine (100 yM) as the stimulus, when the depolarizing agent 
veratridine (10 yM) was used to evoke the release of DA a much longer 
interval was required (see Fig. 3.11). K + (28 mM) evoked release was 
also demonstrated (Fig. 3.11). Comparison of the peaks of released 
radioactivity elicited by the different types of stimuli showed that 
the response to, and the recovery from nicotine (1 yM) and K + (28 mM) 
were relatively fast compared with the action of veratridine (10 y M ) .
The differences between the duration of the responses evoked by 
nicotinic agonists, K+ and veratridine, and the effect of concen­



























Fig. 3.11. Perfusion profile showing the release of [ H]DA from striatal synaptosomes (200 yl, 0.62 mg
protein/filter) in response to (nicotine, 1 yM), (K+, 28 mM) and (veratridine, 10 yM) 
^indicates time of arrival of the pulse. Dashed line shows the level of basal release.
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3.2.6. Calculation of the release data
a) The effect of repetitive stimulation
Various methods for calculating release data have been reported 
(see Section 3.1.2).
3
A ntethod was required for quantifying the [ H ] DA released in 
experiments using the final perfusion conditions which allowed for 
possible differences between perfusion chambers and day to day 
variables (e.g. basal release rates).
Throughout the development of the perfusion system the efflux of
3
tritium in response to stimulation was converted to fmoles [ H ] DA 
released per mg protein. Alternatively, the fractional release was 
calculated.
To compare these two methods,striatal synaptosomes were repeatedly 
stimulated with increasing concentrations of K+ (Figs. 3.12 and 3.13). 
The results show that with time the amount of radioactivity released 
represents a higher proportion of the amount of radioactivity 
remaining on the filter (Fig. 3.13b). This is a result of the gradual 
depletion of the transmitter pool within the synaptosomes with 
increased length of perfusion time. Maximum release was observed at 
about 45 mM K+ and a half maximum release at 29 mM. These results are 
in agreement with those reported by Minnema and Michaelson (1985) who 
obtained a half maximum response at 28.5 mM K+ and a maximum response 
at 42.75 mM.
In subsequent experiments to measure the effects of increasing 
concentrations of drug (agonist, K+ or veratridine),only the release 
data obtained by the initial stimulation ( ,  t = 40) were used. In 
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Fig. 3.12. Effect of increasing concentrations of K+ on [^HJDA release using perfusion conditions V
(250 pi synaptosome on filter and 4 drop fractions). After a 40 min washout period(preloaded 
synaptosomes were stimulated with increasing concentrations of K+, at 20 min intervals.
*4“ 3Summary of the K -evoked release of [ H]DA shown in Fig
2
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pulses of drugs, stimulation was usually carried out only three times 
at 30 min intervals after the 40 min washout period.
b ) The effect of antagonists on stimulated release: the final 
perfusion schedule
In early experiments, the effect of an antagonist was studied 
by running three perfusion chambers in parallel, one chamber acting as 
a control which was perfused with normal medium, one system to 
determine basal release which was perfused with normal medium, but 
which was not stimulated, and one test system in which the perfusion 
medium contained the antagonist. Towards the end of each experiment a 
pulse of K+(28 mM) was administered to standardise each system. The 
stimulated release in the presence of the antagonist was compared to 
the control system. However, because there are minor differences in 
the local conditions within each system, slight differences in release 
rates between systems were observed.
To overcome this problem the perfusion schedule was changed. Four 
perfusion systems were operated in parallel and all were initially 
perfused with normal perfusion medium. As described above, after the 
40 min washout period the synaptosomes were stimulated (S^ , t = 40 
min) and the stimulation was repeated at t = 70 min and 110 min 
designated and respectively, see Fig. 3.14.
The effect of an antagonist on evoked release was determined by
changing the medium in two of the systems to medium containing the
antagonist 10 min before and continuing throughout the response
3
until 10 min before S^ . The [ H ] DA released by the and the 
pulses were expressed as a percentage of the initial stimulation (S^) 
to give S /S and S^/S^, values respectively.
Fig. 3.14. The final perfusion schedule.
A typical perfusion profile showing the time schedule 
used to study the effect of an antagonist on agonist 
evoked release. Synaptosomes were stimulated 3 times 
(Sr  S^, Sg) at 30 min intervals. The antagonist was 
introduced into the medium 10 min before and continued 
until 20 min- after S^. The ratio in the presence
of an antagonist was calculated as a percentage of the 
S^/S^ ratio obtained in normal medium. Comparison of 
the values gave information about the recovery of
the response after exposure to the antagonist.
The profile shown is typical of results obtained for 
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Fig. 3.14. The final perfusion schedule.
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The test (antagonist present during S^) and the control and
S3/S1 values were then compared.
149.
3.3. CHARACTERISATION OF THE FINAL SYSTEM
3
3.3.1. Determination of the possible reuptake of released [ H ]DA
3
A requirement of the perfusion system was that the [ H ] DA 
released from the preloaded synaptosomes was removed sufficiently 
quickly to prevent any reuptake. As previously determined,little
3
binding of [ H ] DA to glass fibre filters occurs (Table 3.3).
3
The possible interaction of released [ H ] DA with the striatal 
synaptosomes was investigated by perfusing synaptosomes that had not 
been loaded and exposing them to pulses (100 yl) of [ H ] DA at a
concentration approximately twice the amount estimated to be usually
+ -9 4
released in response to K (28 mM), (1.1 x 10 M, 1.1 x 10 dpm/100 yl,
see p. 165). However, this was an underestimate of endogenous DA levels which
were later determined (see Section 3.3.3).A further pulse of K+ (28 mM) was
administered 25 min later to release any radioactivity that had been
taken up by the synaptosomes. The effect of the DA uptake inhibitor
nomifensine (10 yM) was determined by the continual perfusion of the
drug in a parallel system.
Fig. 3.15 shows the distribution of the radioactivity after
3
passage of a 100 yl pulse of [ H ] DA through the perfusion system in 
the presence and absence of synaptosomes. In both conditions the peak 
of tritium is distributed over 6 fractions which is equivalent to a 
volume of 2.04 ml and a time of about 13 min 10 s. This represents the 
diffusion of a pulse and was considered to be the minimum time 
required between successive stimulations. Analysis of the radio­
activity remaining on the filter (Table 3.8) showed that in the
3
presence of synaptosomes,four times as much [ HJ DA was retained than 
by the filters alone. Stimulation with K+ failed to release the
3
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Fig. 3.15. Distribution of a 100 \i 1 pulse of [ ] DA (1.1 x 104 dpm) using
the final perfusion conditions (p.137 )
a) Filters alone, b) Filters and synaptosomes (150 y 1, 0.315 mg protein)
indicates pulse of K+ (28 mM).
*
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Table 3.8. Radioactivity remaining on filters after perfusion of a pulse of [ HJDA (1.1 x 10 dpm). 
Results from a single experiment.
Perfusion details Radioactivity remaining fmoles DA retained
cpm % pulse
a) Filters alone 133 3.6 2.8
b) Filters with
synaptosomes 466 12.7 11.2
c) Filter with synapto­
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Fig. 3.16. Distribution of a 100 w 1 pulse of [ Hj nicotine using the final perfusion conditions (p 137J
.5(i) 10 mM Nicotine (3.3 x 103 cpm/*100 yl) (ii) 1 yM Nicotine (3.3 x 104 cpm/lOOyl)
(a) filters alone, (b) filters and synaptosomes (0.54 mg protein), 1 indicates pulse of K+ (28 mM
Table 3.9. Radioactivity retained by the filters and synaptosomes after perfusion with a pulse of
3








































tissue or that uptake may have been into non-releasable pools.
However, the DA uptake inhibitor nomifensine (10 yM) had no effect on 
the distribution of radioactivity either released or retained 
(profiles not included because they were identical to control), which 
strongly suggests that no specific uptake had occurred.
3.3.2. Determination of nicotine binding to glass fibre filters and 
tissue during a perfusion experiment
Nicotine has been reported to bind to glass fibre filters with
high affinity (Abood et at. 3 1979). To determine whether significant
binding of nicotine to the filters and synaptosomes occurs during a
perfusion experiment, synaptosomes were prepared and perfused as
described in section 3.3.1. Pulses of [ H ]nicotine (29.8 Ci/mmol)
were administered at two concentrations, 1 yM and 10 yM. Control
systems were operated in parallel in the absence of synaptosomes.
Fig. 3.16 and Table 3.9 summarise the results obtained. The
radioactivity was distributed over 6 to 7 fractions, similar to the
2
diffusion profiles obtained with the pulses of [ H JDA (Section 3.3.1, 
Fig. 3.15). Residual binding of the ligand to the filters was the same 
at the two nicotine concentrations studied. In contrast, in the 
presence of synaptosomes approximately twice the amount of nicotine 
was associated with the synaptosomes at the higher concentration (10 
yM).These results support the decision to use low (1 yM)
concentrations of nicotine to reduce the amount of residual nicotine
binding between successive stimulations.
3.3.3. Analysis of the perfusate by HPLC with ECD.
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Time (min)
Fig. 3.17. A typical HPLC chromatogram obtained from a standard 
solution containing 10 pmoles/100 yl of (i) dopamine,
(2) homovanillic acid, (3) dihydroxybenzylamine and
(4) 3, 4- dihydroxyphenylacetic acid. Solvent front (SF).
Arrow indicates time of injection.
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estimate the levels of unlabelled (endogenous) DA, analysis of the 
perfusate by High Performance Liquid Chromatography with 
electrochemical detection (HPLC with ECD) was carried out.
The HPLC method was based on the chromatographic procedure 
described by Eriksson and Persson, (1982).
a) The HPLC system
The liquid chromatography system was composed of an LDC model 
III constametric pump, a Rheodyne 7125 injection valve with a 100 ju 1 
loop, a 20 cm stainless steel analytical column packed with 5 ym 
diameter Hypersil octadecylsilane (ODS) particles, and an electro­
chemical detector BAS LC-4A. The detector was operated at +0.65 V with 
a Ag/AgCl reference electrode (BAS RE-1) and a glassy carbon working 
electrode.
The mobile phase was an acetate-citrate buffer (pH 5.2) containing 
sodium acetate (100 mM), sodium hydroxide (60 mM), citric acid 
(40 mM), 1-octane sulphonic acid, sodium salt (0.5 mM) and methanol 
(HPLC grade, 10% v/v). The water used was deionised and filtered 
through a Millipore Milli-Q-reagent grade water system. Before use the 
mobile phase was filtered through a 0.45 ym pore nitrocellulose filter 
under vacuum and degassed by bubbling with helium for 30 min.
b) Operation and calibration of the column
The mobile phase was pumped through the column at a flow rate 
of 1 ml/min. A pressure of 1500 p.s.i. was maintained throughout the 
procedure and ambient temperatures were used. To demonstrate that DA 
and its metabolites could be resolved using the described system, 
fresh solutions (1 yM) of DA, D0PAC, homovanillic acid (HVA) and the 
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Fig. 3.18 Calibration curves for a) DOPAC and b) DA
Standard solutions (listed in the Table 3.10 below) 
were analysed in triplicate and the mean peak height 
ratio calculated.
a) DOPAC : y = 0.0586 x + 0.0047 (r = 0.999)
b) DA : y = 0.0261 x + 0.0055 (r = 0.996;
Table 3.10















Millipore-filtered water and a sample (100 yl) of each solution 
injected into the column. The sensitivity of the ECD was set at 5 nA 
and the retention time determined for each test compound (Table 3.11). 
The retention time was dependent on daily variables such as room 
temperature and the percentage methanol composition of the mobile 
phase.
Table 3.11. The characteristic retention time of each compound studied 
using the HPLC system
Compound Retention time 
min, sec
DOPAC 3, 55
DHBA 6 , 45
HVA 8 , 30
DA 10, 45
Solvent front 2 , 0
Because the retention time of DHBA did not overlap with that of 
any of the other test compounds (Fig. 3.17) it was a suitable internal 
standard. DHBA, at a constant concentration, 20 pmoles/100 yl, was 
added to each sample to be analysed, as an internal standard to 
correct for variation in sample injection size and manipulation. The 
ratio of the peak height of the test compound to the height of the 
DHBA peak on the HPLC chromatogram was used to calculate the 
concentration of the test compound by reference to calibration curves 
(Fig. 3.18). This is known as the peak height ratio.
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c) Analysis of [^H]DA by HPLC with ECD
3
To determine the purity of [7,8- H]DA used in the perfusion
3
experiments, a 100 yl sample of [ H]DA, diluted with Millipore-
*—8filtered water,to a concentration of 2 x 10 M, was injected into the 
HPLC cblumn and 30 s fractions (0.5 ml) of the eluate collected in 
scintillation vials at the waste pipe from the E.C.D. The radio­
activity in each fraction was measured (p.74 ) and expressed as a 
percentage of the total radioactivity recovered from the column, 
corrections for background counts and counting efficiency being made. 
The time taken from the ECD to the waste pipe was 30 s, hence the 
retention time for each peak of radioactivity could be determined and 
the tritiated compound identified. Two samples of [ H]DA were 
analysed; sample a) which had been stored for 18 months and sample b) 
for 3 months. Analysis of the distribution of tritium indicated that a 
large amount of decomposition had occurred in the older sample, with 
unidentifiable products eluting with the solvent front (Fig. 3.19).
The HPLC chromatograms (not included) had horizontal baselines 
characteristic of clean samples. Using a sensitivity of 5 nA a single 
peak at t = 11 was obtained for each sample, which correlates well 
with the expected position of DA (Fig. 3.17).
d) Extraction of DA
The extraction of DA from aqueous samples was carried out 
following the method of Smedes et at. (1982), with the modifications 
by Ian MacDonald (personal communication).
To a sample (1 ml) of perfusate or standard solution, in a glass 
test tube, 0.5 ml of 2 M NH^Cl-NH^OH buffer (pH 8.5) containing 0.2% 














J L J I I L _L _L J L _L





















0 7 8 9 10 11 12 13 14 15 16 Retention time
(min)
Fig. 3.19 Distribution of tritium in samples of radiolabelled dopamine 
(2 pmoles/100 yl) stored as described in "Methods".
Sample a) 18 months old
Recovery of radioactivity = 99.5%
Tritium associated with DA = 44%
Sample b) 3 months old
Recovery of radioactivity = 96.5%
Tritium associated with DA = 77.5%
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added followed by 2.5 ml of n-heptane containing 1% (v/v) octanol and 
0.35% (w/v) tetraoctylammonium bromide (TOABr). The mixture was 
vortexed for 2 min and then left for 5 min at 4°C to allow the organic 
and aqueous layers to separate. A portion of the organic layer (2 ml) 
was transferred to a glass centrifugate tube. Reversion to the aqueous 
phase was achieved by addition of 1 ml octanol and 250 yl 0.08 M 
acetic acid. The mixture was vortexed for 1 min and then left for 5 
min to allow separation of the layers. Using a Pasteur pipette the 
lower aqueous phase was removed and stored in an Eppendorf tube at 4°C 
until analysis by HPLC with ECD.
To determine the concentration of the DA in the acetic acid, the 
internal standard (DHBA) was included in the 0.08 M acetic acid (20 
pmol DHBA/100 yl) and the peak-height ratio calculated.
e) Analysis by HPLC with ECD of the perfusate released 
from striatal synaptosomes
A suspension of striatal synaptosomes was prepared (p.63 ) and
3
divided into two. To one half [ H]DA was added, using the loading 
conditions described in Section 2.3.5 (p. 95 ). The remaining sample
was incubated at 37°C for an equivalent incubation period. Samples 
(200 yl) of the synaptosomes were layered onto the filters in the 
perfusion chambers. Three chambers were operated in parallel, two 
containing tissue preloaded with [ H]DA and one with unloaded tissue. 
Perfusion was carried out using the final conditions (p. 137 ) except 
that a longer washout period of 60 min was used before exposure to a 
pulse of test substance, and larger fractions (30 drops, 1.35 ml) were 
collected. The fractions containing tritium were analysed as follows:
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1) The radioactivity in a sample (50 yl) from each fraction was 
counted (p.74 ) to give a perfusion profile (Fig. 3.20).
2) 100 yl from each of the 3 fractions around the peak of stimulation 
was injected into the HPLC column and 1 min fractions of the 
el^ate collected from the waste pipe of the ECD.The fractions were 
counted for radioactivity (p.74 ) and the distribution of tritium 
determined (Fig. 3.20; lower profiles).
3) Samples (1 ml) from the 3 fractions around the peak of stimulation 
were extracted using the method described on p.159. 100 yl portions 
of the final extracts, containing 20 pmoles DHBA/100 yl 0.08 M 
acetic acid, were counted for radioactivity (p.74 ) and analysed 
by HPLC with ECD (Table 3.13).
Fractions containing DA released from the unloaded synaptosomes 
were extracted by the method described in Section 3.3.3d and the 
extract analysed by HPLC with ECD (Table 3.14).
To determine the effectiveness of the extraction process three 
samples were compared,
i) an extract from a standard solution originally containing 10 
pmoles DA, 10 pmoles DOPAC and 20 pmoles DHBA per 100 yl; 
ii) an extract from a standard solution containing 10 pmoles
DA/100 yl, the internal standard DHBA (20 pmoles/100 yl) added 
to the final extract; 
iii) a standard solution containing 10 pmoles DA and 20 pmoles DHBA 
per 100 yl (no extraction); see Table 3.12.
The peak-height ratios of DA relative to DHBA were similar for 
samples i) and iii), indicating that DHBA and DA were equally ex-
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tracted. Calculation of the DA concentration in sample (ii), by 
extrapolation of the calibration curve, gave a concentration of 
greater than 20 pmoles DA/100 yl indicating that the extraction method 
produced a two-fold increase in the concentration of DA. Inclusion of 
DOPAC/in the standards (i) gave no additional peak on the 
chromatogram, indicating that DOPAC was not extracted.
Table 3.12. Comparison of extracted DA/DHBA samples by HPLC.






Results are the means of three determinations, range in peak-height 
ratio ± 0 .02.
0
Table 3.13. The concentration of [ h ]DA in samples of the 
perfusate fractions from perfusion system 
a) (K+ stim., Fig. 3.20a) was calculated 
by reference to the specific activity of
5
the radiolabel (10 dpm/pmole)and the 
percentage of the tritium associated 
with DA.
dpm/iQO Ml x % DA = pmoles [^H]DA/100 Ml 
105
The efficiency of the extraction process was 
determined by comparing the concentration of
3
[ H]DA in the extracted samples with the 
untreated fractions. The results showed that 
a correction factor of 2.15 (mean of 3 samples) 
was required to take account of the concentration 
effect of the extraction process.
2
Table 3.13. Estimation of the concentration of [ H]DA in perfusate samples.
3
Fraction dpm/100 yl % dpm % dpm pmoles [ H ]DA Increase in concentration






6A 1 8817 91
7A' 12483 94





0 0.080 x 2
0 0.117 x 2.29
0 0.084 x 2.15
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Table 3.14. Measurement of endogenous DA
Fraction Number 










5 0.025 0.346 1.7
7 0.03 0.432 2.2
9 0.024 0.329 1.6
The perfusate released from the unloaded synaptosomes was analysed 
by HPLC with ECD after extraction of the fractions by the method 
described on p.159 . Small peaks with a retention time of 11 min were 
observed on the HPLC chromatograms. Using the peak-height ratio, the 
concentration of DA in the extracted samples was estimated and the 
true level of DA in the non-extracted samples determined, (assuming 
the doubling of the DA concentration in the final extract; Tables 3.12 
and 3.13).
3
Fig. 3.20. Analysis of the [ H]DA released from perfused striatal 
synaptosomes in response to a) K+ (28 mM) and b) 
nicotine (1 yM).
Upper profiles show the radioactivity present in 50.yl 
samples of consecutive fractions (1.3 ml). The lower 
profiles show the separation by HPLC of the tritium in 
100 yl samples of the 3 fractions around the peak of 
stimulation (6 , 7, 8 ). Recovery of radioactivity from 
the HPLC column was approximately 80%. In response to K+ 
and nicotine stimulation (fractions 7a and 7b 
respectively), 8% of the radioactivity recovered was 
associated with a peak of retention time characteristic 
of DOPAC (shaded area). The other peak of tritium with a 
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f) Discussion: Analysis of DA by HPLC with ECD
The HPLC system used, that of reverse phase ion-pair
chromatography, allowed the separation of DA from its metabolites
(Fig. 3.17). However, the usefulness of the system was limited by
the detection limit of the ECD (0.5 pmole DA/100 pi). Furthermore,
because the concentration of DA in the perfusate was low (~ 0.5 nM
pH ]DA and ~ 2 nM DA) (Tables 3.13 and 3.14), accurate measurement
of the peaks on the chromatogram was difficult. The HPLC system was
therefore initially used to separate samples containing tritium and
to analyse the eluate from the column for radioactivity. Using this
2
approach the purity of stock [ H]DA was determined; a 3 month old 
sample (stored as described in the "Methods") had a purity of 77.5% 
(Fig. 3.19). The period of storage is therefore important. 
Stabilising agents such as ascorbic acid are often added, but this 
has been shown to produce a front peak on the chromatogram 
(Eriksson et at., 1982). The importance of refrigeration, storage 
in the dark and the addition of perchloric acid (0.1 M, to 
deproteinise the sample) have also been used to minimise 
degradation of DA (Eriksson et at., 1982 ; Verbiese-Genard 
et at., 1983). To ensure minimum degradation of the DA used in 
subsequent experiments [ H]DA was stored for a maximum of 3 months 
in 2.5 mM ascorbic acid at -20°C.
2
The tritium present in the perfusate was assumed to be [ H]DA. 
The major route of DA metabolism in striatal synaptosomes is by 
deamination to form DOPAC (de Belleroche et at., 1976). However, 
little degradation of the released [ H ]DA was expected because of 
the presence of the MAO inhibitor pargyline (10 yM) and the anti­
oxidant ascorbic acid (1 mM) in the perfusion medium. Pargyline
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inhibits the breakdown of DA to form DOPAC by inactivating MAO 
whereas ascorbic acid prevents oxidation of DA by atmospheric 
oxygen.
Many groups who have studied the release of DA from striatal 
synaptosomes have included MAO inhibitors and ascorbic acid at
f
concentrations similar to those used in the experiments in this 
thesis (e.g. Raiteri et at., 1974, 1979; Mulder et at., 1975; 
Minnema and Michaelson, 1985). Indeed, their presence has been 
shown to reduce the basal efflux of the primary metabolite DOPAC 
from perfused striatal slices (Becker et at,, 1984; Arbuthnot 
et at,, 1984) and,when MAO is not inhibited,the spontaneous outflow 
of radioactivity consists primarily of [ H]DA metabolites 
(Cubeddu et at,, 1979).
Using perfusion medium containing pargyline and ascorbic acid, 
approximately 80% of the released tritium had a retention time 
characteristic of DA (Fig. 3.20), suggesting that little 
degradation had occurred. The purity of the stock [ H]DA used to 
radiolabel the synaptosomal transmitter pools was also about 80% 
(Fig. 3.19) and so the original assumption that the released
3
radioactivity was mainly [ H]DA was correct. Of particular interest
3
was the finding that no [ H]DA metabolites were detected in the 
fractions before and after stimulation, but during K+ (28 mM) and 
nicotine (1 yM) evoked release an additional peak of tritium was 
observed characteristic of DOPAC (Fig. 3.20). The DOPAC released 
upon stimulation is possibly formed from DA released from the 
storage granules into the cytoplasm where it is accessible to MAO 
(Cubeddu et at,, 1979). This also agrees with the work of Arbilla 
and Langer (1978) who suggest that K+-evoked release causes the
3
efflux of [ H]DA from reserpine-sensitive stores (storage 
granules).
In a preliminary experimentfthe omission of pargyline resulted
in a low uptake of radiolabel corresponding to a reduced level of
basal efflux (20% normal) and small peaks of evoked radioactivity.
Despite the reported criticisms of the use of MAO inhibitors and
ascorbic acid in release studies (Hadjiconstantiou. and Neff, 1983;
Arbilla and Langer, 1980; Collard et at., 1980), pargyline
(0.01 mM) and ascorbic acid (1 mM, a concentration half that used
by Mills and Wonnacott, 1984) were always included in the perfusion
3medium. This was to ensure a high uptake of [ HjDA which was 
required for the improved sensitivity of the final perfusion 
system.
To measure the endogenous levels of the released DA, the 
extraction method of Smedes et at. (1982). was used. The procedure 
makes use of the complex formation in alkaline medium, between the 
diphenylborate and the diol group of the catecholamines in 
combination with ion-pair formation. The method did not extract 
DOPAC and therefore no information about the endogenous levels of 
this metabolite was obtained. DA and the internal standard DHBA 
were extracted with similar efficiency (Table 3.12). Using standard 
solutions, the extraction method approximately doubled the 
concentration of DA (Table 3.13). The concentration of DA in the 
final extract was at a level which was just above the detection 
limit of the ECD; the endogenous level was calculated as approx­
imately 2 nM, giving a ratio of labelled to unlabelled DA of 1 : 4.
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3
3.3.4 The physiological relevance of the released [ H]DA
a) Basal release
The release of transmitter from perfused tissue, in the 
absence of stimulating agents, is often referred to as the basal or 
spontaneous efflux/outflow.
Perfusion of a tissue preparation allows the study of both 
basal and evoked release. For a synaptosomal preparation preloaded 
with radiolabelled transmitter precursor, high levels of basal 
release can lead to difficulties in studying the release mechanisms 
(Mulder, 1982). Basal efflux may represent leakage from damaged 
particles, although efflux from ruptured nerve endings has no 
physiological relevance but is one of the disadvantages of using a 
synaptosomal preparation to study transmitter release (Levi and 
Raiteri, 1976). The amount of basal release is dependent upon the 
amount of tissue and on the integrity of the preparation. Residual 
radiolabelled transmitter which has not been taken up by the 
synaptosomes can also contribute to the basal level of 
radioactivity. Using the final perfusion conditions (p.1 3 7) a 
stable basal rate of release was established after 40 min. Similar 
washout periods have been used by other groups (e.g. Mulder 
et a t 1975; Taube et at., 1977 and Gillet et at., 1985).
A Ca^+-dependent component of the basal release was 
demonstrated by initially perfusing striatal synaptosomes with 
Ca^+-free medium (p.137 ) and then introducing Ca^+ into the medium 
(Fig. 3.21). There was a marked increase in the spontaneous release 
of [ 3H]DA upon the addition of Ca2+. A similar Ca^+-dependent 
component of basal release of radiolabelled transmitter from 
perfused synaptosomes has been reported by Raiteri et at. (1979);
Minnema and Michaelson (1985). However, there remained a large
proportion of the basal efflux which was Ca^+-independent. This may
represent efflux from non-vesicular transmitter stores (Mulder et
at., 1975), or the non-quantal spontaneous release reported by Katz
and Miledi (1977). It may also represent efflux from damaged
synaptosomes. Alternatively, the observed Ca^+-independent release
may be a result of high levels of endogenous Ca^+ present in the
synaptosomal preparation. Examination of the synaptosomal fraction
by electron microscopy (Fig. 2.3, p.78 ) showed that free
mitochondria were present in the preparation. These Ca^+-rich
2+
organelles may therefore supply the Ca required for transmitter 
release.
In an attempt to obtain a complete Ca^+-free condition, perfus­
ion of striatal synaptosomes was carried out using Ca^+-free medium 
containing 0.5 mM EGTA. However, after 40 min perfusion with this 
medium and one stimulation with 0.01 pM nicotine, there was a 
massive continual release of transmitter which levelled off at a 
basal rate twice the control value. Further studies using EGTA were 
not carried out because of this observed effect on the basal 
release.
b) The Ca -dependency of K -evoked [ H]DA release
To demonstrate the Ca^+-dependency of K+-evoked release of 
pH ]DA from perfused striatal synaptosomes, preloaded striatal 
synaptosomes were initially perfused with Ca^+-free medium (p.137 ) 
and then with normal perfusion medium containing 2.5 mM Ca^+. Two 
systems were operated in parallel, one serving as a control to 
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Fig. 3.21 Ca^+-dependency of K+-evoked release of [^HjDA from
striatal synaptosomes 
Preloaded striatal synaptosomes (250 pi) were perfused using the 
final conditions (p.137) and small (4 drop) fractions were collected. 
The synaptosomes were initially perfused with Ca^+ free medium and 
then with normal medium (after dotted line). Pulses of K+ (28 mM) 
were administered in the presence and absence of Ca^+ at the times 
indicated (f). Two systems were operated in parallel, test system 
(heavy line) and control (light line).
The evoked release of ["Hj DA by K (28 mM) in the absence of Ca 
was 20% of the release value (S^ ) obtained when Ca2+ was present.
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The evoked release by K+ (28 mM) in the absence of Ca^+ was 20% 
of the release obtained when Ca^+ was present (Fig. 3.21). The 
perfusion profiles obtained from the test and control systems 
clearly demonstrated the return to normal response when Ca^+ was 
added/to the medium; after 110 min perfusion both control and test 
systems gave comparable responses (107% and 96% of the first K+ 
pulse in Ca^+ medium (S^) respectively). Complete Ca^+ dependency 
was not expected because of the possibility of residual Ca^+ (as 
discussed above in the Ca^+ dependency of basal release). Indeed 
Minnema and Michaelson (1985), have shown that maximum transmitter 
release (evoked by K+ depolarization) occurred at Ca^+ concen­
trations as low as 0.254 mM.
These results confirm the Ca^+ dependency of transmitter 
release evoked by depolarization (Cotman et at. 3 1976; Rubin,
1982) and show that the perfusion system can clearly demonstrate 
this effect, an important criterion of physiological transmitter 
release.
c) The effect of tetrodotoxin on stimulated release of [ H]DA 
from striatal synaptosomes
Using the synaptosomal perfusion system three different 
types of stimuli, nicotine, K+ and veratridine had been shown to 
evoke [ H]DA from striatal synaptosomes (Fig. 3.11, p. 141 ). The 
alkaloid veratridine acts specifically at voltage-dependent sodium 
channels in such a way that the channels remain open and there is 
an increase in permeability to Na+ (Ohta et at., 1973; Ulbricht, 
1969). The influx of Na+ leads to membrane depolarization and 
enhanced Ca^+ permeability which initiates transmitter release. The
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action of veratridine in eliciting transmitter release from the 
striatal synaptosomes is evidence for voltage-dependent sodium 
channels on the synaptosomes. The voltage-dependent sodium channel 
is normally involved in the generation and propagation of nerve 
impulses (Hodgkin and Huxley, 1952) along the nerve axon and has 
been studied using the specific blocking agent tetrodotoxin (TTX) 
(Kao, 1966).
Experiments were therefore carried out to determine the effect
3
of continuous perfusion of TTX (0.5 yM) on [ HjDA release evoked by 
the three different stimuli, veratridine, K+ and nicotine.
3
Striatal synaptosomes preloaded with [ HjDA were perfused con­
tinuously with either normal perfusion medium (p.135 ) or medium 
containing TTX (0.5 y M ). After the 40 min washout period the synap­
tosomes were successively stimulated with nicotine (1 y M ), K+
(28 mM) and veratridine (10 yM; Fig. 3.11, p.141 ). The radio­
activity released by each stimulus in the presence of TTX was 
expressed as a percentage of the normal response obtained in a 
parallel control system (Table 3.15). The inclusion of TTX (0.5 yM) 
had no effect on the basal rate of release but completely abolished 
the 10 yM veratridine evoked [ HjDA release. The responses by 1 yM 
nicotine and 28 mM K+ were unaffected by the presence of TTX.
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Table 3.15. The effect of TTX (0.5 pM) on stimulated [^H]DA
/
release from striatal synaptosomes
Stimuli
Response in the presence 
of TTX (0.5 pM) 
(Percentage control)
Nicotine 1 pM 94.8
K+ 28 mM 104.0
Veratridine 10 pM 3.2
Results expressed as mean with variance ± 10% (n > 4).
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3.3.5 Discussion
The final perfusion system fulfilled the original aim to 
produce a sensitive synaptosomal perfusion procedure in which 
synaptosomes could be repeatedly stimulated with little reuptake of 
the released transmitter. A factor contributing to the improved 
sensitivity of the perfusion system was the use of [. H]DA of high 
specific activity. However, the use of radiolabelled neurotrans­
mitters in release studies has been criticised (Besson et at., 
1969). The radiolabelled neurotransmitters may label intracellular 
DA pools that are not readily releasable. The DA that is most 
recently released is also that which has most recently been taken 
up (Besson et at., 1969). However, in view of the long duration of 
the perfusion experiments, the preloading of the striatal synapto- 
somes with [ H]DA cannot be considered as a recent event. Despite 
the criticisms.of the use of radiolabelled neurotransmitters, they 
are commonly used to study presynaptic events. Recent studies by 
Bonnano et at. (1985) have shown that the measurement of either 
endogenous DA or [ H]DA previously taken up by striatal synapto­
somes gives similar results when studying K+-evoked transmitter 
release, supporting the use of radiolabelled transmitters. Indeed 
the HPLC studies described above showed that both endogenous DA and 
[ HjDA, in the presence of pargyline, are released in response to 
stimulation. However, the amount of DA in the perfusate is low and 
it would be inaccurate (as well as impractical) to routinely 
measure the DA in each fraction using HPLC with ECD. The radio­
labelling of the DA pools in striatal synaptosomes was therefore
required for a detailed study of the nicotine regulation of DA
3 3release. [ HjDA was selected instead of [ H]tyrosine to avoid the
3 3necessary separation of [ Hjdopamine from the perfusate. [ H]DA is
also of a higher specific activity than [ H]tyrosine. In support of
3 2+the use of [ H ]DA was the demonstration of the Ca -dependency of
both the basal and K+-evoked release of tritium.
In contrast to the sensitivity of the veratridine-evoked
3
release of [ H ]DA to TTX (which confirms that voltage-dependent 
sodium channels are present on striatal nerve terminals), the lack 
of effect of TTX on nicotine evoked release provides evidence that 
the nicotinic mechanism does not involve the voltage-dependent 
sodium channel. Using the same concentrations of nicotine and TTX, 
Giorguieff-Chesselet et at. (1979) obtained similar results using a 
perfused striatal slice preparation. However, contrary to the 
results reported in this thesis, Giorguieff et at. (1977) reported 
that the basal release was partially TTX-sensitive, indicating the 
possible involvement of interneurones. These results show that when 
using slice preparations it is important to carry out control 
experiments in the presence of TTX to abolish any excitatory 
effects produced by interneurones.
The agreement between the results of Giorguieff et at. (1979) 
and the results reported in this thesis is of interest because of 
the differences in the preparation and labelling methods. Giorgueff
3
and coworkers continuously perfused striatal slices with [ H J
3
tyrosine and measured the release of newly synthesised [ HjDA in
3
contrast to the measurement of the release of newly taken up [ H] DA 
from striatal synaptosomes. This suggests that in release studies 
either the precursor or the transmitter may be used to radiolabel 
the dopaminergic transmitter pools. Indeed, de Langen et at. (1979) 
reported that [14C]DA synthesised within striatal synaptosomes from
[■^C ]tyrosine is not released by K+ depolarisation in preference to 
[ H ]DA previously taken up by the synaptosomes.
The similarity between the results reported in this thesis and 
those of Giorguieff et at. (1979) also confirms the validity of the 
synaptbsomal perfusion technique. The advantages and disadvantages 
of a synaptosomal or slice preparation have been reviewed by Gibson 
and Blass (1982) and Weiler et at. (1982). A slice preparation more 
closely resembles the situation in vivo, although the measurement 
of presynaptic events is complicated by the presence of 
non-neuronal and neuronal interconnections. Synaptosomes are devoid 
of axons and cell bodies which may normally influence nerve 
activity. Another disadvantage of a synaptosomal preparation is 
that it is usually contaminated with mitochondria which could alter 
the levels of Ca^+ and hence the release of transmitter. Neverthe­
less , synaptosomes have several advantages including the ease and 
reproducibility of their preparation. They are also probably more 
sensitive to low concentrations of drugs and will not have the 
problems of diffusion associated with slice preparations (Wood and 
Sidhu, 1986).
CHAPTER 4 
CHARACTERISATION OF THE NICOTINIC 
REGULATION OF STRIATAL DA RELEASE
182.
4.1 INTRODUCTION
From the reports in the literature the nicotinic regulation of
DA release in the striatum has been shown to be sensitive to both
and antagonists (see Table 1.2). The characterised perfusion
6 10
system provides an appropriate method for a detailed pharmaco­
logical analysis of the nicotinic heteroreceptor mediating the 
release of [ ^h ] DA from striatal synaptosomes. Because of the 
problems associated with using ACh as an agonist (p.54 ), nicotine
was mainly used and the stimulating effect of nicotine was compared 
with that of other cholinergic agonists and K+. The effect of a 
range of cholinergic antagonists on agonist evoked release was 
determined in an attempt to classify the nicotinic heteroreceptor
as either a or a C,_ related nAChR.6 10
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4.2 METHODS
4.2.1 Effect of cholinergic agonists, veratridine and K+ on the
3
release of [ H]DA from striatal synaptosomes
The efficacy of a range of nicotinic agonists, veratridine 
and K* (for chemical strutures see Appendix) in releasing[ H]DA 
from perfused striatal synaptosomes was determined using a single 
pulse of each stimulus at t = 40 min.
ACh was dissolved in perfusion medium (in the absence of 
acetylcholinesterase inhibitors) immediately before use.
4.2.2 Repetitive stimulation
After the 40 min washout period the synaptosomes were 
stimulated 3 times at 30 min intervals (Fig. 3.14; p.146 ). The 
evoked release was calculated by summing the radioactivity released 
in each peak and subtracting the basal efflux (see p.142 ). The 
radioactivity released by the second and third stimulations (S^ and
Sg) was expressed as a percentage of the initial response to give
S2/Si and values respectively.
The effect of the DA uptake inhibitor nomifensine (50 yM) on 
the nicotine (1 yM) evoked release was determined by including 
nomifensine in the perfusion medium from the beginning of the 
washout period.
2+ 34.2.3 Ca -dependency of stimulated [ H]DA release
2+ 3
To study the Ca -dependency of [ HjDA release evoked by
various stimuli, four perfusion systems were operated in parallel,
two were continually washed with Ca^+-free medium (p.137 ) and two
were washed with normal medium. Pulses of stimulating agents pre-
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pared in either Ca -containing or Ca -free medium were 
administered in the normal manner at t = 40, 70 and 100 min. The 
release in the Ca^+-free medium was expressed as a percentage of 
the release obtained by an analogous pulse (of equivalent perfusion 
time)' in normal medium.
3
4.2.4 Effect of cholinergic antagonists on stimulated [ HjDA 
release
The effect of various cholinergic antagonists on K+ (16 or 
28 mM) and agonist (0.5 - 5 yM) evoked release was determined as 
described in Section 3.2.6b (p.145 ). Stimulating agents were 
prepared in normal and antagonist-containing medium.
4.2.5 The effect of pharmacological agents on synaptosomal 
integrity
To determine whether exposure of the striatal synaptosomes 
to various pharmacological agents caused any damage which could 
lead to leaky membranes, the occluded LDH activity was measured 
(Section 2.2.3, p.67 ) after incubation of a sample of synaptosomes 
for 2 min with each agent.
Statistical analysis of all data was performed using a two 




4.3.1 The effect of nicotine concentration on the release of
[ H ]DA from striatal synaptosomes
0
The release of [ H]DA from the perfused synaptosomes evoked
by (-)<-nicotine (free base) was studied over the concentration
—8 —3 3range 10 - 10 M. A plot of [ H]DA released (above
spontaneous)/mg protein,against log nicotine concentration showed
that the release of radiolabelled transmitter by nicotine was
dose-dependent, with the response saturating at concentrations
3
greater than 0.1 mM (Fig. 4.1). Evoked release of [ H]DA could be
—8
detected using nicotine concentrations as low as 10 M but the
peak of radioactivity released by this concentration was small,
making it difficult to quantify. A detailed study was carried out
-7 —3at higher concentrations (10 - 10 M) where the peaks of
released tritium were well defined. Analysis of the dose-response 
data using the Hill plot (Fig. 4.2) gave an EC^q value of 3.8 yM.
The duration of the response, measured by counting the number 
of fractions contributing to the peak of stimulation before return 
to baseline, increased with increasing concentration of nicotine.
At low concentrations (0.01 - 1 yM) the peak was spread over 4 
fractions, at 0.5 - 10 yM nicotine over 4 - 6  fractions and at 
concentrations greater than 50 yM over 6-8 fractions (Table 4.1).
3
4.3.2 The release of [ H ]DA from striatal synaptosomes by 
cholinergic agonists
All the cholinergic agonists tested,stimulated the release
3
of [ H] DA from the perfused striatal synaptosomes (Table 4.1). The 
release of radiolabel evoked by nicotine, DMPP and cytisine was not
3
Fig. 4.1. The effect of nicotine concentration on the release of [ H]DA
3The release of [ h ]DA by (-)-nicotine (0.1 - 1000 pM) was measured by 
exposing the perfused striatal synaptosomes to pulses of (-)-nicotine 
at t = 40 (S^). The radioactivity released in response to stimulation 
was expressed as fmoles [ H]DA released above spontaneous level/mg protein. 














































Fig. 4.2. Hill Plot of the dose-response data for (-)-nicotine.
The data obtained for the log dose response curve 
for (-)-nicotine (Fig. 4.1) were analysed using the
/
method of Hill (1910). The logarithmic Hill equation 
is as follows:
l0g ( ~ 00~ F  ) = n 108 [Ll " 108 EC50
where P is the response expressed as a percentage
of the maximum response obtained at 1 mM nicotine,
n is the interaction coefficient, EC_^ is the
50
concentration which produces half the maximum 
response, and L is the concentration of the 
ligand used (nicotine).
p
A plot of log (^ qq p) versus log [nicotine] 
gives a straight line, the slope being n and
the intercept on the ordinate, -log EC,_^ .
50
An EC,.a value of 3.8 yM was obtained and a 
50














Fig. 4.2. Hill Plot of the (-)-nicotine dose-response 
curve data(Fig. 4.1).
3
Table 4.1. The effect of various stimuli on the release of [ HJDA from striatal synaptosomes.
Concentration Stimulus Release 
(fmoles [^HjDA/mg protein)









174.2 ± 9.8 
184.9 ± 13.7
207.3 ± 22.6









16 mM K+ 170.9 ± 13.0 3-4
additional 16 mM Na+ 57.3 ±9.7* 3-4
(-)-nicotine 419 ± 85.9 4-6
10 MM ACh 381 ± 10 3-5
Choline 225 ± 26 (n=2) 4
oxotremorine 176 ± 20 (n=2) 4
28 mM K+ 411.5 ±39.2 3-4
(-)-nicotine 689.5 ± 96 6-8
100 MM ACh 721 ± 183 (n=2) 4-5
Choline 517 ± (n=l) 4
Carbamylcholine 421 + 52.3** 4-5
10 MM Veratridine 1423 ± 291 14-16
30 MM " 4568 ± 150 15-17
100 MM 12780 ± 635 15-17
The release of [^H]DA by various cholinergic agonists, K+ and veratridine was determined by measuring the [^H]DA
released by a single pulse (S-j) of each agent at t = 40 min. The radioactivity released above the spontaneous
3 '
level was calculated as fmoles [ HjDA/mg protein and the results averaged, mean ± SEM (n > 4) or mean ± range 
(n=2).
* indicates that the value is significantly lower than the release evoked by nicotine (1 mM) with P < 0.0005.
** indicates that the value is significantlijdifferent from the release evoked by nicotine (100 wM) with P < 0.05. 190
due to structural damage of the synaptosomal membranes as 
determined by measurement of the occluded LDH activity (Table 4.2). 
At a low agonist concentration (1 pM) the release by (-)-nicotine, 
(-)-nicotine hydrogen (+)-tartrate and the two ganglionic agonists 
DMPP and cytisine were comparable. However, the release evoked by 
the same concentration of the ganglionic agonists lobeline and 
coniine was slightly lower.
The effect of ACh and choline was determined at 10 and 100 pM. 
The release by ACh was similar to the release evoked by nicotine at 
the same concentration, whereas the [ H]DA released by choline was 
substantially lower. The release of [ H]DA evoked by 
carbamylcholine (100 pM) was comparable with that released by 
nicotine and ACh at 10 pM and was significantly lower (P < 0.05) 
than that obtained using nicotine or ACh at an equal concentration.
The muscarinic agonist oxotremorine (10 pM) evoked the release
3 3of [ HjDA at a level equivalent to the [ H]DA released by the
nicotinic agonists at a lower concentration of 1 pM.
The time courses of the responses produced by each nicotinic
agonist at 1 pM were comparable,whereas at high agonist
concentrations (100 pM) the time course of the response to nicotine
was notably longer than that of the other cholinergic agonists that
were tested (Table 4.1).
4.3.3 The release of [ ^ H]DA by K+ and veratridine
A 100 pi pulse of K+(16 mM) released about the same amount
3
of [ HjDA as (-)-nicotine (1 pM); Table 4.1). In contrast, a sample 
containing elevated Na+ (additional 16 mM) evoked only a small
3
amount of [ H]DA release.
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Table 4.2. The effect of various pharmacological agents on 
striatal synaptosome integrity; determined by 
measurement of the occluded LDH activity after 






Occluded LDH activity, 
percentage of total activity
No addition N/A 78.5 ± 1*
(-)-nicotine 20 yM 78
DMPP I 79.5
Cytisine I 77.5
Pempidine 10 y M 77.5
DHBE 10 y M 78.5
Hexamethonium 10 y M 79
K+ 16 mM 77.5
DMSO** 0 .02% (v/v) 78
* Result expressed as mean ± S.D. (n=5)
All other values are the average of 2 determinations 
(variance ± 1%)
** Dimethylsulphoxide (used to dissolve NSTX).
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Veratridine (10 - 100 pM) was very effective at eliciting
3
release of [ HjDA. This effect was not due to the presence of 
ethanol (used to dissolve the alkaloid),as perfusion with a pulse 
of medium containing an equivalent concentration of ethanol (0.25% 
v/v) that was present in a sample of veratridine (100 pM), caused 
no observable change in the basal release. The time course of the 
veratridine induced response was considerably longer than the 
responses to nicotine or K+. At high concentrations of veratridine 
(30 - 100 pM) the duration of response was almost 40 min. In 
comparison, K+ (16 and 28 mM) evoked release of short duration, the 
peak of radioactivity being spread over 3-4 fractions with a sharp 
increase and return to basal release (see also Fig. 3.11).
2+ 34.3.4 The Ca —dependency of stimulated [ HjDA release
3
The [ H ]DA released in response to the nicotinic agonists 
(-)-nicotine and DMPP, and the depolarizing agents K+ and 
veratridine, was shown to be partially Ca2+-dependent (Table 4.3). 
The response to (-)-nicotine and DMPP at a low concentration of 
0.5 pM showed a greater requirement for Ca2+ than at the higher 
concentration of 1 pM. Similarly, a greater percentage of the 
response by veratridine (10 pM) was Ca2+-dependent than at a higher 
concentration of 30 pM.
4.3.5 The effect of repetitive stimulation
The effect of repeated stimulation with (-)-nicotine (0.1 -
3
1000 pM) on the amount of [ HjDA released is shown in Fig. 4.3.
0
Over the concentration range 1 - 10 pM the [ HjDA released by the 
second stimulation (S2 ) was at least 80% that of
194.
Table 4.3. The Ca^+-dependency of stimulated [^H]DA release
Stimulus Concentration Percentage normal 
response
(-)-nicotine 0 . 5  pM 2 9 . 5  .
(-)-nicotine 1 pM 40.6
DMPP 0. 5  pM 36.3
DMPP 1 pM 54.7
K+ 28 m M 36.1
Veratridine 10 pM 58.7
Veratridine 30 pM 77.4
2+ 3
The Ca -dependency of [ H]DA release evoked by nicotinic agonists
(nicotine and DMPP) and depolarizing agents (K+, veratridine) was
determined by comparing the release in the absence of Ca^+ with
that in normal perfusion medium.
The synaptosomes in the test systems were perfused with Ca^+-free 
medium from the beginning of the washout period until the end of 
the experiment.
Results expressed as the mean percentage of the control response 
(in normal perfusion medium). Variance± 10%, n > 4.
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2
The possibility that reuptake of [ H]DA may occur, and hence affect 
2
the levels of [ H ]DA released,was examined by the inclusion of the
DA uptake inhibitor nomifensine (50 yM) in the perfusion medium.
This drug had no effect on the percentage and values
obtained for (-)-nicotine (1 yM) suggesting that little reuptake of 
3
the released [ HjDA occurred.
At concentrations less than 1 yM and greater than 10 yM the 
release by was lower than S^. Comparison of the radioactivity
evoked by the third pulse (S^) with was only made over the range 
1 - 1000 yM. At 1 yM nicotine,release by was comparable with 
that of S_ and S-,but at concentrations greater than 1 yM the S
c  1 O
response was reduced.
The S^/S^ and Sg/S^ values were obtained for other nicotinic 
agonists (Table 4.4). At a concentration of 1 yM all the nicotinic 
agonists studied showed little attenuation of the responses on 
repetitive stimulation; and S^/S^ values were similar to
those of (-)-nicotine. However, K+ (16 mM), which evoked
2
approximately the same amount of [ H]DA release as 1 yM 
concentrations of the agonists (Table 4.1), gave a value
significantly lower (P < 0.01) than the S^/S^ values for the 
nicotinic agonists (1 yM).
Included in Table 4.4 are the results obtained using high 
concentrations (100 yM) of cholinergic agonists. (-)-Nicotine, ACh
3
and carbamylcholine repeatedly stimulated the release of [ H]DA 
resulting in comparable values.although the S2/S1 value for
carbamylcholine was slightly higher (P <0.1) than that for 
nicotine.
Fig. 4.3. Repetitive stimulation of striatal synaptosomes 
with (-)-nicotine (0.1 - 1000 yM).
2
Striatal synaptosomes preloaded with [ H]DA 
were repeatedly stimulated with (-)-nicotine at 
t = 40,70, IQ 0 rriin.The release of [ H]DA evoked 
by the second (Sg) and third (S^) responses 
were expressed as a percentage of the initial 
response (S^) to give and values.
Results expressed as mean ± SEM (n > 4).
[(-)-nicotine] (M)
Table 4.4. Repetitive stimulation
Stimul us Concentration V S1(%) V S1(%)
(-)-nicotine 1 pM 89.6 ± 5.4 96.2 ± 4.9
(-)-nicotine + nomifensine (50 pM) 1 pM 89.5 ± 3.5 (n=2) 101.5 ± 11.5(n=2
(-)-nicotine hydrogen (+)-tartrate 1 pM 90.1 ± 3.5 95.5 ± 3.5
DMPP 1 pM 110.3 ± 7.2* 104.2 ± 11.9
Cytisine 1 pM 93.9 ± 5.5 84.4 ± 6.5
K+ 16 mM 90.8 ± 5.5 67.8 ± 5.7**
K+ 28 mM 91.2 ± 4.6 ND
(-)-nicotine 100 pM 38 ± 2.9 19.5 ± 2.9
ACh 100 pM 46 ± 2 .5(n=2) ND
Carbamylcholine 100 mm 49.7 ± 5.1*** ND
Striatal synaptosomes were repeatedly stimulated at 30 min intervals (see Fig. 3.14; p.146 ) with
a pulse of the same stimulus. The [ h^ ]DA released by the second (Sg) and third (S^) pulses were
expressed as a percentage of the first stimulation (S^).
Results expressed as mean ± SEM, n > 4. or mean ± range, n = 2.
* Denotes the response is significantly different from the (-)-nicotine (1 pM) S^/S^ value with P < 0.1
** Denotes the response is significantly lower than the (-)-nicotine (1 pM) S-/S, response with P < 0.01
*** Denotes the response is significantly different from the (-)-nicotine (100 pM) S2/S1 value with P < 0.1.
*8
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The effect of ( + ) and (-)-nicotine on the release
of [ H]DA from perfused striatal synaptosomes.
Striatal synaptosomes were stimulated with 
2 pulses of nicotine at t = 40 and t = 70 min.
= (-)-nicotine hydrogen (+)-tartrate (1 yM) 
= (+)-nicotine di(-)-tartrate or 
(-)-nicotine hydrogen (+)-tartrate 
(0.3 - 100 i>M).
The x-axis indicates the log concentration of 
nicotine in and the y-axis shows the response 
by as a percentage of the response,
(S2/Si value).
The value obtained from 2 successive
stimulations of 1 yM (-)-nicotine hydrogen 
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The mean S^/S^ anci S3^Sl values obtained for each stimulus 
(Table 4.4) were used as control values in the experiments carried
out to determine the effect of nicotinic antagonists on evoked 
[ H]DA release from striatal synaptosomes.
4.3.6 Stereoselectivity of the nicotine response
The sample of (+)-nicotine obtained for these studies was 
in the form (+)-nicotine di(-)-tartrate and was >99% pure. To 
compare its efficacy with its enantiomer, a tartrate salt of the 
(-)-form was used, (-)-nicotine hydrogen-(+)-tartrate, the 
(-)-nicotine tartrate being of equal potency to the free base 
(Table 4.1).
By initially stimulating with a pulse of (-)-nicotine (1 uM) 
followed by a pulse of either (+) or (-)-nicotine (0.3 - 100 yM) 
the stereoselectivity of the response was clearly demonstrated 
(Fig. 4.4). The dose-response curve for the (+) enantiomer was 
markedly shifted to the right. Taking the S^/S^ value for the 
standard condition of successive pulses of 1 pM (-)-nicotine as the 
control response an equivalent S^/S^ value was only obtained when 
the concentration of (+)-nicotine was increased to 100 pM. This 
corresponds to a relative potency of (-) : ( + ) of 100 : 1 .
4.3.7 The effect of cholinergic antagonists on [ H]DA release 
from perfused striatal synaptosomes
The effect of a single concentration nicotinic antagonists
3
on the release of [ H]DA stimulated by low concentrations (< 5 pM) 
of nicotinic agonists ((-)-nicotine, DMPP and cytisine) is
0
Table 4.5. The effect of nicotinic antagonists on stimulated [ H]DA release from striatal synaptosomes.
Antagonist





1 yM 0.5 yM 1 yM
■ S
5yM 16 and 28 mM
DHBE 0.5 yM ND 27.1 ND 32.4 ND 42.1 83.9
NSTX 0.05 yM 62 46. 5* ND ND 59.2 ND 106
Pempidine 5 yM 27.4 37.8 51.5 61.3 ND ND 95.8
Mecamylamine 5 yM 55. 5* 45.3 68* 54.4 ND 49.4 98.4
aBGT 0.25 yM 87 98.5 97.5* 112.2 ND ND 95.3
D-tubocurarine 
10 yM ND ND ND 85 ND ND ND
Hexamethonium 
10 yM ND 87 ND ND ND 100.5 ND
Decamethonium 
10 yM ND 66.7 ND ND ND ND ND
Chlorisondamine 
5 yM ND 84* ND 84* ND 82* 80*
Perfusion was carried out as described in Fig. 3.14. The mean value in the presence of an antagoni
was calculated and expressed as a percentage of the value obtained in normal medium (Table 4.4).
Results are from at least 4 experiments with variance <10% except those indicated by * which denotes a 




























10 30 Fraction number10
t_ _ _ _ _ _ _ _ 1_ _ _ _ _ _ _ 1_ _ _ _
40 70 110 Time (min)
Fig. 4.5. The effect of DH3E (0.5 |jM) on DMPP (1 yM) evoked release
3
of [ H ]DA from striatal synaptosomes.
Striatal synaptosomes (200 yl, 0.54 mg protein/filter) were 
perfused and stimulated at the times indicated by the arrows 
with a pulse of DMPP (1 yM).
a) Test system, DHBE (0.5 pM) was present in the perfusion 
medium for the duration of the bar, the small peaks
either side of S2 correspond to changes in the perfusion medium.
b) Control system, continual perfusion with normal perfusion 
medium.
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summarised in Table 4.5. The concentration of antagonist was 
selected on the basis of reports in the literature. Using the 
protocol devised in Fig. 3.14 antagonism of agonist-evoked release 
was clearly demonstrable by comparing the responses in the 
presence and absence of antagonist. This is illustrated in Fig. 4.5 
which shows the effect of dihydro-B-erythroidine on DMPP-evoked H ] 
DA release. The possibility that some antagonists might cause 
non-specific transmitter release (thereby obscuring any antagonism 
of the nicotinic response) by disruption of the synaptosomal 
membrane was tested by measurement of the occluded LDH activity.
None of the antagonists tested appeared to cause any such effects 
(Table 4.2).
a) Neosurugatoxin (NSTX)
Studies with NSTX were carried out during the development of 
the perfusion system when slightly higher concentrations of 
agonists were used and the antagonist was present from the 
beginning of the washout period; the agonist-evoked release in the 
presence of the antagonist was compared with a parallel control 
system (Fig. 4.6). Using this method, a freshly prepared solution 
of NSTX (0.05 yM) was shown to be an effective inhibitor of DMPP (5 
yM) evoked release of,L HjDA, inhibiting the normal response by 
about 80%. However, there was only a small amount of starting 
material which was stored as a stock solution as described in 
"Materials" and because NSTX is unstable in aqueous solution 
(Kosuge ot. , 1982) a ' deterioration of the activity of NSTX was 
observed (Table 4.6). After 57 days in solution NSTX was 
ineffective at preventing DMPP (5 MM) evoked transmitter release.
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Table/4.6 . Deterioration of NSTX activity
Number of days in solution Percentage inhibition of
normal response 
(mean ± S.D., n > 3)
1 87.5 ± 10.6
5 52.3 ± 8.1
11 45.0 1 ' 7.2
50 17.2 1 9.3
57 0
The deterioration of NSTX activity was determined by measuring the
inhibition by NSTX (0.05 yM) of the normal D M P P  (5 yM) evoked 
3
release of [ HjDA from striatal synaptosomes.
Fig. 4.6. The effect of neosurugatoxin on stimulated
3release of [ H]DA from striatal synaptosomes.
Striatal synaptosomes (0.75 mg protein/filter), 
preloaded with [ H]DA (0.1 |iM, 15 Ci/mmol) were 
perfused with a) normal medium or b) medium 
containing 5 x 10 ^VINSTX for 110 min {//////),
In test systems (a and b) 100 \il pulses of 
(DMPP 5 nM; | ) or K+ (28 mMj^J^), resulted 
in responses indicated by the arrows.
In a control system(c, not shown) release 
throughout the perfusion period was measured 
and this was subtracted from the transmitter 




























Fig. 4.6 The effect of neosurugatoxin on stimulated release
0
of [ H]DA from striatal synaptosomes
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The results shown in Table 4.5 of the effect of NSTX (0.05 yM) on 
DMPP (5 yM) and nicotine (0.5 - 1 yM) evoked release are the 
average of a series of experiments carried out during the period 
when the toxin was active. The observed antagonism by NSTX is 
therefpre probably an underestimate of its true potency which was 
observed on day 1 (Table 4.6). The effect of NSTX on nicotine (0.5
3
- 1 yM) stimulated [ H]DA release was carried out using toxin which
had been in solution for 20 - 30 days. The observed antagonism of
about 50% further demonstrated the potency of NSTX. The specificity
of the action of NSTX was indicated by its lack of effect on K+
evoked release (Table 4.5). The effect of NSTX was also shown to be
reversible (Fig. 4.6); the response to DMPP (5 yM) gradually
recovered after withdrawal of the toxin and washing with normal
perfusion medium. After 20 min, the response (S^) had recovered to
83% control and after 40 min the response (S_) was 100% of theb
control value.
b) ot-Bungarotoxin (ot-BGT)
Using the normal perfusion schedule (Fig. 3.14) ot-BGT (0.05
- 0.25 yM) was ineffective at inhibiting agonist evoked release of
r 3
[ H]DA from striatal synaptosomes and did not affect the release by 
K+ (Table 4.5). However, with prolonged exposure to a-BGT 
(0.125 yM) a partial antagonism of (-)-nicotine (10 yM) evoked 
release was observed (Table 4.7). After 30 min perfusion with the 
neuromuscular blocking agent a 10% block was observed,and after 55 
min the normal response was blocked by 30%.
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Table 4.7. The effect of a-BGT (0.125 pM) on (-)-nicotine (10 pM)
3stimulated release of [ H ]DA from striatal synaptosomes
Perfusion details $2/Si (%) V si(%)
normal (control) 99.5 ±0.5 * !+ 5
+ a-BGT (0.125 pM) 89.5 ± 2.5 50.5 ± 5.5
Striatal synaptosomes
r 3
preloaded with [ HjDA were perfused and
stimulated 3 times with nicotine (10 pM) at t = 40, 95, 120 min. In 
the test system at t = 65, a-BGT (0.125 pM) was introduced into the 
perfusion medium and continued until the end of the experiment. The 
release of radioactivity (above the spontaneous level) by the 
second and third stimulations (S^ and S^) were expressed as a 
percentage of the initial response (S^).
Results expressed as mean ± range (n = 2).
c) Perhydrohistrionicotoxin The effect of H^HTX on stimulated 
((-)-nicotine and K+) release of [^HjDA from striatal synaptosomes 
was studied by repeatedly stimulating at 40 min intervals (instead 
of 30 min). This was to allow a 15 min pre-exposure of the 
synaptosomes to H^HTX before (after Kato and Changeux, 1976), 
by introducing the toxin into the medium at t = 65 min. In some 
experiments, the toxin was present throughout the remainder of the 
perfusion, in others it was present only for 30 or 35 min.
In the control systems repetitive stimulation with pulses of 
(-)-nicotine (1 or 10 pM) or K+ (16 mM) at 40 min intervals 
resulted in and S^/S^ values (Table 4.8) which were within
the ranges obtained using stimulation at 30 min intervals (see Fig. 
4.3 and Table 4.4).
Table 4.8. Repetitive stimulation of striatal synaptosomes at 
40 min intervals.
 Stimulus_______________Sg/S-| (%)_________________S3/S2 (%)____
(-)-nicotine 1 pM 86.5 ± 5.1 (5) 94 ± 2.6 (4)
(-)-nicotine 10 pM 84 ± 6.8 (4) 57.6 ± 3.2 (4)
K+ (16 mM) 86 ± 5 (2) 65.5 ± 2.5 (2)
Results expressed as the mean of n determinations.
For n ^ 4, the variance is expressed as the SEM and for n = 2 
as the range.
The effect of increasing concentrations of H^HTX on 1 yM 
nicotine evoked striatal £ H^DA release was examined (Fig. 4.7). A 
steep dose-response curve over a narrow range of toxin concen­
tration ( 1 - 5  pM) was observed and at the highest concentration 
used (5 pM) the normal response was inhibited by approximately 50%. 
Using identical experimental conditions,K+ (16 mM) evoked release 
was unaffected by the presence of 5 pM H^HTX (Table 4.9). At a 
higher- agonist concentration of 10 yM, antagonism by 5 yM H^HTX 
was also observed, the normal response being reduced by 34%.
The effect of prolonged exposure to H^HTX and the recovery 
from the inhibition was investigated (Table 4.9). When striatal 
synaptomes were stimulated a third time with 1 yM nicotine in the 
continued presence of 5 yM H^HTX no further inhibition of the 
response by was observed. The value of 42.4 agrees
with the S^/S^ value. Furthermore, if perfusion with the toxin was 
terminated 10 min before and washing was continued with normal 
perfusion medium the inhibition of the normal response was still 
observed. However, extending the wash period before to 15 min 
revealed that the effect of H^HTX was reversible; for nicotine
3
(10 yM) stimulated [ H ]DA release the value was about 90% of
the control value.
d) Ketamine
The anaesthetic ketamine was also shown to be an effective 
inhibitor of (-)-nicotine (1 yM) stimulated release of [ HjDA 
from striatal synaptosomes. At a concentration of 1 pM,ketamine 
inhibited approximately 40% of the normal nicotinic response 
whereas K+ evoked release was unaffected (Table 4.9). However, 
higher concentrations of ketamine (10 pM) failed to inhibit 
nicotine evoked release. The inhibition produced by 1 pM ketamine 
was reversible, the response returned to about 80% control after 






Fig. 4.7. Inhibition of nicotine (1 pM) evoked release of
3 -[ Hjdopamine from striatal synaptosomes by H^HTX. 
Striatal synaptosomes were repeatedly stimulated at 
40 min intervals with (-)-nicotine (1 pM), initially 
in the absence and then either in the absence or presence 
of H^HTX. The S^/S^ percentage obtained in the 
presence of the toxin was expressed as a percentage of 
the control S2/Si value*
Results represent the mean of n determinations +/- the 
range for n = 2,and ± SEM n = 7.
3
Table 4.9. The effect of H^HTX and ketamine on stimulated release of [ H]DA from striatal synaptosomes.
1) The effect of H HTX (5 yM)
Perfused synaptosomes were stimulated 3 times at 40 min intervals and H^HTX introduced into 
the perfusion medium 15 min before and continued throughout the response or stopped 
10 or 15 min before S^.
2) The effectcf ketamine (1 and 10 yM)
Striatal synaptosomes were stimulated 3 times at 30 min intervals; ketamine was introduced
10 min before and continued for 30 min before return to normal perfusion medium.
The S^/S^ and S^/S^ values were calculated for the test systems and the results expressed 
as the percentage of analogous values obtained in control systems (Table 4.8).
Results are expressed as the mean of (n) determinations with a variance of <10%.
Table 4.9
__________________________________________________________Percentage normal response ____________
Perfusion conditions S0/S.. S0/S S0/S.. S0/S
4 1  3 1 3 1 3 1
(in presence of (after 10 min (after 15 min
channel blocker) wash) wash)
Striatal synaptosomes
(-)-nicotine (1 yM) + H HTX (5 yM) 47.9 (7)
(-)-nicotine (1 yM) + ketamine
(1 yM) 63.7 (4)
(-)-nicotine (l yM) + ketamine
(10 yM) 97.1 (4)
(-)-nicotine (10 yM) + H HTX
(5 yM) 66 (2)
K + (16 mM) + H12HTX (5 yM) 91.9 (2)
K + (16 mM) + ketamine (1 yM) 106 (2)
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92 .5 (2) 
N.D.
e) Other antagonists
Dihydro-8-erythroidine (DH0E, 0.5 yM) was an effective 
inhibitor of [ H]DA release evoked by the three nicotinic agonists, 
nicotine, DMPP and cytisine (Table 4.5). Another two antagonists 
pempidine and mecamylamine, at a higher concentration of 5 yM were 
also potent inhibitors of agonist evoked release. The effect of 
pempidine was determined using continual exposure to the anta­
gonist. For comparison, the effect of mecamylamine was studied by 
both continuous exposure and using the final perfusion schedule 
with the antagonist present during only. Identical results were 
obtained using the two different methods, suggesting that a 10 min 
pre-exposure to mecamylamine was sufficient for antagonism of the 
nicotinic response. The specificity of these antagonists was shown 
by the lack of inhibition of K+-evoked release.
Preliminary studies were also carried out using D-tubocurarine 
(10 PM), decamethonium (10 yM), hexamethonium (10 yM) and chlori- 
sondamine (5 yM). The only antagonist in this group to show notable 
inhibition of agonist evoked release at the concentration tested was 
the neuromuscular blocking agent decamethonium (Table 4.5).
To assess the reversibility of antagonism, S^/S^ values were 
determined after the removal of the antagonist and a 10 min wash 
with normal perfusion medium. These experiments clearly showed that 
there was full recovery after perfusion with DH0E (0.5 yM) but 
partial antagonism remained when mecamylamine (5 yM) or 
decamethonium (10 yM) had been present (Table 4.10).
Preliminary experiments were also carried out using DH6E 
(0.5 PM) and the muscarinic antagonist atropine (0.5 pM) to assess
3
the nature of the receptor(s) mediating the [ H ] DA release evoked
216.
by ACh (100 yM) and carbamylcholine (100 yM). Both agonists were 
sensitive to DH0E (0.5 yM) but antagonism by atropine (0.5 yM) was 
not observed (Table 4.11).
217.
3
Table 4.10. Recovery of agonist stimulated release of [ H]DA





(1 yM) (1 yM) (1 yM)
DHBE (0.5 yM) 99.8 94.5 90.2
Mecamylamine (5 yM) 78.6 79 83.6
D-tubocurarine (10 yM) ND ND 89.4
Hexamethonium (10 yM) ND 93.5 ND
Decamethonium (10 yM) 56.1 ND ND
Perfusion was carried out as described in Fig. 3.14 and the S0/S., 3 1
values calculated. The mean value obtained for each
agonist (after exposure to an antagonist) was expressed as a 
percentage of the normal value (continual perfusion
with normal medium; see Table 4.4).
Results are from at least 4 experiments, with variance <10%.









DH BE 73 26
(0.5 yM)
Perfusion was carried out as described in Fig. 3.14.
The value in the presence of an antagonist was
expressed as a percentage of the normal S^/S^ value for each 
agonist (Table 4.4).
Results are single determinations.
4.4 DISCUSSION
3
4.4.1 The release of [ H]DA by a range of pharmacological agents
In this study a wide range of stimulating agents was shown
3
to evoke [ H]DA from striatal synaptosomes. The effect was not a 
result of synaptosomal damage leading to leakage of the radiolabel, 
as incubation of synaptosomes with each drug for 2 min had no 
effect on the level of the intrasynaptosomal enzyme marker, LDH 
(Table 4.2). Connelly and Littleton (1983) have also shown, by the 
measurement of LDH activity, that nicotine (100 pM) causes no 
structural damage to synaptosomes from whole brain. Additional 
information about the integrity of perfused synaptosomes was 
obtained by the analysis of the basal release. After stimulation 
with a pulse of pharmacological agent a return to basal release 
suggested that the synaptosomes were still intact.
The duration of each response was clearly dependent upon the 
concentration and nature of the stimulus (Table 4.1). Release 
evoked by both K+ and nicotine was of short duration compared with 
the length of recovery from veratridine. However, the K+ and 
nicotine responses were different (see Fig. 3.11), the peak of 
released radioactivity resulting from nicotine stimulation being 
slightly longer than K+-evoked release. This observation is in 
agreement with previous reports (Arqueros et at., 1978; Westfall, 
1974a, b; Marien et at., 1983). The nicotine-evoked release is 
probably an immediate response because even at high concentrations 
(100 pM), the duration of the nicotine response observed using the 
perfusion system described in this thesis was about the same as the 
distribution of a pulse of radioactivity (Sections 3.3.1 and 
3.3.2). The 30 min interval between nicotine and K+ stimulations is
therefore adequate.
In contrast, the long duration of veratridine evoked release 
may be a result of the action of veratridine on the inner surface 
of the voltage sensitive Na+ channel, holding the channel open 
(Richie, 1979). A period of washing is therefore required to remove 
veratridine.
The effect of introducing an antagonist often resulted in a 
transient increase in the basal release (see Fig. 4.5). This small 
peak was spread over 1 - 2  fractions and at the most represented 
15% of the initial response to 1 yM-agonist. A similar small peak 
was also observed at t = 90 min when perfusion with the antagonist 
was terminated and washing was continued with normal medium, 
suggesting that the effect was artefactual. However, the small peaks 
were partially dependent upon the antagonist. Decamethonium (10 yM) 
gave the most pronounced change in baseline and this might reflect 
its depolarising action.There are also reports in the literature 
that certain cholinergic antagonists show agonist properties e.g. 
the excitation of central neurons by curare-like antagonists 
(Krnjevic, 1975) and the release of [^HJDA from striatal tissue by 
high concentrations of mecamylamine (Giorguieff et al. 3 1976;
Mills and Wonnacott, 1984). Giorguieff and coworkers suggest that 
drugs may show agonist or antagonist properties according to the 
drug concentration and the tissue system employed.
34.4.2 Nicotine—evoked [ H^DA release from striatal synaptosomes
3
The dose-dependent release of [ HJDA from striatal 
synaptosomes by nicotine is in agreement with the results of Rowell
3
and Winkler (1984) for the nicotine-evoked release of [ HjACh from
cortical synaptosomes. Nicotine concentrations greater them 1 mM 
were not tested because of the reported desensitisation of 
peripheral nAChRs to high and/or prolonged exposure to agonist 
(Katz and Thesleff, 1957) and the non-specific effects of nicotine
at high concentrations (Arqueros et at. 1978; Marien et at., 1983).
0
The nicotine-evoked release of [ H]DA from striatal synapto­
somes appeared linear over the concentration range 1 - 100 yM (Fig.
4.1) and the value obtained (Fig. 4.2) of 3.79 UM accords with50
the action of nicotine on the release of [ H ]DA from the amygdala 
(Rowell, 1987) and the nicotine stimulated release of catechol­
amines from bovine adrenal chromaffin cells (Adams et at., 1986).
There is no report of a full dose-response curve for nicotine 
facilitating [ H]DA from striatal tissue, although
Giorguieff-Chesselet et at. (1979) used nicotine concentrations as
0
low as 1 vM to stimulate [ H]DA release from striatal slices.
More often, concentrations of nicotine greater than 0.5 mM have 
been used to study the nicotinic heteroreceptor modulating DA 
release in the striata (Arqueros et at., 1978; Westfall, 1974a; 
1983a; Sakurai et at., 1982; Marien et at., 1983; Connelly and 
Littleton, 1983). The reason for using such high concentrations is 
not stated, but it is possible that the sensitivity of the systems 
employed for measuring the release were too low.
At high nicotine concentration (> 100 y M) the observed
0
reduction in the amount of [ H ]DA released by successive pulses may 
be a result of either depletion of the radiolabelled transmitter 
pools and/or desensitisation of the nicotinic receptors. Using the 
the revised perfusion system described in this thesis, the release
3
of [ H]DA by nicotine was therefore studied using more physiolo-
gically relevant concentrations. The nicotine concentration range
chosen (1 - 10 yM) is consistent with the EC,.^  value. ThisoU
concentration range also agrees with the micromolar concentrations 
which have been suggested to be active in the brain (Rowell, 1987). 
The abtual concentration of nicotine which is found in the brain 
during cigarette smoking is unknown, although the range 0.1 - 0.5 y 
M nicotine is found in the blood of cigarette smokers (Russell 
et at., 1980). What proportion of the blood nicotine penetrates the 
brain is unknown and estimates have been difficult because nicotine 
is rapidly metabolised. In contrast to these micromolar concen­
trations, from [^Hjnicotine and. ACh binding studies to rat 
brain membranes, high affinity agonist binding sites have been 
shown to have nanomolar affinity constants (Clarke et at. 3 1985a). 
However, in binding assays, the long incubation periods used 
(approximately 1 h) may cause the high affinity nicotine binding 
sites to transform to a desensitised state (Romano and Goldstein, 
1980; Schwartz and Kellar, 1983).
At a concentration of 1 yM, nicotine evoked the release of well 
defined consistent responses (Fig. 4.3 and Table 4.4) and at this 
agonist concentration nomifensine (50 yM) had no effect on the 
nicotine response indicating that little if any reuptake of 
released radiolabelled transmitter occurred. Micromolar 
concentrations of agonists were therefore used to study the effect 
of antagonists on agonist-evoked transmitter release.
a) Stereoselectivity of the nicotine response
Many of the classical pharmacological receptors show stereo­
selectivity, that is stereoisomers of drugs act at the receptors
with different affinities. Using the perfused striatal synaptosome 
preparation the presynaptic nAChR facilitating DA release displays 
this receptor characteristic, the heteroreceptor being highly 
selective for the naturally occurring (-) isomer (Fig. 4.4). The 
100 fold difference in the relative potencies of the (+) and (-) 
isomer was observed when 1 yM (-)-nicotine was used as the control 
response. To observe an equivalent response using (+)-nicotine, a 
concentration of 100 yM was required. This 100 fold difference in 
sensitivity could mean that (+)-nicotine is completely inactive, 
then a 1% contamination of the (+)-nicotine with (-)-nicotine could 
account for these results (Barlow at. s 1972). Absolute pure 
(+)-nicotine is difficult to chemically prepare (Barlow and 
Hamilton, 1965) and this may explain the conflicting reports in the 
literature of the relative potencies of the two isomers (see 
Wonnacott, 1985). However, using (+)- nicotine of high purity 
(97.8%) Barlow and Hamilton (1965) reported that the 
stereoselectivity of different tissue preparations varied greatly; 
the relative potency of (-)-nicotine was greatest at receptors in 
ganglia.
The non-linear extremities of the nicotine dose resonse curve 
(Fig. 4.1) could explain the levelling off of the C+)-nicotine 
curve in Fig. 4.4 and hence the lower stereoselectivity observed at 
low nicotine concentrations. Similarly, at high saturating 
concentrations of nicotine (> 100 yM) the same effect was observed. 
Furthermore, this would explain the failure of Connelly and 
Littleton (1983) to show stereoselectivity of nicotine-evoked 
release of [^HjDA from whole brain synaptosomes using nicotine 
concentrations greater than 1 mM.
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The observed stereoselectivity of the heteroreceptors is
3
consistent with the high affinity £ Hjnicotine binding site in rat
brain (Sloan et al. , 1985; Abood et al., 1985; Wonnacott, 1986). In
125contrast, central cholinergic binding sites labelled with [ ij
a-BGT display little stereoselectivity; both (+) and (-) displacing
the toxin binding with similar potency (Wonnacott, 1986). On the
125
basis of low stereoselectivity the £ iJa-BGT binding site in rat 
brain resembles the neuromuscular and Torpedo type of nAChRs, 
whereas the [ Hjnicotine binding site shares the stereoselective 
characteristics of ganglionic type of receptors (Wonnacott, 1986).
4.4.3 Comparison of the release ofu[ H]DA from striatal 
synaptosomes evoked by nicotinic agonists
The observed equipotency of 1 yM concentrations of ACh, 
(-)-nicotine and the ganglionic agonist DMPP is in agreement with 
previous reports. Rowell and Winkler (1984) and Westfall et al. y 
(1983a) showed that (-)-nicotine and DMPP were equally effective in 
their transmitter releasing actions. DMPP has also been shown to be 
of a similar potency to ACh in releasing p*HJACh from synaptosomes 
of the myenteric plexus (Briggs and Cooper, 1982). There are 
however few reports of cytisine-evoked transmitter release.
Instead, the central effects of cytisine have been demonstrated 
using binding and behavioural studies. Romano and Goldstein (1980) 
reported that cytisine and nicotine were more effective at 
displacing £ Hjnicotine binding to rat brain membranes than were 
lobeline or DMPP. Similarly, Clarke et al. (1984) reported a 
similar order of potency although cytisine was six times more 
effective than (-)-nicotine. In contrast, behavioural studies in
mice demonstrated that (-)-nicotine and DMPP were more potent 
convulsants than lobeline, (+)-nicotine and cytisine (Caulfield and 
Higgins, 1983). However, the results of many behavioural studies 
are sometimes misleading because cytisine does not pass readily 
into the brain (Romano et al., 1981). The relative central potency 
of various drugs given systemically therefore depends on their 
respective permeabilities into the brain.
The preliminary experiments carried out with the ganglionic 
agonists lobeline and coniine (Table 4.1) showed that they were 
slightly less potent than the other agonists discussed above. This 
agrees with the low relative potency of lobeline in the ganglia 
(Taylor, 1985a) but disagrees with the release studies carried out 
by Sakurai et al. (1982). This group demonstrated that the
3
ganglionic agonists lobeline, coniine and sparteine stimulated [ H ] 
DA release from striatal tissue with greater efficacy than 
nicotine. However, the concentration of agonists used in these 
studies was high (> 50 piM) and the tissue was incubated with each 
drug for long periods (12 min). Under these conditions it is 
possible that nicotine causes more desensitization of the. receptors 
than the other ganglionic agonists (Taylor, 1985a).
At the lower concentrations used in this thesis comparison of
the and values for (-)-nicotine, DMPP and cytisine
(Table 4.4) showed that the three agonists were similar. At a
concentration of 1 yM the value for DMPP was only slightly
higher than that of nicotine or cytisine. The S /S value for DMPP3 1
was also slightly higher than the others, although this was not 
statistically significant. This may indicate that DMPP is more 
effective than (-)-nicotine at releasing HJDA from striatal
226.
synaptosomes. This would agree with the potency of DMPP in the 
ganglia being three times that of nicotine (Taylor, 1985a).
However, to confirm this suggestion a full range dose-response 
curve for DMPP is required.
3
4.4.4 The effect of nicotinic antagonists on evoked f HjDA 
release from striatal synaptosomes
The effect of a range of nicotinic antagonists on
agonist-evoked . [ HjDA release was tested to determine whether i)
the agonists were acting specifically at nAChR; ii) if the
nicotinic heteroreceptor could be classified as either or
and iii) to gain an insight into the functioning of the receptor.
A useful advantage of the final perfusion schedule is that
information about the recovery of the nicotinic response after
exposure of the synaptosomes to an antagonist can be obtained by
measuring the response. The protocol is also flexible in that
different pre-exposure times may be used (e.g. to study the effect
of toxins). As mentioned in Section 3.1.1 (p.110 ) in studies where
the effects of drugs are observed on either electrical or K+-evoked
transmitter release it is quite common to repeatedly stimulate
slice preparations. In contrast, repetitive nicotine-evoked release 
3
of [ HJDA from striatal slices has only been reported by Giorgueff 
et at. (1976) and there are no reports of repeatedly stimulated 
synaptosomal preparations.
The perfusion schedule described in this thesis is similar to 
that used by Giorguieff et al. (1976) which can be summarised as 
follows: after a 15 - 20 min washout period the slices were 






the stimuli. The effect of an antagonist such as mecamylamine on 
ACh (10 mM) evoked release was studied by introducing the 
antagonist into the perfusion medium 15 min before the second 
stimulation and continuing throughout the last stimulation 
(Giorguieff et al. y 1976). There are some notable differences in 
the timing, but the overall approach is similar. The results 
obtained in this thesis have therefore been compared, where 
applicable, to the findings of Giorguieff et al., (1976).
The period of pre-exposure of the synaptosomes to the 
antagonist before the second stimulation (S^) was usually 10 min, 
which is also the time period reported by Ascher et al. (1979) to 
be adequate to study the effect of nicotinic antagonists on 
parasympathetic neurones. Longer pre-exposure times were also used 
(e.g. for NSTX, a-BGT, H^HTX) ancj these will be discussed 
separately below. An important control was the K+-evoked release in 
the presence of the nicotinic antagonists. This provided evidence 
for the specificity of the nicotinic response and in all cases the 




3The action of a-BGT on nicotine-evoked release of [_ HjDA 
from striatal synaptosomes was of particular interest because of 
the mixed reports of its action in the CNS (Section 1.3.2, p. 29 )•
Antagonism of the normal nicotine (10 mM) response was only 
observed after prolonged exposure (30 - Sb min) of the synaptosomes
228.
to the toxin (0.125 pM) suggesting that a-BGT may require time to
bind before it is effective.
Futerman et al. (1982) reported that a-BGT (0.1 pM) caused a
3
20% inhibition of nicotine (100 pM) evoked release of [_ HjDA from 
striatal synaptosomes (the release measured using static incubation 
rather than perfusion) which is consistent with the work of de 
Belleroche and Bradford (1978) who showed a 38.7% inhibition of 
r14clDA release by 0.18 mM a-BGT (using a perfused striatal 
synaptosomal preparation). However, Misgeld et al. (1980) found 
0.6 mM a-BGT to be without effect on the intrinsic cholinergic 
excitation in striatal slices and Mills and Wonnacott (1984) found
3
the inhibition of nicotine (100 pM) evoked release of f HjDA from 
perfused striatal synaptosomes by a-BGT (0.001 - 0.2 pM) to be 
inconsistent and ineffective at concentrations greater than 0.1 pM.
The differences in the literature may be attributed to the 
different experimental procedures employed. Another possibility is 
that some of the a_BGT preparations are contaminated with j(-BGT 
(see p. 12 ) which is active at both and Cir. receptors. Because
D 1U
relatively high concentrations of a-BGT were employed in the
perfusion experiments (compared with the nanomolar concentrations
• 125reported for the affinity constant of|_ ija-BGT binding to rat
brain membranes, see Schmidt et al., 1980) a small amount of
contamination (e.g. 1%) of a-BGT could account for the observed
partial antagonism.
The lack of effect of a-BGT in striatal preparations is
consistent with its lack of effect in ganglia (Brown and Fumigelli,
1977; Ascher et al. , 1979) and the adrenals (Kilpatrick et al. ,
3
1981). a-BGT is also ineffective at displacing [ H]nicotine binding
to rat brain membranes (Rapier et at., 1985) indicating that the
2
nicotinic heteroreceptor may be similar to the high affinity [ H]
nicotine binding site as well as receptors.o
D-tubocurarine
The ineffectiveness of d-tubocurarine (10 yM) in blocking
3
1 yM DMPP-evoked [ H]DA release from striatal synaptosomes is in 
complete contrast to the almost total antagonism reported by 
Giorgueff-Chesselet et at. (1979) using a lower concentration of 
antagonist (5 yM and 1 yM nicotine . Antagonism of 10 yM 
DMPP-evoked [ H]ACh release from ileal synaptosomes by 
d-tubocurarine at concentrations less than 10 yM has also been 
reported by Briggs and Cooper (1983). These workers report an 
increase in the basal release when concentrations greater than 10 y 
M are employed. This accords with the reported excitation of 
central neurons by d-tubocurarine (Krnjevic, 1975). It is therefore 
possible that the concentration of d-tubocurarine used in the 
experiments reported in this thesis was too high, although 
introduction of d-tubocurarine alone did not notably change the 
basal rate of release compared with the control system.
Decamethonium
Decamethonium has been reported to be a more potent
3
inhibitor of both [ Hjnicotine binding (Romano and Goldstein, 1980) 
125
and [ Ija-BGT binding (Schmidt, 1977) to rat brain membranes than 
hexamethonium but the same relative potency was found in the 
perfused striatal synaptosomal preparation. The failure of the 
nicotine S^/S^ responses to recover after exposure to decamethonium
(Table 4.10) is possibly a result of the complex nature of the 
antagonism caused by decamethonium (see p. 14 ). Decamethonium is
therefore probably not a useful antagonist to study the nicotinic 
regulation of DA release in the striatum.
Dihydro-g-erythroidine
DHgE was one of the most potent antagonists of [ h}DA 
released from striatal synaptosomes evoked by nicotinic agonists, 
its action being readily reversible (Table 4.10). These results 
agree with the potency of DHgE in displacing both [" H] nicotine 
(Clarke et al. , 1984) and [^^iJa-BGT binding (Schmidt, 1977) to
rat brain membranes, indicatingthat DHgE may act directly at the 
agonist binding site. Although there are no other reports of DH$E 
preventing transmitter release evoked by nicotinic agonists, using 
perfusion techniques, electrophysiological studies carried out by 
McLennan and Hicks (1978) and Lichtensteiger et al. (1982) have 
shown that ACh-evoked excitations are blocked by application of
DHgE. However, in view of the equipotency of DHgE at both C_ and
6
nAChR (Megirian et al., 1955) the usefulness of DHgE as a 
specific ligand for differentiating central nAChR is limited.
ii) C_ antagonists o
Neosurugatoxin
NSTX is highly specific for neuronal nAChR (Hayashi 
et al., 1975) and is extremely potent at nanomolar concentrations
(Hayashi et al., /98U). However, biochemical and pharmacological 
studies have been limited because of the scarcity of the toxin and 
the difficulties encountered in its purification and storage
2 31.
(Kosuge et al., 1982). Indeed, the early reports of the potent 
antagonist 'surugatoxin1 (Hayashi and Yamada, 1975; Brown 
et al., 1976; Ascher et al. , 1979) have now been attributed to 
contamination of the preparation with NSTX (Kosuge et al., 1982).
The action of NSTX in preventing DMPP and nicotine evoked 
release of |j3H2DA from striatal synaptosomes (Fig. 4.6) agrees with 
its action in displacing high affinity [^Hjnicotine binding from 
rat forebrain membranes (Hayashi et al., 1984; Rapier et al., 1985; 
Yamada et al., 1985) and also its effect on autonomic ganglia 
(Ascher et al 1979; Hayashi et al., 1975). In all cases NSTX is at 
least 3 orders of magnitude more potent than hexamethonium. The 
same relative potency has also recently been shown in behavioural 
studies (Yamada et al., 1986) in which NSTX prevented 
nicotine-induced antinociception.
The observed reversibility of the antagonism caused by NSTX in 
the striatal synaptosomal preparation is also in agreement with its 
action at autonomic ganglia (Brown et al., 1976; Ascher et al. 3
1979). However, more recent studies by Yamada et al. (1986)
forebrain membranes is irreversible, and the group conclude that 
NSTX acts as a noncompetitive antagonist. However, the 
classification of Yamada et al. (1986) is different from that used 
in this thesis (see p.10 ) where a noncompetitive antagonist is
defined as acting at a region of the receptor other than the 
agonist binding site. Using this classification, the results of 




the blockade^ Hjnicotine binding sites by NSTX in rat
2 32 .
Hexamethonium
The observed lack of effect of hexamethonium (10 yM) on 
DMPP (1 yM) evoked release ofj^  ^h]dA from striatal synaptosomes is 
consistent with the work of Futerman et at., 1982; Sakurai et at., 
1982; Connelly and Littleton, 1983; Marien et at., (1983). However, 
there are reports that hexamethonium causes partial antagonism of 
transmitter release evoked by nicotinic agonists (Westfall, 1974; 
1983a; de Belleroche and Bradford, 1978; Giorguieff et al. , 1976; 
Rowell and Winkler, 1984). These discrepancies are difficult to 
explain because of the differences in experimental procedures used 
such as the concentrations of nicotinic agents and the period of 
stimulation. The results are also difficult to compare because of 
the reported increase in basal release caused by hexamethonium at 
concentrations greater than 100 yM (Giorguieff et at., 1976). In 
behavioural studies hexamethonium is also less effective than other 
antagonists (e.g. pempidine and mecamylamine) in preventing 
nicotine-evoked responses (Romano et at., 1981; Caulfield and 
Higgins, 1983; Stolerman et at., 1983; Yamada et at., 1986), 
although this is because hexamethonium does not readily penetrate 
the blood-brain barrier.
In binding studies hexamethonium is a poor inhibitor of H~|
125 -nicotine and  ^ ij a-BGT binding to rat brain membranes (e.g.
Abood et at,. 1980; Schmidt, 1977) although hexamethonium is an 
effective competitive antagonist at ganglionic nAChR (Brown, 1980). 
Recently, hexamethonium has been shown to exert its action by 
blocking the receptor ionophore when it is open (Ascher et al. , 
1979; Rang, 1982; Gurney and Rang, 1984). Antagonism by 
hexamethonium therefore occurs after the agonist has bound. This
could explain the ineffectiveness of hexamethonium in the revised 
perfusion system in which a short period (40 s) of stimulation with 
a low concentration of agonist was used. Using a longer stimulation 
period and/or a higher nicotine concentration inhibition of the 
nicotinic response might be observed. This would explain the 
antagonism by hexamethonium reported by Giorgueff et al, (1976).
Mecamylamine
Mecamylamine is similar to hexamethonium in that it is a
125 3poor inhibitor of [_ ija-BGT binding (Schmidt, 1977) and also Hj
nicotine and [ Hj ACh binding (Abood et al,, 1980; Schwartz et al.,
1982). However, in contrast to hexamethonium, in the perfused
synaptosomal preparation 5y«M mecamylamine was an effective
antagonist of [ H]DA release evoked by either nicotine, DMPP and
cytisine (Table 4.5). These results agree with the earlier reports
from the laboratory (Mills and Wonnacott, 1984) and also the
antagonism of nicotine or carbamylcholine induced release of [ Hj
noradrenaline from hypothalamic synaptosomes (Yoshida et al. s
1980). The blockade of the nicotinic response is also in agreement
with the work of Giorguieff et al. (1976), who showed that
mecamylamine at a concentration of 10 yM almost completely blocked
ACh (10 yM) evoked release of [ H] DA from striatal slices. This
suggests that a higher concentration of mecamylamine should be
tested in the synaptosomal system. The lack of recovery of the
response after exposure to mecamylamine (Table 4.10) suggests that
the inhibition is only slowly reversible. This agrees with the work
of Ascher et al. (1979) who reported that a 60 min wash period was
required after exposure to mecamylamine to restore activity of the
rat ganglion preparation, in contrast to the 30 min wash period 
required for the other nicotinic antagonists tested (Ascher et al. 
1979). At parasympathetic ganglia mecamylamine acts as both a 
competitive and noncompetitive inhibitor, and this mixed type of 
antagonism, although much lower, is also displayed at nAChR 
(Brown, 1980). Indeed recent studies by Varanda et al. (1985) have 
shown that mecamylamine acts as a noncompetitive antagonist of 
nAChR by modulating the receptor ionophore (as shown by the 
inhibition of Ph]h HTX binding). In keeping with the nature of the 
observed antagonism in the perfusion experiments reported in this 
thesis, Varanda et al. (1985) found that exposure of the frog 
sartorius muscle preparation for 30 min to 10 mecamylamine 
caused complete blockade of the neuromuscular transmission and a 
1 h period of washing was required to restore activity.
The inhibitory action of mecamylamine accords with the numerous 
reports of its action in the CNS. Morgan and Pfeil (1979) and Roth 
et al. (1982) have shown that nicotine induced depletion of rat 
brain catecholamines is prevented by mecamylamine, which is in 
keeping with the action of mecamylamine in reducing nicotine-evoked 
brain activity (London et al., 1985b). Similarly, the excitation of 
central neurones by iontophoretic application of nicotine has been 
blocked by mecamylamine (McLennan and Hicks, 1978; Clarke et al., 
1985b).
Mecamylamine is also effective at preventing many behavioural 
responses (e.g. Romano et al., 1981; Stolerman et al., 1983; 
Caulfield and Higgins, 1983; Yamada et al., 1986).
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Pempidine
Pharmacologically, pempidine is similar in action to
2
mecamylamine (Taylor, 1985a). It is a poor inhibitor of[ H] nicotine 
125and [ ifa-BGT binding to rat brain(e.g. Romano and Goldstein,
1980; Wonnacott, unpublished) and proved to be an effective 
inhibitor of nicotine and DMPP-evoked [^h]dA release from striatal 
synaptosomes (Table 4.5). These results agree with the action of 
pempidine in preventing nicotine-evoked [^h]dA release from 
striatal slices (Giorguieff-Chesselet et al. , 1979) and [ h]DA 
release from whole brain synaptosomes (Connelly and Littleton,
1983). Although pempidine has not been used as much as mecamylamine 
it has been shown to block nicotine-evoked behavioural responses 
(Romano et al. , 1981; Caulfield and Higgins, 1983; Yamada et al., 
1986).
Chlorisondamine
In a preliminary experiment chlorisondamine (5 pM) was found 
to block nicotine, DMPP and K+-evoked [^H]DA release from striatal 
synaptosomes by about 20%, suggesting that it is not a specific 
inhibitor of the nicotinic response. This agrees with the 
ineffectiveness of chlorisondamine at preventing nicotine-evoked
activation of dopaminergic neurones in the substantia nigra pars
- 2
compacta, a brain region rich in high affinity [ Hjnicotine binding 
sites (Clarke et al., 1984, 1985b).
At paresympathetic ganglia chlorisondamine is a potent noncom­
petitive antagonist (Brown, 1980) which would account for the
2
inability of chlorisondamine to prevent [ Hjnicotine binding to rat 
brain membranes (Romano and Goldstein, 1980). However, in the CNS
chlorisondamine has been shown to cause long term blockade of 
nicotine-evoked behavioural responses (Reavil et al., 1986) 
suggesting that more detailed studies should be carried out 
employing chlorisondamine in the perfusion experiments.
iii) Classification of the nicotinic heteroreceptor: or
In agreement with previous reports the nicotinic
heteroreceptor modulating DA release in the striatum is sensitive
to both C_ and C. antagonists (see Table 1.2). As already 
b 1U
mentioned the classification of nicotinic drugs into either or
b
is not well defined (p.8 ), with most compounds acting at
both receptors although with different relative potencies. It is
therefore not surprising that both and C. antagonists were
b 1U
effective at preventing the nicotinic facilitation of DA release 
(Table 4.5).
The action of pempidine, mecamylamine and particularly NSTX in
3
preventing both nicotine as well as DMPP evoked[ H] da release,
provides strong evidence for the nicotinic heteroreceptor being
related to the C. nAChR. However, the classical ganglionic 
6
antagonist mecamylamine also acts at receptors (Varanda
et al., 1985). This dual action is particularly interesting as 
mecamylamine has recently been shown at different concentrations to 
block two very different behavioural responses in mice (Collins 
et al., 1986), leading to the proposal that mecamylamine may act at
two distinct central receptors which may correlate with the high
3 125affinity [ Hjnicotine binding site and the [ ]a-BGT binding site
(Collins et al., 1986). The classification of nicotine-evoked
responses in the CNS as "ganglionic" on the basis of their
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sensitivity to mecamylamine (e.g. Brown, 1979) may therefore be 
inappropriate.
So far NSTX has only been shown to be effective at receptors
(p. 13 )> its potency at blocking nicotine and DMPP-evoked DA
release is good evidence for the C nature of the nicotinic hetero-o
receptor. The ability of NSTX to prevent [ ^ Hjnicotine binding but 
not <*-BGT binding to rat brain membranes (see p.36 ) also suggests
that the nicotinic heteroreceptor is similar to the high affinity 
[ Hjnicotine binding site. However, the antagonism of the nicotinic 
heteroreceptor by DHBE and the partial block observed by deca­
methonium and a-BGT suggest that the presynaptic nAChR is related 
to nAChR. DH^E is however equipotent at C^ receptors and the 
weak action of a-BGT may be due to K-BGT.
In conclusion, the nicotinic heteroreceptor modulating DA 
release has pharmacological properties characteristic of both C^ 
and C^q receptors.
4.4.5 The physiological role of the nicotinic heteroreceptor
The studies reported in this thesis confirm the earlier 
reports (see Table 1.2) that the nicotinic heteroreceptor on 
striatal dopaminergic nerve terminals enhances transmitter release. 
The observed stereoselectivity of this response (Fig. 4.4) and the 
sensitivity to NSTX but not a_BGT suggests that the nicotinic
2
heteroreceptor resembles the C_ nAChR and the high affinity [ H ]
6
2
nicotine binding site. Binding studies using [ Hj ACh have shown
2
that high affinity [ HjACh binding sites may be equivalent to high 
affinity [ Hjnicotine binding sites (Clarke et al., 1985a). It was 
therefore of interest to compare the action of the endogenous
compound ACh with that of nicotine. In some experiments carbamyl- 
choline was used to avoid the problems associated with using ACh 
(see p. 54 ) .
ACh and carbamylcholine are cholinergic agonists which interact 
with both mAChR and nAChR. ACh acts equally at both receptors 
whereas carbamylcholine may have a preference for mAChR (Lucchelli 
et al. y 1986). In order to examine the action of ACh, anticholin­
esterases were not included in the perfusion medium because of 
their reported interaction with the nAChR-ionophore (Shaw et al., 
1985). ACh was effective at releasing [ h] DA from the perfused 
synaptosomes and was equipotent with (-)-nicotine., Interestingly, 
carbamylcholine was of lower efficacy than ACh and nicotine (Table 
4.1). This order of relative potency is in keeping with Ascher 
et al., (1979) who found that nicotine and ACh (in the presence of 
acetylcholinesterase inhibitors) were more potent than carbamyl­
choline in the rat ganglion. However, the results are contrary to 
those of Yoshida et al. (1980) who demonstrated that 1 - 10 yM 
nicotine and carbamylcholine were equipotent at releasing 
noradrenaline from hypothalamic synaptosomes.
If no hydrolysis of ACh had occurred it would be expected that 
the response by ACh would be greater than (acting at both facili- 
tatory muscarinic and nicotinic receptors) or equal to (acting 
mainly on nAChR) the response to nicotine. To determine whether ACh 
was interacting with muscarinic or nicotinic or both types of 
cholinergic receptors, the effect of the nicotinic antagonist DH0E 
(0.5 ^ M) and the muscarinic antagonist atropine (0.5 yM) were 
tested on ACh evoked release oft h ]dA. The radioactivity released 
by ACh (100yM) was not inhibited by atropine but was partially
prevented by DHBE (Table 4.11). Similarly, the response by 
carbamylcholine (100 MM) was sensitive to DH/3E but not atropine. No 
obvious interaction of ACh or carbamylcholine with muscarinic 
heteroreceptors was therefore observed.
However, the muscarinic agonist oxotremorine (10 MM) was found 
to release! h]dA from the perfused striatal synaptosomes. The 
action of oxotremorine on basal release of DA from striatal tissue 
although previously observed (Giorguieff et al. 3 1977; Bartholini, 
1980; Futerman et al.3 1982) has not been well characterised. Its 
facilitatory action is usually measured on stimulated release of 
radiolabelled transmitter from perfused slices (Lehmann and Langer, 
1982; de Belleroche and Gardiner, 1982) and is associated with 
muscarinic heteroreceptors. Recently, oxotremorine has been shown 
to be a partial nicotinic agonist in frog rectus abdominus and 
cultured chick myotubes. (Lucchelli et al.3 1986; Haggbald et al. 3 
1985) but it is of very low potency (Lucchelli et al. 3 1986). The 
possibility of the observed release of oxotremorine being a result 
of the interaction with nAChRs is therefore doubtful. More likely 
is the interaction of oxotremorine with muscarinic heteroreceptors 
as reported by Giorguieff et al. 3 (1977), who showed that at 10 mM
it was 60 times less effective at eliciting transmitter release 
than ACh of an equal concentration. The release by oxotremorine was 
also completely blocked by the muscarinic antagonist atropine (lM 
M) (Giorguieff et al. 3 1977) confirming the muscarinic nature of 
the response. Further studies using a range of cholinergic 
antagonists would help characterise the observed effects of 
oxotremorine described in this thesis.
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In view of the anticipated hydrolysis of ACh, the action of 
choline was tested. Choline (10 pM) was found to evoke the release 
of [^H]DA from striatal synaptosomes although the response was 
about half that observed with ACh (10 pM) (Table 4.1). These 
results are contrary to those of Giorguieff et al. (1976) who found
3
that choline (10 MM) was without effect on [ HjDA release from 
striatal slices. This difference might reflect differences in the 
sensitivities of the perfusion systems employed and/or the tissue 
preparations used.
In the periphery choline interacts with both mAChR and nAChR 
(Dale, 1914), although choline is much less potent than ACh. 
Evidence for choline acting at a functional nAChR in the PNS was 
provided by Sorimachi and Nishimura (1982) who showed that 100 mM 
choline induced the secretion of catecholamines from cat adrenal 
medulla which was comparable to that elicited by an ACh concen­
tration of 0.02 mM, showing that there is a large difference in the 
relative potencies of choline and ACh. In contrast, in the CNS, 
choline has been shown to be an effective agonist or "false 
transmitter" (Krnjevic and Reinhardt, 1979; Ropert and Krnjevic,
1982), its action being about 5 times weaker than ACh. The observed 
choline-evoked release of [ HjDA, whether it be via muscarinic or 
nicotinic heteroreceptors, is therefore of particular interest, 
especially if it is also applicable at cholinergic synapses (via 
autoreceptors) where high concentrations of choline would be 
expected. This may be of relevance to the treatment of Alzheimer's 
disease in which choline is often administered in an attempt to 
enhance the levels of ACh in the hippocampus (Growdon and Wurtman,
1983).
In the brain nicotine is not an endogenous compound. There must
therefore be a naturally occurring substance which interacts
specifically with central nAChR. It is possible that the ligand is
ACh, although the possibility remains that it is one of the
'endogenous' ligands that prevents the binding of[ H]nicotine or 
X 25[ i] a-BGT to rat brain membranes (Shershen et al., 1984; Perry 
et al., 1986; Quik, 1982; see p.105 ). The method of perfusion 
would however ensure that any such ligand is washed away. It is 
possible that in vivo the presynaptic receptors are activated by 
'cotransmitters' released together with the main transmitter 
(Bartfai, 1985). Both substance P agonists and antagonists have 
been shown to inhibit ion conductance through nAChR on PC12 cells
5
(Eardley and McGee, 1985). Morphine and (Met )enkephalin have also 
been shown to inhibit the release of [ h]DA or endogenous DA 
following activation of nicotinic cholinergic receptors, whereas K+ 
or field stimulation is unaffected (Westfall, 1983b).
The latter observation is particularly interesting because 
opioid peptides have been shown to reduce nicotine-evoked release 
of catecholamines from the adrenal medulla (e.g. Dean et al. ,
1982). These interactions may be purely artefactual or of 
physiological relevance.
4.4.6 Mechanism of nicotinic modulation of transmitter release
From electrophysiological studies the mechanism of action of 
the nAChR at the neuromuscular junction has been well characterised 
(p. 3 ) and it has been shown that activation of these nAChR leads
to an influx of Na+ through an associated ion channel. At the nerve 
terminal presynaptic nAChR may function by a similar mechanism,
with an influx of Na+ ions resulting in local depolarisation and 
the opening of Ca^+ channels. Indeed, using a striatal synaptosomal 
system the release of [^ h ]dA has been shown to be associated with 
the influx of Ca^+ (Drapeau and Blaustein, 1983).
It is generally accepted that extracellular Ca^+ is 
essential for transmitter release, although Ca^+-independent
release has been reported. The observed partial Ca^+-dependency on
3
nicotine-evoked [ HjDA release from synaptosomes (Table 4.3) agrees 
with the work of Connelly and Littleton (1983), and Rowell and
Winkler (1984). Complete Ca^+-dependency was not expected because
2+ 2+ 
of the presence of endogenous amounts of Ca (see the Ca
dependency of basal release, p. 173 ). However, total Ca^+
dependency has been reported for nicotine stimulated release of [ h)
DA from striatal slices (Westfall et al. y 1974a; Giorguieff
et al., 1977; 1979) whereas other groups (Arqueros et al., 1978;
Marien et al., 1983) have demonstrated complete Ca^+-independency.
This lack of requirement for external Ca^+ was observed when high
nicotine concentration ( 3 - 5  mM) were used suggests that at such
concentrations the release is largely non-specific (Arqueros
et al. y 1978). This agrees with the greater amount of Ca^+-
dependent release observed using low concentrations of stimulus
(see Table 4.3) in the synaptosomal perfusion system and reinforces
the importance of using low concentrations of agonists in release
studies. The Ca^+-dependency of K+ (28 mM) and veratridine (10 mM)
evoked [^h JdA release from striatal synaptosomes was about the same
(although veratridine was slightly higher) than that of low (1 MM)
concentrations of either DMPP or nicotine stimulated release. This
suggests that the nicotinic agonists are acting via the normal
physiological process by which neurotransmitters are released in 
response to depolarisation.
3
The inhibition of the nicotine-evoked release of [ H]DA by 
H^HTX (Fig. 4.7, Table 4.9) suggests that the nicotinic 
heteroreceptor may have an associated ionophore and agrees with the 
action of HTX at nAChR on Electrophorus electroplaques (Kato and 
Changeux, 1976; Bartels-Bernal et al. y 1933), neuromuscular 
preparations (e.g. Spivak et al., 1982), cultured muscle cells 
(Burgermeister et al., 1977) and adrenal medullary cells 
(Kilpatrick et al., 1980; McKay et al., 1985).
In the CNS,a nAChR-associated ion channel is implicated in the 
characteristic fast depolarisations recorded in response to the 
iontophoresis of nicotinic drugs (Krnjevic, 1975), and HTX has been 
shown to block the excitation of cholinoreceptor cortical neurones
O
by ACh (Glavinovic et al. , 1974). [ H]H ^HTX has been shown to bind 
to electroplaque membranes (Eldefrawi et al. 3 1980; Heidmann 
et al. y 1983; McKay et al., 1985) and to chick optic lobe (Betz,
1982). However, the binding data are difficult to interpret because 
HTX also acts (at higher concentrations) with Na+ and K+ channels 
(Bartels-Bernal et al. , 1983). The lack of effect on H^HTX on 
K+-evoked [ ^H]DA release from striatal synaptosomes supports the 
specificity of H^HTX (a  ^^he concentrations used) for the 
nicotinic ionophore. The EC^q value obtained of 5 PM (Fig. 4.7) is 
the same as the concentration required to produce a 50% blockade in 
frog sartorius muscle (Spivak et al. 3 1982) but is higher than the 
value of 0.8 pM reported by Kato and Changeux (1976) in 
Electrophorus electroplaques. The similarity between the EC^ value 
reported in this thesis and those obtained for peripheral nAChR
244.
suggests that the presynaptic nAChR on dopaminergic neurones acts 
via a similar ionophore. The time courses observed are consistent 
with a slow reversible interaction with the nAChR as observed with 
the electroplaque nAChR. Thus, the preincubation period used of 15 
min, after Kato and Changeux (1976), provides evidence for a 
similarity between the ionophores of the brain and 
Electophorus nAChR, although Bartels-Bernal et al. (1983) report a 
30 min period is required for maximum blockade. In agreement with 
Kato and Changeux (1976), a 15 min wash period after partial 
blockade by H^PITX (Table 4.9) resulted in almost a complete 
recovery of the nicotinic response.
The inhibition of nicotine-evoked [ h] DA release from striatal 
synaptosomes by 1 MM ketamine agrees with the action of ketamine at 
the ion channel of C ^  nAChR (Maleque et al. , 1981) and provides 
additional evidence for the nicotinic heteroreceptor having an 
associated ion channel. The antagonism by ketamine was readily 
reversible (Table 4.9) which agrees with the action of ketamine 
(5 MM) in preventing nicotine-stimulated release of catecholamines 
from perfused adrenal glands (Sumikawa et al., 1983). Higher 
concentrations of ketamine (10 MM) were ineffective at reducing the 
nicotinic response, however, there are reports that high 
concentration of agents such as ketamine may have marked effects on 
membrane fluidity that are distinct from its more specific channel 
properties (Bradford and Marinetti, 1982).
These results suggest that nicotinic heteroreceptors have an
HTX-sensitive ion channel and in this respect closely resemble C
nAChR. Although electrophysiological studies have shown that the C_
6
receptor displays channel properties similar to receptors
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(Ascher et at., 1979; MacDermott et at., 1980) there is no direct
evidence for an ionophore being an integral part of the C_o
receptor. Purification of C„ nAChR has not yet been possible
6
because ganglia are a low source of receptor. However, predictions 
are being made about its structure using cloning techniques 
employing PC-12 cells (p.34 )• The presence of the amphipathic
region in the amino acid sequence of the isolated PC-12 nAChR 
subunit suggests that the ion channel may be highly conserved in 
different classes of nAChR.
CHAPTER 5
CHARACTERISATION OF THE NICOTINIC REGULATION OF 
[3H]ACh RELEASE FROM HIPPOCAMPAL SYNAPTOSOMES
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5.1 INTRODUCTION
The results reported in this thesis so far, have clearly demon­
strated the presence of presynaptic nicotinic heteroreceptors in 
rat brain. However, there is little evidence for nicotinic auto­
receptors (p. 41 ).
The hippocampus is an attractive region in which to study chol­
inergic autoregulation because its extrinsic cholinergic innerv­
ation is entirely derived from the septum. This cholinergic pathway 
is known as the septo-hippocampal pathway (see Nicoll, 1985) and is 
analogous to the nigro-striatal dopaminergic pathway which makes 
the striatum an ideal brain region in which to study the release of 
DA.
The hippocampus has been shown to be associated with memory and 
learning functions (Meek et al. , 1984) and the involvement of 
cholinergic pathways has been implicated (e.g. Davis et al. , 1978). 
The reports that nicotine improves memory and behaviour (Nordberg 
and Bergh, 1985) therefore makes the hippocampus an obvious area in 
which to study the effect of nicotine on transmitter release.
In our laboratory Moss and Wonnacott (1985), using the original 
perfusion system described by Mills and Wonnacott (1984), demon­
strated the presence of presynaptic nicotinic autoreceptors in rat 
hippocampus. Hippocampal synaptosomes preloaded with P h]choline, 
were shown to specifically release [ HjACh in response to either 
nicotine or DMPP (0.1 - 1 mM). Of particular interest was the mixed 
pharmacology shown by the autoreceptor; the nicotinic facilitation 
of [ h]ACh being sensitive to the ganglionic antagonists 
mecamylamine and pempidine and also the neuromuscular blocking 
agent a_BGT (Moss and Wonnacott, 1985).
5.2 METHODS
5.2.1 Preparation and perfusion of hippocampal synaptosomes
The brain was removed from one male Wistar rat (200 g) and 
the hippocampus dissected as described in Fig. 2.1 (p.64 ).
Synaptosomes were prepared from the tissue as described for 
striatal synaptosomes (Section 2.2.1, p. 63 )• To radiolabel the 
transmitter pools^ the synaptosomes resuspended in perfusion medium 
to a protein concentration of 2 - 4 mg/ml, were preincubated for 10
3
min at 37°C followed by the addition of [ Hjcholine (31 Ci/mmol, 
final concentration 0.8 pM choline). Incubation at 37°C was 
continued for a further 20 min and the uptake determined by washing 
samples (20 pi) of the suspension by vacuum filtration (Section 
2.2.6, p. 71 ). The remaining synaptosomes were washed by
centrifugation (p.117 ) and samples (200 Ml) layered onto the 
filters in the perfusion system. Perfusion was carried out using 
the final conditions (Section 3.2.4, p.137) except that the 
perfusion medium contained no pargyline or ascorbic acid. 
Acetylcholinesterase inhibitors were not included in the medium 
because of the recent reports of their possible interaction with 
the nAChR-ionophore (Shaw et at., 1985).
5.2.2 The effect of nicotine and nicotinic antagonists on the
3
release of [ H]ACh from hippocampal synaptosomes
The effect of DHBE (0.5 pM) and a-BGT (0.125 pM) On nicotine 
(10 nM) stimulated release of radiolabelled transmitter was carried 
out as described for striatal synaptosomes (Fig. 4.5 (p.203) and 
Table 4.7 (p.209) respectively).
The effect of H^HTX (4 was determined by stimulating the 
hippocampal synaptosomes 3 times with (-)-nicotine (10 pM) at 40 
min intervals; H^HTX was introduced into the perfusion medium 15 
min before S^ and continued until 15 min before at which time 
washing was continued with normal perfusion medium.
Statistical analysis of all data was performed using a two 




5.3.1 Uptake of [ Hjcholine by hippocampal synaptosomes and 
nicotine-stimulated release of radiolabelled transmitter
Using the loading conditions described in the Methods 
section above, the hippocampal synaptosomes accumulated 8.19 ±
3
0.25% (mean ± SEM, n = 7) of the total [ Hjcholine present in the 
incubation medium,
Perfusion of preloaded hippocampal synaptosomes resulted in a 
perfusion profile (Fig. 5.1) comparable with those obtained using 
striatal synaptosomes. After a 40 min wash-out period the basal 
efflux of tritium was almost constant and (-)-nicotine (10 yM) 
clearly stimulated the release of radioactivity above the baseline. 
The release was dose-dependent (Fig. 5.2), the response to 100 yM 
(-)-nicotine being significantly greater \P < 0.002) than that 
obtained with 10 yM (-)-nicotine.
The release of radiolabelled transmitter from hippocampal 
synaptosomes that were repeatedly stimulated with (-)-nicotine was 
different from the levels of release obtained using striatal 
synaptosomes (Table 5.1). At high (100 yM) (-)-nicotine 
concentrations the release by the 3 stimulations, S^, and S^, 
remained constant.
5.3.2 The effect of nicotinic antagonists on nicotine evoked 
transmitter release
a) Dihydro-3-erythroidine
DHBE (0.5 yM) inhibited the (-)-nicotine (10 yM) evoked
3
release of [ HjACh from the hippocampal synaptosomes by almost 60% 
and at a higher nicotine concentration (100 yM) approximately 30%
of the normal response was prevented (Table 5.1).
2
Fig. 5.1. Nicotine stimulated release of [ HjACh from
hippocampal synaptosomes.
Hippocampal synaptosomes (200 yl, 0.4 mg 
protein/filter) preloaded with [ Hjcholine 
(0.8 yM) were perfused using the final 
perfusion conditions (Section 3.2.4, p.137). 
After a 40 min wash-out period the 
synaptosomes were repeatedly stimulated 
with 100 yl pulses of (-)-nicotine 
(10 yM) at 40 min intervals. Arrows 
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Fig. 5.2.Nicotine-evoked release of 
1 J ACh (above spontaneous 
release) from hippocampal synaptosomes. 
Results expressed as mean ± SEM (n > 4).
* indicates that the value is significantly 
greater than the release by 10 pM nicotine, 
with P < 0.002.
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Table 5.1. Comparison of repetitive nicotine-stimulated release of







DHPE (0. 5 MM) 
present 
during S2
s2/s1 (%) s3/s1 (%)
Striatal 10 - 84 ± 6.8 59.1 ± 5.5
Hippocampal 10 - 88 ± 3.4 76.5 ± 2.1*
Hippocampal 10 y 37 ± 4(n=2) ND
Striatal 100 - 38 ± 2.9 19.5 ± 2.9
Hippocampal 100 - 82. 5 ±4. 3** 105.8±6.8**
Hippocampal 100 y 61.5±0.5(n=2) ND
Synaptosomes preloaded with radiolabelled transmitter were 
repeatedly stimulated with (-)-nicotine at 30 min intervals. The 
response by the second (S^ ) and third (S^) pulses were expressed as 
a percentage of the initial response (S^). The effect of DH8E 
(0.5 yM) was tested on nicotine stimulated release of [ H]ACh from 
hippocampal synaptosomes as described in Fig. 4.5. The response 
in the presence of DH0E was calculated as a percentage of S^. 
Results are expressed as mean ± SEM (n > 4) and mean ± range (n=2). 
* indicates that the value is significantly greater than the
S3/Sl striatal value with P < 0.05.
** indicates that the value is significantly greater than the
corresponding striatal value with P < 0.0005 .
b) a-Bungarotoxin
Introduction of the medium containing g-BGT resulted in a 
peak equivalent to about 20% of (nicotine, 10 yM) which spread 
over 2-3 fractions. The action of g-BGT (0.125 yM) on (-)-nicotine 
(10 yM) stimulated release was similar to that observed using 
striatal synaptosomes (p.209). After 55 mins exposure to a-BGT a 
reduction in the normal response of approximately 30% was observed 
(Table 5.2).
Table 5.2. The effect of g-BGT (0.125 yM) on nicotine (10 yM)
3
stimulated release of [ H]ACh from hippocampal 
synaptosomes
Perfusion details s2/s1 (%) V si(%)
normal (control) 94.5 ± 7.5 76.5 i: 3.2
+ g-BGT
(0.125 yM) 84 ± 10 55 ± 1.5
3
Hippocampal synaptosomes preloaded with [ H]choline were perfused 
using the final perfusion conditions and stimulated 3 times with 
(-)-nicotine (10 yM) at t = 40, 95, 120 min. In the test system at t 
65 min, g-BGT (0.125 yM) was introduced into the perfusion medium 
and continued until the end of the perfusion. The release of 
radioactivity (above the spontaneous level) by the second and third 
stimulations (S^ and S^) were expressed as a percentage of the 
initial response (S^).
Results expressed as mean ± range (n = 2).
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c) Perhydrohistrionicotoxin
Stimulation of hippocampal synaptosomes with 10 yM 
(-)-nicotine at 40 min intervals (instead of 30 min) gave S^/S^ and 
S3/S1 values of 89.1 ± 4.4 and 77.4 ± 2.5 respectively, (results 
expressed as mean ± SEM, n = 4). These values lie within the ranges 
obtained for stimulation at 30 min intervals (Table 5.1).
H^HTX (4 yM) blocked the normal 10 yM nicotine response
by about 25% (Table 5.3). This antagonism was shown to be 
reversible after 15 min wash with normal perfusion medium.
Table 5.3. The effect of H^HTX (4 yM) Qn (-)-nicotine (10 yM) 
stimulated release of radiolabelled transmitter from 
hippocampal synaptosomes.
Stimulus s2/s1 (%) s3/s1 (%)
(-)-nicotine 10 yM 75.5 (4) 89.8 (2)
Perfused synaptosomes were stimulated 3 times at 40 min intervals 
and H^HTX (4 y^ ) introduced into the perfusion medium 15 min 
before and continued until 15 min before S^.
The and S^/S^ values were calculated for the test systems and
the result expressed as the percentage of analogous S^/S^ values 
obtained in control systems.




5.4.1 Perfusion of hippocampal synaptosomes
These preliminary results demonstrate the existence of 
nicotinic autoreceptors on hippocampal cholinergic nerve terminals 
and confirm the earlier report from the laboratory by Moss and 
Wonnacott (1985). The facilitatory action of the nicotinic auto­
receptor in the hippocampus is consistent with the nicotinic
3
regulation of [ H ]ACh release in the cortex (Rowell and Winkler,
1984) and the myenteric plexus (Briggs and Cooper, 1983). The 
conditions for labelling the synaptosomes was based on previous 
studies in the laboratory (Moss and Wonnacott, personal communi­
cation) and the level of choline uptake agrees with other studies 
(see Jope, 1979). The lower level of uptake than found with [ H ]DA 
(using striatal synaptosomes, p.87 ) and the incomplete acetyl-
ation of choline to form ACh (approximately 70%, see Wonnacott and 
Marchbanks, 1976) resulted in lower levels of tritium released from 
the perfused synaptosomes (Fig. 5.1). This necessitates the higher 
concentration of nicotine required to evoke quantifiable tritium 
release, although concentrations lower than 10 yM were not tested.
3
The nicotine evoked release of [ HjACh was dose-dependent (Fig.
5.2) which is in agreement with the nicotinic autoreceptors 
reported by Rowell and Winkler (1984), and Moss and Wonnacott 
(1985).
In the experiments reported in this chapter no cholinesterase
inhibitors were present. This meant that the tritium present in the
2
perfusate probably contained a high proportion of [ H]choline. 
Experiments carried out by Moss and Wonnacott (198 ) showed that in 
the presence of a cholinesterase inhibitor about 75% of the tritium
3
release in response to 0.1 mM nicotine was [ HjACh. The nicotine 
evoked release of tritium (above spontaneous) in the experiments 
described in this chapter was therefore taken as representing
3
mainly [ H]ACh. Using this assumption the improved sensitivity of
3
the revised perfusion system was shown. The release of [ H ]ACh by 
nicotine (0.1 mM) was about 100 fmoles/mg protein (Fig. 5.2) 
compared with the release using the original system of 0.2 
fmoles/mg protein (Moss and Wonnacott, 1985).
Although the results show that auto- and heteroreceptors are 
similar in their facilitatory actions of neurotransmitter release, 
there is a notable difference in the sensitivities of the two 
receptors (Table 5.1). The and values for 10 pM and
100 p M  nicotine-evoked transmitter release are significantly higher 
for hippocampal than striatal. However, the striatal and hippo­
campal preparations are not directly comparable because of the 
differences in the labelling of the respective transmitter pools.
Nevertheless, preloading of the synaptosomes with either the
3 3precursor [ H]choline (hippocampal) or the transmitter [ H]DA
(striatal) gave similar results in terms of the pharmacology
displayed by the auto- and heteroreceptor. This suggests that the
precursor and transmitter may label similar transmitter pools
within the nerve terminal as already discussed for the use of [ H ]
3
tyrosine and [ HjDA.in striatal release studies (p.180 ).
Of interest was the observation that DH$E (the potent
r 3
antagonist of nicotine-evoked release of [ H]DA from striatal 
synaptosomes) was an effective inhibitor of 10 pM nicotine-evoked 
release of [ H]ACh from hippocampal synaptosomes (Table 5.1). The 
lower antagonism by DHffi found using 100 pM nicotine is consistent
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with DH8E acting as a competitive antagonist. Unlike the results of 
Moss and Wonnacott (1985), complete antagonism by a-BGT was not 
observed. Instead, partial antagonism of 10 uM nicotine-evoked [ H] 
ACh release was shown to be identical to that found using striatal 
synaptosomes (see Tables 4.7 and 5.2). The difference between the 
results obtained by Moss and Wonnacott (1985) and those reported in 
this thesis probably reflect differences in the experimental 
conditions employed, including the high concentrations of nicotine 
and the longer periods of stimulation used in the earlier studies. 
The results are therefore not directly comparable. It is possible 
that the observed transient increase in basal release of 20% 
(compared with <5% in the striatal preparation) when a-BGT was 
introduced into the perfusion medium was also present in the 
earlier studies but the original system was not sensitive enough to 
detect such small changes. Whether a-BGT is an effective antagonist 
of nicotinic function in the hippocampus has therefore still to be 
confirmed. As mentioned in the striatal work, a-BGT may require 
time to bind before inhibition is observed (for both striatal and 
hippocampal synaptosomes 55 min was required to observe partial 
antagonism). Alternatively, the partial antagonism observed by the 
relatively high concentrations of a-BGT used, may possibly be 
attributed to contamination of a-BGT with k-BGT (see p. 12 ).
a-BGT may therefore not be a suitable antagonist in perfusion 
studies. Instead, DHBE, pempidine and mecamylamine might be more 
useful in the further characterisation of the nicotinic auto­
receptor. The sensitivity of the nicotinic response to H^HTX 
(Table 5.3) provides evidence that the nicotine autoreceptor may 
also contain an ionophore as already suggested by similar
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experiments using striatal synaptosomes (p.213 ). At a 
concentration of 4 yM, H^HTX inhibited the response of 10 yM
nicotine in the hippocampal preparation by 25% and after 15 min 
washing there was a partial recovery. These results are directly 
comparable with those obtained using striatal synaptosomes 
(Table 4.9).
These preliminary experiments strongly suggest that the 
nicotinic facilitatory autoreceptors on hippocampal synaptosomes 
are sensitive to DHBE, H^HTX ancj a-BGT. In this respect they 
resemble the striatal nicotinic heteroreceptors modulating DA 
release described in Chapter 4. Further studies using a range of 
nicotinic agonists and antagonists will reveal how similar the 
autoreceptor is to the heteroreceptor.
OVERVIEW
The synaptosomal procedure described in this thesis is a novel
system for studying the release of transmitter from nerve endings.
It has been used to study the nicotinic heteroreceptor modulating
DA release in the striatum and preliminary experiments employing
hipp ocampal synaptosomes have shown that it can be readily adapted
to look at other release systems.
The nicotinic heteroreceptor shows properties characteristic of
C„ nAChR and also high affinity [*^ h| nicotine binding sites, o L
However, antagonists are also partially effective in preventing
the action of the nicotinic heteroreceptor, indicating a
relationship between the central nAChR and both C_ and C._ nAChR.o 10
The preliminary experiments reported in Chapter 5 indicate that the 
nicotinic autoreceptor may be similar to the heteroreceptor. 
However, more detailed studies are required before analogies can be 
made.
The sensitivity of the central presynaptic nAChR to H^HTX 
suggests that these nAChR may have an associated ion channel 
comparable with their peripheral counterparts and may therefore be 
structurally related. This agrees with the reported immunological 
cross-reactivity between antibodies raised against peripheral (C-^ q ) 
receptors and purified central receptors (see p.32 ).
The facilitatory nature of the nicotinic heteroreceptor 
modulating DA release in the striatum agrees with the reported 
action of nicotinic heteroreceptors modulating the release of 
noradrenaline from hypothalamic synaptosomes (Yoshida et al., 1980) 
and 5-hydroxytryptamine release from striatal slices (Westfall, 
1983a). The facilitatory nature of the muscarinic heteroreceptor on
2 6 2 .
striatal dopaminergic nerve terminals (see Table 1.2) also agrees 
with the action of the muscarinic heteroreceptor modulating DA 
release in the nucleus accumbens (de Belleroche and Gardiner,
1985). Both central muscarinic and nicotinic heteroreceptors are 
therefore similar in their enhancing effect on transmitter release. 
This is in contrast to the cholinergic modulation of noradrenaline 
release in the PNS, where the muscarinic response is inhibitory and 
the nicotinic response excitatory (Muscholl, 1979).
The preliminary experiments reported in this thesis employing 
hippocampal synaptosomes confirms previous reports that nicotinic 
autoreceptors are facilitatory (see p.41 ). However, muscarinic
autoreceptors have been shown to exert an inhibitory action on 
transmitter release (see p. 41 ).In this way muscarinic and 
nicotinic autoreceptors provide a dual regulation of ACh release 
which is analogous to the modulation by ot2 and B adrenergic 
autoreceptors of noradrenaline release (Langer, 198I).
Future directions
To further characterise central nAChR using perfusion 
techniques, the perfusion system could be modified. Finer control 
of the temperature and pressure may reduce the slight day to day 
variation in release rates. The construction of a glass enclosure 
similar to that recently described by Minnema and Michaelson (1985) 
would allow such control.
A more detailed study of the pharmacology of the nicotinic 
response would help in the classification of the nicotinic 
heteroreceptor as either Cg or C1Q. Changes in the perfusion 
schedule, such as the length of the pre-exposure and wash-off
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periods would give more information about the reversibility of the
inhibition caused by an antagonist. The determination of the effect
of antagonist concentration on a range of agonist concentrations
would give information about the nature of the blockade. However,
the classification of central nAChR as either or receptors
o l'J
is complicated by the fact that most and antagonists act at
both receptors. The classification of nicotinic antagonists as
either C„ or C.,^  is therefore difficult and demonstrates the 
6 10
limitations of this classification. There is therefore a 
requirement for ligands specific only for one type of receptor.
NSTX may be such a ligand, although detailed studies have not been 
possible because of its scarcity (p.J3 ). The antagonists
mecamylamine, pempidine, chlorisondamine and DHyJE may also be 
useful in the further characterisation of central presynaptic 
nAChR.
Although the facilitatory action of the nicotinic hetero- 
receptor was only studied on the basal efflux of £ H^DA, there are 
also reports that these receptors are functional under depolarising 
conditions (Table 1.2). Similarly, nicotinic autoreceptors have 
been shown to be operational under either basal or depolarising 
conditions (Rowell and Winkler, 1984; Moss and Wonnacott, 1985; 
Beani et al., 1985). Central presynaptic nAChR may therefore be 
classified as Type I REC (see p.41 ). To complement the studies
reported in this thesis it would be interesting to look at the 
effect of nicotinic agonists and antagonists on K+ (16 mM) evoked 
transmitter release, employing a slightly modified perfusion 
protocol.
To further study the mechanism of action of the presynaptic
26U.
nAChR it would be interesting to determine the Ca -dependency of
agonist-evoked transmitter release over a range of agonist
45 2+concentrations. The measurement of Ca entry in response to 
nicotine stimulation following the methods of Leslie et al. (1985) 
and Drapeau and Blaustein (1983) may help in this characterisation, 
Perfusion experiments using a range of noncompetitive 
antagonists that are known to interact with the C ^  nAChR 
ionophore, such as phencyclidine (Aguayo et al., 1982) or 
bupivacaine (Aracava et al., 1984) may provide more evidence in 
support of an ionophore being part of the central presynaptic 
nAChR. More direct examination of this aspect could be achieved by 
carrying out ion-flux studies employing a synaptosomal preparation. 
These studies could be based on the work of Robinson and McGee 
(1985) and Lindstrom et al. (1980) who have studied ion flux 
through nAChR on PC-12 cells and reconstituted vesicles 
respectively.
To summarise, this study has shown that functional central
nAChR exist which are similar to both C_ and C.rt nAChR and a6 10
synaptosomal perfusion system has been developed which will help in 
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A B ST R A C T
Neosurugatoxin, a neurotoxin isolated from the Japanese ivory mollusc
(Babylonia j aponica) is a nicotinic antagonist with a specificity towards 
ganglionic nicotinic receptors. At low concentration (5 x 10"8M)
neosurugatoxin inhibited the release of [3H]dopamine evoked by
1, l-dimethyl-4-phenylpiperazinium (DMPP) ijrom rat striatal nerve terminals, 
without affecting the response to K -depolarisation. In contrast,
abungarotoxin did not antagonise the action of DMPP. Neosurugatoxin also
inhibited [3h ] nicotine binding to rat brain membranes but had no effect on 
[1251 ]abungarotoxin binding to the same tissue preparation. These results 
support the view that functional nicotinic receptors in the CNS resemble
ganglionic nicotinic receptors. Neosurugatoxin has considerable potential as a 
useful probe for such receptors in the brain.
There is an increasing acceptance of the presence of nicotinic acetylcholine
receptors in vertebrate CNS and autonomic ganglia. However, progress in 
understanding the particular functions of these receptors and how they relate 
to the well-characterised peripheral nicotinic receptor has to some extent been 
hampered by lack of availability of suitable probes. The snake toxin,
abungarotoxin, that has contributed so much to our understanding of nicotinic 
receptors in electroplaques and at the neuromuscular junction (Conti-Tronconi & 
Raftery, 1982) has been applied to the study of the neuronal receptor. There 
is considerable evidence, including immunological crossreactivity between brain 
abungarotoxin binding proteins and peripheral nicotinic receptors (Norman et 
a l . , 1982; Wonnacott et a l ., 1982) that this toxin may bind selectively to a
population of neuronal nicotinic receptors. However, its usefulness has been 
questioned, particularly in view of its ineffectiveness as an antagonist of 
many neuronal nicotinic responses (see Barnard & Dolly, 1982).
We have sought to complement our binding studies by developing a 
functional assay system for nicotinic receptors in which we measure the pre- 
synaptic nicotinic facilitation of [3H]dopamine release from striatal nerve 
terminals (Mills & Wonnacott, 1984; Rapier et al., 1985). In such a system we
have demonstrated that an antiserum raised against the nicotinic receptor
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purified from rat muscle inhibits the nicotine-evoked release of [3H]dopamine 
(Mills & Wonnacott, 1984) suggesting some degree of identity between peripheral 
receptors and this group of central nicotinic receptors. However, in apparent 
contrast abungarotoxin did not have a pronounced effect on the striatal 
preparation whereas the ganglionic antagonist mecamylamine completely blocked 
the nicotine-evoked response (Mills & Wonnacott, 1984). Recent reports of a 
neurotoxin isolated from the Japanese ivory mollusc (Babylonia japonica) and 
called neosurugatoxin (Kosuge et al., 1982; Hayashi et al., 1984) which may be 
a specific antagonist of some neuronal nicotinic receptors, prompted us to 
compare its action in our functional system with its effect in conventional 
binding assays.
M A T E R IA L S  & METHODS
D ,L-[N-methyl 3H ] nicotine (73.7 Ci/mmol) was purchased from NEN 
Radiochemicals Ltd. (Southampton, Hants., U.K.) [12Sl]Na and 7,8[3H ]dopamine 
(46 Ci/mmol) were purchased from Amersham International (Amersham, Bucks., 
U.K.) abungarotoxin was from the Boehringer Corp. (Lewes, Sussex, U.K.) and 
was iodinated as previously described (Wonnacott et a l ., 1980).
Pure crystalline neosurugatoxin was a gift from Professor T. Kosuge. The 
toxin (250yg) was dissolved in 0.12 ml of dimethylsulphoxide and diluted to 
3.0 ml with water. L-nicotine was from the Sigma Chemical Co. (Poole, Dorset, 
U.K.), 1,l-dimethyl-4-phenylpiperazinium (DMPP) was from Aldrich Chemical Co.
Ltd., (Gillingham, Dorset, U.K.) and all other reagents were from BDH Chemicals 
Ltd. (Poole, Dorset, U.K.) Drugs and toxins were serially diluted in perfusion 
medium or assay buffer just prior to use.
Preparation and perfusion of synaptosomes
Synaptosomes from rat striata were prepared as described by Mills & 
Wonnacott (1984), the final suspension having a protein concentration of 
3mg/ml. The synaptosomes were incubated with [3H]dopamine (0.1/*M; 15 Ci/mmol) 
for 4 min at 37°C (Rapier et al., 1985). Samples (2 5 0 y1) of the synaptosome 
suspension were transferred to Whatman GFF filters positioned in the perfusion 
chambers (modified Millipore glass filter units) and perfused with modified 
Krebs medium at a constant rate (9ml/h).
After a ^0 min washout period, depolarising pulses (lOOul) of KC1 and the 
nicotinic agonist DMPP were applied in the perfusion medium, allowing a 20 min 
interval between successive pulses. Continuous collection of consecutive 0.2 
ml fractions of the perfusate was achieved by using an LKB Redirac fraction 
collector; radioactivity was counted after addition of 3 ml of Aqualuma (LUMAC 
B.V. Ad Schaesberg, The Netherlands) in a Packard scintillation spectrometer 
(counting efficiency 40%).
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In each experiment 3 perfusion chambers were operated in parallel: one served
as a control without toxin and the second as the test system. In the third 
spontaneous release throughout the perfusion period was measured and this was 
subtracted from the transmitter release profiles of the control and test
systems.
Radioligand binding assays
A crude membrane fraction (P2 ) was prepared from rat brain cortices, and 
reconstituted in 5 0mM-phosphate buffer, pH 7.4, containing O.lmM-PMSF and 0.01% 
(w/v) sodium azide, to give a protein concentration of approximately lOmg/ml.
[3H]nicotine binding to this preparation was performed essentially as described, 
by Romano & Goldstein (1980). The tissue was diluted five-fold in 50 mM-HEPES 
buffer, pH 7.4, containing NaCl (118mM), KC1 (4.8mM), CaCl2 (2mM), MgSO„ (2mM). 
Samples (0.25ml) were incubated with 40nM-[3H ]nicotine for 60 min at 22°C, in 
the presence and absence of 10" "M-L-nicotine. Bound radioligand was separated 
by filtration at 4°C.
[1251 ]abungarotoxin binding to P2 membranes was assayed by the method of 
Schmidt (1977). The fraction was diluted ten-fold in 50 mM-phosphate buffer,
pH 7.4, and aliquots (0.5 ml) were incubated with 1 nM-[125 I]abungarotoxin for
60 min at 22°C, in the presence and absence of 2.5 x 1 0-~Jm - abungarotoxin.
Bound radioligand was separated by centrifugation (2 min at 10,000g; MSE 
Microcentaur bench centrifuge); the pellet was washed once with 1.5 ml ice-cold 
phosphate-buffered saline.
Drugs were incubated with the membrane fraction for 10 min prior to the 
addition of radioligand. Non-specific binding (excess cold ligand) was
subtracted; under the conditions used specific binding was 44.7 + 8.8 fmol/mg 
and 9.4 + 1.1 fmol/mg protein for [3H]nicotine and [ 1 25i]abungarotoxin 
respectively (mean + S.E.M. for 3 membrane preparations).
RESULTS
Neosurugatoxin greatly diminished the DMPP-evoked release of [3H ] dopamine from 
striatal synaptosomes (Fig. 1). In the absence of toxin (Fig. la), low doses 
of the ganglionic nicotinic agonist DMPP (5 x 1CT6M) or KC1 (28mM) elicit sharp 
peaks of released radioactivity. After perfusing with neosurugatoxin
(5 x 10“^) for 20 min the DMPP-evoked response was reduced: peaks 1 and 3 (Fig. 
lb) represent only 21% and 15% respectively of the corresponding peaks in the 
normal control (Fig. la). The average inhibition of DMPP-evoked release by 
5 x lCT8M-neosurugatoxin was 59 + 8% (mean + S.E.M. of duplicate determinations 
from 3 independent experiments). K+-evoked release was not significantly 
affected. After washing with normal perfusion medium without neosurugatoxin 
the response to DMPP was gradually restored (83% after 20 min washing, 109%
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Fig. 1 Release of [3H]dopamine from striatal synaptosomes.
Synaptosomes were preincubated with [3H]dopamine and perfused with a) normal 
medium, or b) medium containing 5 x 10-8M neosurugatoxin for 90 min ('////' ) . 
Pulses ( IOOmI ) of DMPP (5 x 10_6M; JL ) or K+ (28 m M , ) resulted in responses
indicated by the arrows. *
after 40 min; Fig. lb). Exposure to abungarotoxin (5 x 10reM) under identical
conditions to those of the neosurugatoxin experiments, was ineffective in
inhibiting DMPP-evoked [3H]dopamine release. Neosurugatoxin also inhibited the
///////////////'////////////////////"////- 
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binding of [3H]nicotine to rat brain membranes (Fig. 2a). L-nicotine displaced 
radio-labelled nicotine but abungarotoxin was largely ineffective up to 10“ 'm . 
In contrast, when these ligands were tested against [1251 ]abungarotoxin binding 
to the same tissue (Fig. 2b) abungarotoxin was the most potent competitor and 
neosurugatoxin was without any effect, at concentrations up to 10“ SM. However, 
nicotine and DMPP were also good inhibitors of [125I ]abungarotoxin binding.
DISCUSSION
The presynaptic nicotinic facilitation of dopamine release from striatal nerve 
terminals (Chesselet, 1984) provides a functional assay for a population of 
nicotinic receptors in the brain. This system has been partially characterised 
pharmacologically (Giorguieff et al ., 1977). We have previously demonstrated
that antibodies raised against the nicotinic receptor from skeletal muscle 
block the cholinergic facilitation of dopamine release from striatal 
synaptosomes (Futerman et al., 1982; Mills & Wonnacott, 1984) but abungarotoxin 
was not very effective in our preparations. We have now greatly improved the 
sensitivity of our synaptosomal perfusion system (Rapier et al., 1985) and
Fig. 2 Effect of drugs and toxins on a) [3H]nicotine and b) [^^i]- 
abungarotoxin binding to rat brain membranes.
Membranes (P2 fraction) were preincubated with L-nicotine (o— o ), DMPP 
(•— •), abungarotoxin (A— A  ) or neosurugatoxin (A— ▲) at the final 
concentrations indicated for 10 min before addition of radioligand and assay 
as described in the Materials & Methods section. Data from a representative 
experiment are presented as a percentage of specific binding; each point is 
the mean of triplicate determinations, with variance of less than 10%.
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clear repetitive responses are obtained to drugs in the^wnolar range and below 
(Fig.la). In this system the response to the nicotinic agonist DMPP is greatly 
diminished following exposure of the synaptosomes to neosurugatoxin whereas 
such treatment is without effect on the Ca++-dependent, K+-stimulated release 
(Fig. lb). These findings strongly suggest that the toxin specifically blocks 
the presynaptic nicotinic facilitatory receptor. aBungarotoxin was without 
effect under identical conditions. Continuous perfusion with abungarotoxin 
would be expected to achieve a more effective blockade than the brief exposure 
previously employed (Mills & Wonnacott, 1984). This clearcut negative result 
would seem to confirm that abungarotoxin is not an antagonist at this nicotinic 
receptor. This conclusion is in agreement with the study of Misgeld et al. 
(1980) in which 6 x lCT7M-abungarotoxin was without effect on the intrinsic 
cholinergic excitation in striatal slices, although de Belleroche & Bradford 
(1978) reported a modest inhibition (38%) of acetylcholine - evoked 
[3 H] dopamine release from striatal slices by 1.8 x 1(T7M- abungarotoxin (see 
Mills & Wonnacott, 1984).
It has been reported that surugatoxin and neosurugatoxin (Kosuge et a l . , 
1982), are potent antagonists of nicotinic receptors in sympathetic and
parasympathetic ganglia but not at the neuromuscular junction (Hayashi & 
Yamada, 1975; Brown et a l ., 1976; Ascher et a l . , 1979). Indeed in the study of 
Hayashi and Yamada (1975) surugatoxin specifically inhibited the actions of 
DMPP on blood pressure and ganglionic transmission in the cat and DMPP-evoked 
contraction of the guinea pig ileum. The latter action has been reproduced 
with neosurugatoxin itself (Hayashi et al., 1984). In this case, the toxin may 
act at presynaptic nicotinic receptors that facilitate transmitter release from 
myenteric varicosities (Briggs & Cooper, 1982; White, 1982), since the 
post-ganglionic response to acetylcholine (via muscarinic receptors on the 
muscle surface) was unaffected by neosurugatoxin (Hayashi er al., 1984). The 
present study is the first report of the antagonism by neosurugatoxin of
nicotinic receptor function in the brain, and supports the view that many 
central nicotinic receptors may be ganglionic in character (see Schmidt et al., 
1980).
In agreement with Hayashi et a l . (1984) we find that neosurugatoxin
inhibits [3H]nicotine binding to brain membranes (Fig. 2a). Quantitative 
assessment of the inhibition in our experiments was difficult because of the 
instability of neosurugatoxin in aqueous solution (Kosuge et al., 1982). What 
is clear however, is its differential effect on binding of [3Hlnicotine and 
[1251 ]abungarotoxin to brain membranes (Fig. 2); the binding assays were 
performed in parallel using the same serial dilutions of neosurugatoxin. 
Nicotinic antagonists generally are very poor inhibitors of [3Hlnicotine 
binding to nervous tissue (Romano & Goldstein, 1980; Marks & Collins, 1982; 
Costa & Murphy, 1983), and we find that abungarotoxin has little effect on r3Hj 
nicotine binding, in agreement with other studies. Neosurugatoxin, however,
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shows strong inhibition of binding and is the first antagonist to be shown 
to have potent effect at the nicotine binding site. In contrast, although 
nicotine and DMPP are effective competitors for [ 1 2 5 Ijabungarotoxin binding 
sites (Fig. 2b; Marks & Collins, 1982), neosurugatoxin is without effect. Such 
data do not preclude binding of [3H]nicotine and [ 1 25I ] abungarotoxin at 
distinct sites on the same oligomers, which would be consistent with the 
inhibition of nicotine-evoked release by an antiserum that crossreacts with the 
abungarotoxin binding component from rat brain (Mills & Wonnacott, 1984). 
Irrespective of the precise relationship of the binding sites, our results are 
consistent with the widely held view that abungarotoxin is a poor antagonist of 
known nicotinic cholinergic function in the CNS. Conversely, neosurugatoxin 
shows considerable promise as a potent, selective probe for functional central 
nicotinic receptors.
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